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Abstract
The Epstein-Barr virus (EBV) is a ubiquitous human oncogemc herpesvirus which 
causes infectious mononucleosis (IM) and contributes to the development of many 
important cancers in man The objectives of this thesis were twofold
(1)the development of recombinant EBV antigens as reagents for the serodiagnosis of 
EBV-related disease,
(2) the identification of peptides that bind EBV neutralising antibody using phage display 
technology
Serology testing is of paramount importance in the diagnosis of EBV-related diseases, 
with viral antigen for these tests usually being derived from cell culture The production 
of the appropriate recombinant EBV antigens in a prokaryotic system would eliminate 
many of the disadvantages associated with cell culture-derived EBV antigens, le 
reproducibility, cross-reactivity and expense The coding sequences for several targeted 
EBV proteins were cloned into an E  coh expression vector (Thiofusion system) In this 
system recombinant proteins were fused to E coh  thioredoxin thus offering the 
advantages of stability, solubility, mducibility and ease of purification Three EBV 
antigens, pl8VCA, EA-D and EBNA1 were chosen for expression and purification 
These recombinant antigens were assayed with sera that had been previously partially 
characterised for antibodies to EBV A cut-off point was determined by comparison of 
ELISA and Western blot results The antibody profiles of each serotype, 1 e infectious 
mononucleosis-positive sera, sera from normal healthy individuals, VCA+/- sera and 
EBNA+/- sera, agreed with those determined using cell culture-derived antigen in other 
assay systems Some potential cross reactivity with CMV was noted These recombinant 
proteins may be of use as immunodiagnostic reagents for the diagnosis of EBV-related 
diseases
The EBV envelope glycoprotein gp350 mediates virus adsorption and penetration to it’s 
host cell and is the principal candidate subunit vaccine The monoclonal antibody 72A1 is 
known to neutralise EBV through interaction with gp350 The aim was to identify 
peptides that bind to 72A1 using phage display technology Usmg this antibody, peptide 
sequences were selected which showed specific similarities m ammo acid content and 
arrangement, however it was not possible to show specific interaction between the 
selected clones and 72A1 by other immunological methods As only one group of clones 
from the set of 15mer sequences bears similarity to the native gp350 primary ammo acid 
sequence, it is most likely the epitope is conformational, or that all other selected 
peptides are mimotopes of a linear epitope
VI
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Chapter 1
Introduction to the Epstein-Barr Virus
l
1.1 Historical Aspects of Epstein-Barr Virus
Epstein-Barr vims (EBV) was discovered during the course o f attempts to learn the 
cause o f a lymphoma that was the most common tumour affecting children in certain 
parts o f East Africa. Dennis Burkitt who described the clinical syndrome suggested that 
this lymphoma might be due to a virus (Burkitt, 1962). Virus particles morphologically 
similar to the herpesvirus group were found in thin sections o f Burkitt’ s lymphoma (BL) 
cell lines (Epstein et a l,  1964), in a fraction o f cells in lymphoid lines established from 
patients with various malignancies, from patients with infectious mononucleosis (IM) and 
from apparently normal individuals (Miller, 1971). On the basis o f further studies it was 
determined that EBV was the cause o f IM, since antibodies to the antigens in BL cell 
lines were absent before mononucleosis and appeared after the disease (Henle et al., 
1968). This herpes virus is also consistently detected in nasopharyngeal carcinoma 
(NPC). (Miller, 1990).
1.2.1 EBV Morphology
Herpesviruses are a family o f DNA viruses found commonly in both animals and humans. 
The known herpesviruses have a common virion architecture, and are primarily classified 
on the basis o f morphology, ie. a core containing a large linear double-stranded DNA 
genome, an icosahedral capsid, an amorphous tegument and a lipid envelope with viral 
glycoprotein spikes on it’ s surface. The viral particles have a diameter o f about 120 to 
200 nm and contain 25-35 virus-encoded proteins and host-specific phospholipids 
derived from the nuclear membrane. The DNA is wrapped around a DNA-associated 
spindle-shaped protein consisting o f fibrils attached to the inside o f the capsid. The 
capsid is surrounded by an amorphous material, tegument, composed o f globular 
proteins. The envelope has a typical trilamellar structure and is derived from patches o f 
altered cellular membranes. Due to the high lipid content o f the envelope the virions are 
unstable at room temperature and are rapidly inactivated by lipid solvents and detergents 
(IARC Monographs, 1997). The nucleosome spacing o f the EBV DNA-chromatin 
structure is indistinguishable from that o f cellular chromatin (Dyson and Farrell, 1985). 
Many types o f modification are seen in EBV chromatin, which are typical o f cellular gene 
structure There is extensive methylation o f the DNA at CpG dinucleotides (Diala and 
Hoffman, 1983, Dyson and Farrell, 1985; Kintner and Sugden, 1981; Larocca and
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Clough, 1982), the inactive, latent cycle genomes are more completely methylated than 
productive genomes. In maintenance replication the DNA is on nucleosomes, but in 
productive replication it is not regularly packed on nucleosomes. The herpesviruses are 
subdivided based on their host range, site o f latent infection, cytopathology, and length 
o f replicative cycle. This subdivision includes alpha, beta and gamma herpesvirinae 
(Roizman, 1982).
Designation Common name Sub family
Human viruses
Human herpesvirus 1 Herpes simplex virus 1 a
Human herpesvirus 2 Herpes simplex virus 2 a
Human herpesvirus 3 Varicella-zoster virus a
Human herpesvirus 4 Epstein-Barr virus Yi
Human herpesvirus 5 Cytomegalovirus P
Human herpesvirus 6 P
Human herpesvirus 7 P
Human herpesvirus 8 Y2
Viruses of non-human
primates
Aotine herpesvirus 1 Herpesvirus aotus type 1 P
Cercopithecine herpesvirus 5 African green monkey 
cytomegalovirus
P
Ateline herpesvirus 1 Spider monkey herpesvirus a
Callitrichine herpesvirus 2 Marmoset cytomegalovirus P
Cebine herpesvirus 1 Capuchin herpesvirus (AL-5) P
Pongine herpesvirus 3 Gorilla herpesvirus Yi
Samiriine herpesvirus 1 Marmoset herepesvirus a
Bovine viruses
Bovine herpesvirus 5 Bovine encephalitis herepesvirus a
Ovine herpesvirus 2 Sheep-associated malignant catarrhal 
fever
Y
Caprine herpesvirus 1 Goat herpesvirus a
Alcelaphine herpesvirus 1 Wildebeest herpesvirus Y
Cevid herpesvirus 1 Red deer herpesvirus a
Murid viruses
Murid herpesvirus 1 Mouse cytomegalovirus P
Murid herepsvirus 4 Mouse herpesvirus strain 68 Y2
Gallid viruses
Gallid herpesvirus 2 Marek’s disease herpesvirus 1 a
Gruid viruses
Gruid herpesvirus 2 Turkey herpesvirus a
Ranid viruses
Ranid herpesvirus 2 Frog herpesvirus
Table 1; International nomenclature of herpesviruses (Examples of each
type, Adapted from IARC Monographs, 1997).
1.2.2 Genome Structure
EBY is a member of the gamma herpesvinnae, it’s genome is linear double stranded 
DNA about 172 kilobases m length which circularises inside the host cell This 
circularisation is mediated by the joining of terminal repeat (TR) sequences which are 
about 3-5 in the circularised DNA (Given et a l , 1979, Kmtner and Sugden, 1979) The 
genome is subdivided into four regions, these are the short and long unique regions, 
separated by the major internal repeat (IR), and the terminal repeat (TR) The base 
composition of the EBV genome is biased to an excess of guanosine (G) and cytosine 
(C) B95-8 (a strain of EBV) DNA contains about 59 9% GC, and the GC composition 
is nonuniform throughout the genome, the IR having a higher GC content (Baer et 
al ,1984) During the seventies the DNA of several EBV strains propagated in marmoset 
cells was cloned on bacterial plasmids or lambda phages (Colby et a l , 1980, Skare and 
Strominger 1980) The 172 kb sequence of the B95-8 virus was subsequently determined 
(Baer et a l , 1984) EBV was the first herpesvirus whose genome was completely cloned 
and sequenced
The complete sequence of the B95-8 genome that is in the European Molecular Biology 
Laboratory (EMBL) nucleotide sequence library contains an arbitrary number of major 
IR units (116) and 4 TRs There may be a distribution of numbers of IR and TR m any 
culture of EBV-infected cells No homology exists between the TR and the major IR, 
which has a large imperfect palindromic sequence of about 100 nucleotides (Cheung and 
KiefF, 1982) The nomenclature for EBV open reading frames is based on the BamHI- 
restnction fragment in which they are found Each fragment is designated a letter, and a 
number where there is more than one ORF in a particular BamHl restriction fragment 
The orientation of the ORF is also defined in the name, e g BALF4 - BamHl fragment 
A, leftward reading frame ORF 4 See figure 1 of the BamHl-restriction map of the 
EBV genome
1.2.3 Variant EBV Strains
The genome structure of a number of EBV strains has been studied and is found to be 
very similar, the mam variation being type variations in the EBNA-2 gene (Dambaugh et
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a l , 1984, Adldmger et a l , 1985) Some laboratory strains display substantial deletions, 
eg B95-8(87), Raji(86), P3HR-1(10), and Daudi(57), these may have arisen in vitro 
There are a number o f repeats scattered throughout the EBV  genome, the TRs are at 
both ends o f the linear form o f EBV and mediate the circulansation The number o f 
repeat units vanes between strains, most strains have 3-5 , but Raji has up to 12 copies 
The major IR unit in B95-8 is 3072 bp, and the number o f repeats vary considerably 
between strains, 4-11 Two major EBV types (1 and 2) have been detected in humans, 
their genomes are almost identical except for the genes that encode some o f the nuclear 
proteins (EBNA2, EBNA3A, 3B and 3C) in latently infected cells and to the 
transcnption units o f the EBER RNAs (Nonoyama and Pagano, 1973, Bomkamm et a l , 
1980, Arrand et a l , 1989) Antibodies to type 2 viruses are more prevalent in the sera of 
African people than from people m developed countnes (Young et a l , 1987, Rowe et 
a l , 1989) EBV type 2 infected lymphocytes grow less efficiently in vitro (Rickinson et 
a l , 1987), thus making recovery o f this virus type from blood more difficult In Papua- 
New Guinea an EBV recombinant that encodes both type 1 and type 2 nuclear antigens 
was isolated from the blood o f a healthy adult (Burrows et a l , 1996) In addition to 
type-specific polymorphism there exist polymorphisms which define different viral strains 
within type 1 and type 2 (Aitken et a l , 1994) These changes can cause amino-acid 
substitutions in viral proteins and affect peptides that are important for the immune 
control o f viral infection (de Campos-Lima et a l , 1993, Lee et a l , 1993, de Campos- 
Lima et a l , 1994, Lee et a l , 1995, Burrows et a l , 1996a)
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Figure 1: Bam H I-restnction map of the EBV genome and latent transcripts (Adapted from Masucci and Em berg, (1994) and Rickingon and K ieff (1996))
Abbreviations are explained m the text.
Epstem-Barr virus can establish either fully productive (lytic) or nonproductive (latent) 
infections in target cells The major target cell types for the virus in vivo are B- 
lymphocytes and stratified squamous epithelium (See figure 2) There is strong 
circumstantial evidence to suggest that both lytic and latent infections can be established 
in cells of either lineage, depending on the precise stage of differentiation of the infected 
cell (Crawford and Ando, 1986 , Greenspan el a l , 1985 , Li et a l , 1992 , Rowe et a l , 
1992) Infection of B cells is mediated through interaction of the viral envelope 
glycoprotein gp3 50/220 with the C3d complement component receptor CR2 (CD21) 
(Fingeroth et a l , 1984, 1988) The viral envelope fuses with the host cell membrane 
resulting in endocytosis, this mechanism involves three other viral glycoproteins gp85, 
gp25 and gp42 (Li et a l , 1995) The glycoprotein gp42 can bind to major 
histocompatibility complex class II (MHC II), and uses this molecule as a cofactor in the 
infection of B cells (Li et a l , 1997)
Expression of the C3d receptor is not restricted to B cells and identical or related 
molecules have been detected m T cells, follicular dendritic reticulum cells and possibly 
some epithelial cells (Reynes et a l , 1985, Fingeroth et a l , 1988, Timens et a l , 1991, 
Birkenbach et a l , 1992, Hednck et a l , 1992, Smha et a l , 1993) EBV has been 
detected in non-B cell tumours, certain T cell lymphomas and some carcinomas Table 2 
shows the details of some of the EBV-associated malignancies The mechanism of 
infection of epithelial cells is as yet not fully understood, some reports suggest that direct 
infection of nasopharyngeal and cervical epithelial cells with EBV may be possible 
(Sixbey et a l , 1986, Furukawa et a l , 1990, Yoshizaki et a l , 1994), however, 
mechanisms to facilitate this process have been devised m most studies to date Knox et 
a l , (1996) generated stable EBV-infected subclones using CR-2 negative keratinocytes 
which had been transfected with the gene encoding the B cell EBV receptor Sixbey and 
Yao (1992) succeeded in infecting a human colon carcinoma cell line with EBV by 
coating the virus with gp350-specific polymeric IgA In certain cell types it seems the 
absence of CR2 is the mam obstacle for EBV infection (Ahearn et a l , 1988) It has been 
shown that EBV induces cell fusion between virus-carrying B cells and other cell types, 
including T cells and fibroblasts (Bayliss and Wolf, 1980 and 1981), and also that
1.3.1 Biology of EBV Infection
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endothelial cells can be infected with EBV by co-cultivation with irradiated EBV- 
carrying B cell lines (Jones et a l , 1995) These findings suggest that cell fusion may aid 
virus entry in the absence of the EBV/C3d receptor
NPC EBL HD AIDS-HL PTLD
EBV status 
Clonality
EBV Gene Expression
> 95%
Mono
EBNA1
LMP1 
TP 1/2
>95%
Mono
EBNA1
20-50% 
Mono ? 
EBNA1 
EBNA2
LMP1
TP1
35-75%
Mono
EBNA1
EBNA2
LMP1
TP1
80-90%
Mono / Poly
EBNA1
EBNA2
EBNA3a/3c
LMP1
TP 1/2
Table 2: EBV-Associated Malignancies. (NPC - Nasopharyngeal Carcinoma, EBL
Endemic Burkitt’s Lymphoma, HD - Hodgkin’s Disease, AIDS-HL - Acquired 
Immune Deficiency Syndrome - Hodgkin’s Lymphoma, PTLD - Post-Transplant 
Lymphoproliferative Disease, Mono - Monoclonal, EBNA - EB Nuclear Antigen,
LMP - Latent,Membrane Protein, TP - Terminal Protein)
1.3.2 EBV Latent Infection
Circular episomal EBV DNA is detected in the nuclei of blood lymphocytes infected in 
vitro within 12-16 hr of infection (Hurley and Thorley-Lawson, 1988) It is thought that 
only DNA repair is required for circulansation as significant nucleotide incorporation 
does not occur until 48 hr post-infection (Sixbey and Pagano, 1985) Most or all of the 
copies of the EBV latent genome are replicated once in each cell cycle using orzP, early 
in the S phase by cell DNA polymerase (Adams and Lindahl, 1975, Kaschka-Diench et 
a l , 1976, Shaw, 1985, Adams, 1987) It is most likely that episomal DNA is required for 
lytic cycle EBV DNA replication, since viral production has not been observed in cells 
that contain only integrated EBV DNA, and circular DNA copy numbers increase during 
the lytic infection (Shaw 1985) In the establishment of latent infection, most of the EBV 
genome undergoes progressive methylation (Kintner and Sugden, 1981, Larocca and 
Clough, 1982, Perlmann et a l , 1982) However, the regulatory domains involved in 
maintaining latent infection, such as oriP, tend to remain under-methylated (Minarovtis 
et a l , 1992) Extensive methylation of parts of the genome not expressed in latent 
infection may help to maintain latency by inhibiting lytic cycle gene expression 
(Nonkwelo and Long, 1993) Treatment of latently infected cells with drugs that reduce 
methylation increases the frequency of cells entering the productive cycle (Ben-Sasson 
and Klein, 1981)
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Figure 2: M odel of EBV-host interaction dunng primary infection and persistence. (Adapted from IARC Monographs, 1997)
The maintenance origin of replication, oriP, consists of a series of 30 base pair repeats 
(7,421-8,042) and a dyad symmetry (9,021-9,133) (Reisman et a l , 1985) Both the 
repeats and the dyad symmetry, which are related in sequence, bind the EBNA1 protein 
(Rawlins et a l , 1985) This binding is required for the origin of replication to function 
and for transcription enhancer activity, which resides in the 30 base pair repeats (Lupton 
and Levine, 1985, Reisman and Sugden, 1986) There exists extensive splicing of mRNA 
in EBV, the genome expresses approximately 90 genes, with two of these giving the 
EBER RNAs and the rest viral protems The EBV genome has been compared to that of 
herpes simplex virus (HSV), cytomegalovirus (CMV), varicella zoster virus (VZV), and 
herpesvirus saimin (HVS), however, the latent cycle genes show no obvious relationship 
to other herpesviruses studied and imply a separate viral or cellular origin By comparing 
all the EBV reading frames with computer-based libraries a number of homologues were 
discovered eg HSV ribonucleotide reductase, DNA polymerase, and glycoprotein B 
(Baer et a l , 1984, Gibson et a l , 1984, Pellett et a l , 1985)
1.3.2.1 Types of Latency
Analysis of EBV latent protein expression in cell culture model systems and in EBV- 
associated tumours has highlighted the existence of three different forms of latency 
which are referred to as I,II and III (see table 3) Latency I, seen in BL biopsies is 
characterised by selective expression of EBNA1 (Epstein-Barr virus nuclear antigen 1) 
(Gregory et a l , 1990 , Hitt et a l , 1989, Rowe et a l , 1987), together with a high copy 
number of small polyadenylated transcripts, EBER1 and EBER2 (Rymo, 1979, Howe 
and Shu 1989), and the use of the Fp gene promoter, which allows selective expression 
of EBNA1 (Sample et a l , 1986 and 1991) Latency II, seen in nasopharyngeal 
carcinoma (NPC) and Hodgkins disease (HD), is characterised by expression of EBNA1, 
and the latent membrane protems LMP1 and LMP2A and 2B (Brooks et a l , 1992 , 
Busson et a l , 1992 , Fahraeus et a l , 1988 , Smith and Griffin, 1991 , Young et a l , 
1988) One or more of the LMP promoters are activated in latency II, resulting in 
expression of LMP 1 and/or LMP2A and/or LMP2B (Kerr et a l , 1992) Latency III, 
seen in infectious mononucleosis (IM) and immunoblastic B-cell lymphomas of the 
immunosuppressed (PTLD) is characterised by expression of all six EBNAs 
(EBNA1,2,3A,3B,3C and LP) as well as LMP1 and 2A and 2B (Kieff and Liebowitz,
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1990). There is also expression of cellular genes such as CD23, a ligand for the EBV 
receptor CD21 (Wang et al., 1987). The pattern of promoter usage in latency III is quite 
different from that found in latency I and II (Sample et al., 1986; Rodgers et al., 1990). 
Other viral mRNAs encoded for by the BHRF1 and BARFO open reading frames (ORFs) 
have been detected in latently infected cells, but their products are not well characterised 
(reviewed by Kieff, 1996). EBV-infected proliferating B lymphocytes express activation- 
associated markers, secrete immunoglobulins and have similar intercellular adherence to 
lymphocytes that are proliferating in response to antigens, mitogens, or interleukin IL-4 
and anti-CD40 (Aman et al., 1986; Hurley and Thorley-Lawson, 1988; Alfieri et al., 
1981; Banchereau et al., 1991).
Table 3: Patterns of EBV latent gene expression
(Adapted from IARC Monograph, 1997)
Type of latency Gene product
I EBERs, EBNA-1
Examples
Burkitt’s Lymphoma 
Gastric Carcinoma
II EBERs, EBNA-1,LMP-1, Hodgkin’s Disease
-2A, -2B, BARFO Nasopharyngeal
carcinoma
III EBERs, EBNA-1,-2, -3 A, Post-transplant lympho-
-3B, -3C, -LP, LMP-1, 
-2A, -2B
proliferative disorder 
Infectious mononucleosis
Other EBERs, EBNA-1, -2 Smooth-muscle tumours
1.3.2.2 EBER1 and 2
The most common viral RNAs in latently infected cells are EBER1 and EBER2, with an 
estimated 107 copies per cell (Howe and Steitz, 1986). Most EBERs are located in the
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nucleus and are associated at the 3’ terminus with the cellular La antigen and other 
cellular proteins (Howe and Shu, 1989) A number of functions have been proposed for 
the EBERs based on their sequence similarity to adenovirus VAI and VAII and cell U6 
small RNAs (Ghckman et a l , 1988), however, their function has not yet been elucidated
1.3.2.3 EBV Nuclear Antigen (EBNA)
Transcription of the latency IEBNA1 mRNAs begins at the Qp promoter (Nonkwelo et 
a l , 1997) Transcription of nuclear proteins is initiated at the Cp and Wp promoters in 
the BamHl C and BamHl W regions, by polymerase II (reviewed by Rogers et a l ,
1992), the Fp promoter is a lytic promoter (Nonkwelo et a l , 1995 and 1996) In cells 
that express latency I or II phenotype, the Cp and Wp promoters are extensively 
methylated and are non-functional (Emberg et a l , 1989, Schaefer et a l , 1987) EBNA- 
LP and EBNA2 are the first viral proteins expressed in infected B lymphocytes, they are 
detected 12 hr after infection and within 24-32 hr of infection reach the levels maintained 
in transformed lymphoblastoid cell lines (Alfien et a l , 1991) It is thought that EBNA- 
LP may indirectly or directly up-regulate the expression of autocrine factors required for 
B cell growth, EBNA-LP and EBNA2 co-operate in the induction of GO to G1 
transition, indicated by induction of cyclin D2, but this mechanism is still unknown 
(Sinclair et a l , 1994)
1.3.2.4 EBNA2
EBNA2 differs significantly between the type 1 and type 2 EBV isolates, and it is these 
differences that enable the type 1 strain to transform B lymphocytes more efficiently in 
vitro (Rickinson et a l , 1987) EBNA2 is a specific /ram-activator of cellular genes, such 
as the B cell activation markers CD23 and CD21, and the c-fge oncogene, and viral 
genes including LMP1 and LMP2, and the c/5-acting element upstream of the Cp 
promoter (Wang et a l , 1987, 1990, 1990a, 1991, Knutson, 1990, Abbot et a l , 1990, 
Ghosh and Kieff, 1990, Tsang et a l , 1991, Fahraeus et a l , 1993, Sung et a l , 1991, 
Walls and Pemcaudet, 1991, Sjolblom et a l , 1995a) The EBNA2-responsive elements 
have been partially defined by deletion analysis of EBV promoter constructs or by 
positioning near a heterologous promoter (Laux et a l , 1994) Certain sequences within
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EBNA2 have been found to be essential for transformation and others are important for 
promoter frvms-activating activity (Cohen et a l, 1991) (See figure 3). EBNA2 does not 
interact directly with it’s responsive elements, the recombination signal sequence binding 
protein RBP-Jk, a widely expressed and highly conserved protein acts as a key adapter 
for transcription regulatory factors of cellular genes (Grossman et a l, 1994).
EBNA2
59 100 483
426 462
200 234 463 483
243 379 462
310 336
426-462 Transcriptional activation
200-234 and 463-483 Region not required for nuclear immortalisation
1-243 and 379-462 Region not required for nuclear localisation
310-336 Binding to RBP-Jk
Figure 3: Schematic representation of EBNA 2.
1.3.2.5 EBNA3A, 3B and 3C
EBNA3A, 3B, and 3C are encoded by three genes placed tandemly in the EBV genome, 
the proteins encoded by type 1 and type 2 EBV strains are only 84, 80 and 72% identical 
in the predicted primary amino acid sequence (Sample et a l, 1990). These proteins are 
located in large nuclear clumps in the nuclear matrix, chromatin and nucleoplasmic 
fractions but not in the nucleolus (Petti et a l, 1990). All three proteins can inhibit 
EBNA2-activated transcription, probably by their ability to bind RBP-Jk (Robertson et 
a l, 1995 and 1996; Krauer et a l, 1996). EBNA3C up-regulates the expression of CD21 
(EBV receptor) mRNA in transfected Burkitt’s lymphoma cells and the expression of 
LMP1 in Raji cells (Wang et al., 1990; Allday et al., 1993; Allday and Farrell, 1994). 
EBNA3B up-regulates vimentin and CD40 (involved in cell signal transduction) and 
down-regulates CD77 (involved in apoptosis) expression (Silins and Sculley,1994).
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1.3.2.6 EBNA1
The Epstein-Barr virus nuclear antigen 1 (EBNA1) is a 72kDa multifunctional protein 
which is a major component of the EBNA complex It has been shown that EBNA1 is 
encoded by the BKRF1 open reading frame in the BamK fragment (Hennessy and Kieff, 
1983, Dillner et a l , 1984) The EBNA1 protein from the B95-8 strain of EBV consists 
of 641 amino acids and can be divided into three domains It has a short N-terminal 
sequence of 89 amino acids that is rich in basic amino acids, followed by a 239 amino 
acid glycine-alamne copolymer, flanked by basic arginme-nch sequences followed by a 
highly charged acidic carboxy-terminal sequence (See figure 4) The glycine-alamne 
copolymer is highly antigenic (Dillner and Kallin, 1988) and similar repeat structures 
have been found in several proteins including Plasmodium falciparum  proteins (Berzins 
et a l , 1986) and eukaryotic RNA polymerase II (Corden et a l , 1985) During latent 
infection of human host cells, EBV genomes are maintained as double-stranded DNA 
episomes that replicate once every cell cycle (Adams, 1987, Yates and Guan, 1991) 
EBNA1 functions in conjunction with host replication factors and is the only viral protein 
essential for the replication of the EBV plasmids EBNA1 dimers interact with the 
genetically defined latent origin of replication, onP  (origin of plasmid replication) 
binding to multiple copies of it’s 18-bp recognition sequence (Rawlins et a l , 1985, 
Reisman et a l , 1985) Binding of EBNA1 to the tandem repeats and dyad symmetry 
sites of oriP enables covalently closed circular DNA molecules to replicate and persist as 
episomes The tandem repeat component acts as an EBNA1-dependent enhancer on 
heterologous or neighbouring promoters in transient transfection assays (Reisman and 
Sugden, 1986), the dyad symmetry component is stringently required for episome 
replication The interaction of EBNA1 with both sites is co-operative and results in 
higher-order structures that lead to bending of the DNA, distortion of the duplex and 
looping out of the intervening sequences (Frappier and O’Donnell, 1991 and 1992, 
Orlowski and Miller, 1991) The C-terminal unique domain cames sequence-specific 
DNA-binding, dimensation and transactivation activities (Ambinder, et a l , 1991) The 
ammo terminal of the dimensation domain is important for the formation of 
macromolecular complexes of EBNA 1-homopolymers after association with the DNA 
templates (Goldsmith et a l , 1993), the amino acids 379 - 387 (see figure 4 below) of 
EBNA1 determines it’s nuclear location by interacting with a specific protein that is
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homogeneously distributed on chromosomes (Ohno et a l, 1977; Harris et a l, 1985; 
Petti et a l, 1990). Part of EBNA1 is also associated with the nuclear matrix.
EBNA 1
98 327 641
459 607
4 5 ^ ^ ^ ^ ^ T o4
42 76 450 641
379 387
459-607 Dimérisation
450-604 DNA binding
42-76 and 450-641 Transcriptional activation
379-387 Nuclear localisation
Figure 4: Schematic representation of EBNA 1.
Several reports have shown that EBNA1 is not only involved in viral replication but may 
also play a significant role in the pathogenesis of EBV-related lymphomas (Magrath et 
a l ,  1993 ; Wilson and Levine, 1992). Strong EBNA1 expression has been found in B- 
cell lymphomas (Oudejans et a l ,  1996), this observation supports the opinion that in 
these lymphomas the occurrence of translocations can be facilitated by EBNA 1-induced 
expression of RAG1/2 (Srinivas and Sixbey, 1995), these are V(D)J recombinase 
activating genes. This may explain why EBV-positive AIDS patients with lymphomas 
have a worse prognosis than patients with the EBV-negative variant (Kaplan et a l ,
1995). Differences in the level of expression of EBNA1 in all types of tissue harbouring 
EBV is most likely due to differential EBNA1 promoter usage (Oudejans et a l ,  1996).
Regulation of EBNA1 transcription is complex, in EBV transformed lymphoblastoid cell 
lines and in post-transplant B cell lymphomas EBNA1 and other EBNA mRNAs are 
derived from highly spliced transcripts that are generated by either the C or W 
promoters, located on the BamHI C and W fragments respectively (Middleton et a l ,
15
1991) (See figure 1). In other EBV associated malignancies (eg BL, Hodgkin’s disease, 
T cell lymphomas and NPC) there is selective expression of EBNA1 without the 
expression of the other EBNAs. This occurs as a result of the activation of a different 
EBNA1 promoter, Q, located on the BamHI Q fragment. In lytic infection EBNA1 
transcription is controlled by the BamHI F promoter upstream of the Q promoter (Lear 
et al., 1992; Schaefer et al., 1995), EBNA1 is the only EBNA that continues to be made 
during lytic infection.
EBNA1 fails to be processed and presented in conjunction with major histocompatability 
complex class I on the surface of tumour cells (Levitskaya et al., 1995), this finding is 
consistent with the inability of virus-specific cytotoxic T lymphocytes (CTLs) to 
recognise Burkitt’s Lymphoma tumour cells (Rooney et al., 1985). This means that EBV 
can persist in normal and malignant cells in vivo without being attacked by the immune 
system, this ability is thought to be conferred by the glycine-alanine co-polymer domain 
of the EBNA1 protein. However, a previous study has shown that EBNA1 includes 
sequences which can be recognised by both polyclonal and clonal CTLs (Khanna et al.,
1995). EBNA1 protein from EBV-infected cells may be exogenously endocytosed by 
professional antigen-processing cells and presented in association with MHC class II 
molecules, or epitopes generated by serum protease cleavage may be responsible for the 
activation of CTLs. EBV-infected cells other than B cells could also be involved in the 
activation of CTLs in vivo.
1.3.2.7 LM P1
LMP1 mRNA is the second most abundant viral transcript in latently infected cells 
(Fennewald et al., 1984; Sample and Kieff, 1990). LMP1 is an integral membrane protein 
with a 20-amino acid hydrophilic amino terminus, six hydrophobic alpha helical 
transmembrane segments and a 200-amino acid carboxy terminus. After phophorylation, 
LMP1 is cleaved near the beginning of the carboxy-terminal domain, this results in a 
soluble 25 kDa product (Moorthy and Thorley-Lawson, 1990 and 1993). Like EBNA1, 
LMP1 is transcribed during lytic infection and can be induced by treatment with 
activators of protein kinase C (Rowe et al., 1987a; Laux et al., 1988). LMP1 alters the 
growth of EBV-negative B lymphocytes and induces many of the changes that are 
normally associated with EBV infection, these include, cell clumping, increased numbers
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of villous projections and vimentin expression, increased surface expression of CD23, 
CD39, CD40, CD44, MHC class II and the cell adhesion molecules LFA-1, ICAM-1 and 
LFA-3, and decreased expression of CD10 (Wang et a l, 19881; Birkenbach et a l, 1989; 
Wang et al., 1990, Liebowitz et a l, 1992; Peng and Lundgren, 1992; Zhang et a l, 1994, 
Kieff 1996). Also LMP1 can up-regulate certain cytokines with B cell promoting 
activity, such as IL-10 (Nakagomi et a l, 1994), and can protect B cells from apoptosis 
by inducing bcl-2 expression and possibly A20 also (Rowe et a l, 1994; Henderson et a l, 
1991; Martin et a l, 1993; Fries et a l, 1996). It has also been shown that LMP1 alters 
the growth of multipotent haematpoietic stem cells and epithelial cells (Dawson et a l, 
1990; Fahraeus et a l, 1990; Hu et a l, 1993). EBV recombinants lacking LMP1 are 
unable to induce growth transformation of primary B cells (Kaye et a l, 1993). It seems 
the mechanism by which LMP1 induces growth transformation involves interaction with 
cellular proteins that are mediators of cytoplasmic signalling from the family of tumour 
necrosis factor receptors and thereby induce constitutive activation of the growth, death 
and necrosis factor-KB signalling pathways of those receptors (Hammarskjöld and 
Simurda, 1992).
1.3.2.8 LMP2A and 2B
LMP2A and 2B are encoded by spliced mRNAs transcribed from the circularised EBV 
genome across the terminal repeats (Laux et a l, 1988), the promoters for LMP1 and 2B 
form a bi-directional transcription unit containing a common EBNA2 response element, 
while LMP2A transcription is regulated by a separate EBNA2 response element 
(Zimber-Strobl et a l, 1993). LMP2 co-localises with LMP1 in the plasma membrane of 
latently EBV-infected B cells (Longnecker and Kieff, 1990; Longnecker et a l, 1991).
1.3.2.9 BARFO
In nasopharyngeal carcinoma EBV gene expression includes abundant rightward 
transcription of the BamHI A fragment, consisting of mRNAs ranging in size from 
approximately 4.0-8.0 kb. BamHI A transcription is detected at a lower level of 
expression in EBV-infected lymphoid cells, however, these transcripts have consistently 
been detected in a wide range of EBV-infected samples, including Burkitt’s lymphoma, 
parotid carcinoma biopsy samples, type I and type III Burkitt’s lymphoma lines and type 
III lymphoblastoid cell lines (LCLs). The transcripts found include several distinctly
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spliced forms which are 3’-end coterminal and contain the BARFO open reading frame in 
the final exon The 5’-end analysis has confirmed the presence of a previously reported 
start site and also identified a subset of transcripts of 4 8 kb and larger that initiate 
further 5’ to this site Also 3’-end analysis identified heterogeneous 3’-end processing in 
all of the BamHI A mRNAs, resulting in transcripts that either contain the entire BARFO 
ORF or are cleaved and polyadenylated 5’ to this site (Sadler and Raab-Traub, 1995) 
The BARFO ORF has been translated in vitro and is immunoprecipitable with sera from 
patients with NPC, this is suggestive of it’s expression in vivo (Gilligan et a l , 1991) 
There has also been suggestion that these transcripts may function in the maintenance of 
latency by an antisense regulation of the replicative genes encoded by the opposite strand 
(Hitt e ta l ,  1989)
In a previous study a peptide corresponding to a region of the putative BARFO protein 
was synthesised and used to produce a BARFO-antiserum This serum was shown to 
react with 30- and 35-kDa proteins in EBV-positive cell lines and in EBV-positive 
tumour biopsies (Fries et a l , 1997), one of these proteins is known as RK-BARFO This 
data indicates that one of the nghtward RNA transcripts from the BamHI A region of 
EBV encodes a protein that is expressed in both latent infection and EBV-mfected 
tumours in vivo It has been shown that the BamHI A region of the EBV genome is not 
necessary for transformation of lymphocytes by the virus (Robertson et a l , 1994), 
however it has been detected in two strictly latent LCLs and in neonatal lymphocytes 
early after infection, suggesting-that it functions during latency It is possible that RK- 
BARFO may be involved in latent infection of epithelial cells, presently this cannot be 
assessed in vitro
The transcription of the BamHI A region is significantly higher in NPC than in BL or 
LCLs, this protein has been consistently detected in NPC, which represents latently 
infected epithelial cells, but not in Oral hairy leukoplakia (OHL), a permissively infected 
epithelial cell lesion This supports the suggestion that RK-BARFO is required m latent 
epithelial infection but not in viral replication It does not appear to restrict viral 
replication as there is an increase in the level of RK-BARFO in Akata cells following 
induction of replication However, it’s absence in OHL lesions suggests that it’s function 
may be restricted to viral replication in B cells The RK-BARFO protein was detected in
18
a group 1 BL cell line (Mutu I) and in a BL biopsy, it was thought that EBNA1 was the 
only viral protein expressed in BL cells. It has been suggested that RK-BARFO interferes 
with proteolytic processing and presentation by class I molecules, allowing expression of 
immunogenic proteins, such as EBNA1, without immune recognition. Identification of 
the intracellular location of this protein and interacting cellular proteins will help 
determine the molecular properties of RK-BARFO. It has been shown that the BARFO- 
encoded protein contains a CTL epitope and that BARFO-specific CTL lines could lyse 
EBV-negative BL cells stably transfected with the BARFO gene (Kienzle et al., 1998). 
As high levels of BARFO RNA and protein expression have been observed in NPC, this 
suggests that BARFO-specific CTLs might be of immunotherapeutic value for the 
treatment of this malignancy. As the levels BARFO RNA and protein expression are 
lower in BL cells and LCLs, this may be a contributary factor in the escape of immune 
recognition from virus-specific CTLs present in the host.
1.3.3 EBV Lytic Infection
Some B lymphocytes spontaneously become permissive for viral replication, in these 
cells the viral DNA is amplified several hundred-fold by a lytic origin of DNA replication, 
oriLyt (Hammerschmidt and Sugden, 1988). Cells that have become permissive for viral 
replication undergo cytoplasmic changes including, margination of nuclear chromatin, 
synthesis of viral DNA, assembly of nucleocapsids, envelopment of the virus by budding 
through the inner nuclear membrane and inhibition of host macromolecular synthesis 
(Gergely et al., 1971), these changes are typical of herpesviruses.
The expression of viral genes associated with productive infection follows a temporal 
and sequential order. Some viral genes are expressed early after induction, independently 
of new protein synthesis, these are classified as immediate early genes. Early lytic genes 
are expressed slightly later, and their expression is not affected by inhibition of viral 
DNA synthesis, expression of the late genes is blocked by inhibitors of viral DNA 
synthesis (IARC Monographs, 1997). From in vitro models, it has been shown that all 
three forms of latency can switch directly into the lytic cycle following activation with 
phorbol esters, by cross-linking with surface IgM or treatment with calcium inophore 
(Luka et al., 1979; Takada and Ono, 1989).
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Virus replication can be induced by superinfection of cell lines such as Raji, with virus 
from a latent antigen-defective cell line (P3HR-1) that complements Raji’s defect m 
replicative gene expression (Biggin et a l , 1987) Studies with such cell lines has allowed 
the division of replicative proteins into the early antigen (EA), membrane antigen (MA), 
and virus capsid antigen (VCA) complexes The EA is divided into restricted (EA-R) and 
diffuse (EA-D) components (Henle e t a l , 1971 and 1971a) Serum antibodies to the EA- 
D component were found to be of prognostic value for patients suffering from infectious 
mononucleosis or nasopharyngeal carcinoma, while serum antibodies to the EA-R 
component were of apparent prognostic importance in cases of African Burkitt’s 
lymphoma (Lennette, 1991) The BMRF1 ORF encodes an accessory protem which is a 
major component of the EA-D complex and is the major early phosphoprotem induced 
during EBV infection (Epstein, 1984 , Pearson et a l , 1983) The in vitro activity of the 
EBV DNA polymerase is dependent on the functional interaction between the catalytic 
subunit (BALF5 product) and the accessory subunit (BMRF1 product) (Kiehl and 
Dorsky, 1991, Li et a l , 1987, Tsurami et a l , 1993 and 1993a) The genes for both 
components are required for in vivo replication of the viral lytic origin of replication, 
onLyt, but not for orzP, which is responsible for the maintenance of latency (Fixman et 
a l ,  1992) (Kiehl and Dorsky, 1995)
Most strains of EBV contain two copies of onLyt, one copy is sufficient for replication 
(Hammerschmidt and Sugden, 1988) OnLyt overlaps the divergent promoters of the 
BHRF1 and BHLF1 genes The BMRF1 gene product transactivates the early BHLF1 
promoter but does not affect the BHRF1 promoter (Zhang ^  a l , 1996) Combined with 
the activity of the BZLF1 gene product maximum activation is achieved The BMRF1- 
response element in oriLyi has been precisely mapped to the essential downstream 
component (Zhang et a l , 1997) The upstream component of the onLyt is 
transcriptionally activated by BZLF1 Both the BMRF1 and BZLF1 gene products co- 
locahse within the intranuclear replication compartments during lytic infection (Takagi et 
a l , 1991) and can physically and functionally mteract (Zhang et a l , 1996) If BMRF1 is 
bound to the downstream element by interaction with a cellular transcription factor, 
direct action between BMRF1 and BZLF1 could result m looping of oriLyt 
Alternatively, BMRF1-induced transcriptional activation of the onLyt downstream
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component could be required for opening the chromatin during the onset of replication 
(Zhang et a l , 1997) However, the exact mechanism by which BMRF1 transcriptionally 
activates onLyt is as yet unknown
1.3.3.1 Immediate Early Genes
Three leftward mRNAs are transcribed after P3HR-1 supennfection of Raji or surface Ig 
cross-linking of Akata cells in the presence of protein synthesis inhibitors The BZLF1, 
BRLF1 and BI'LF4-encoded protems are potent transactivators of early EBV gene 
expression (Takada and Ono, 1989, Marschall et a l , 1991, KiefF, 1996) Two early 
promoter regulatory elements with left and right duplications that include the origins of 
lytic viral DNA replication are co-ordinately up-regulated by BZLF1 and BRLF1 
(Hudewentz et a l , 1982, Hummel and Kieff, 1982, Freese et a l , 1983, Nuebling and 
Mueler-Lantzsch, 1991) The R protein is a DNA sequence-specific acidic trans- 
activator that has distant homology to c-myb (Gruffat and Sergeant, 1994, Kieff, 1996) 
The Z (ZEBRA) protein is spliced and consists of three exons which have different 
functions The first 167 amino acids make up the ira/w-activating domain (Taylor et a l , 
1991, Chi and Carey, 1993), the second exon confers the ability to interact with AP1-
related sites m DNA and also targets Z to the nucleus (Mikaehan et a l , 1993) The third
exon is required for interaction of Z with p53 (Zhang et a l , 1994a)
1.3.3.2 Early Genes
The early genes are expressed when the lytic cycle is induced in the presence of DNA 
synthesis inhibitors, several of these genes are linked to DNA replication These include 
DNA polymerase (BALF5), the major DNA-binding protein (BALF2), ribonucleotide 
reductase (BORF2 and BARF1), thymidine kinase (BXLF1) and alkaline exonuclease 
(BGLF5), which are distributed through the unique long domain of EBV DNA (Kieff, 
1996) The BALF2 and BHRF1 gene products are two very abundant early protems 
BHRF1 mRNA has been identified in strictly latently infected cells, however, the protein 
it encodes can only be found in cells in early lytic infection (Austin et a l , 1988, Alfien et 
a l , 1991) The BHRF1 protein is expressed in moderate abundance, has extensive 
collinear homology with bcl-2 (Pearson et a l , 1983, Austm et a l , 1988), and can protect
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EBV-negative Burkitt’s lymphoma cells from apoptosis (McCarthy et al., 1996). 
However, EBV recombinants lacking the BHRF1 ORF are capable of initiating and 
maintaining cell growth transformation and can also enter the lytic cycle and produce 
virus (Lee and Yates, 1992; Marchini et a l, 1991).
1.3.3.3 Late Genes
The late genes code for structural glycoproteins or proteins that modify the infected cells 
in order to permit viral envelopment or egress. Of the non-glycoproteins, the major 
nucleocapsid protein is probably encoded by BcLFl, BNRF1 encodes the major external 
non-glycoprotein of the virion, and BXRF1 is likely to encode a basic core protein 
(Kieff, 1996). The BFRF3 ORF encodes a highly basic viral structural capsid protein, 
pi 8 VC A, which is strongly immunogenic in humans (van Grunsven et al., 1994), this 
will be discussed later in further detail. It does not appear to have any sequence 
homologues among other herpesviruses. The known EBV glycoprotein genes are BLLF1 
(gp350/220), BALF4 (gpllO), BXLF2 (gp85), BILF2 (gp55/80), BDLF3 (gpl00-150) 
and BZLF2 (gp42) (Kieff, 1996). The membrane antigen complex is involved in 
mediating virus binding to the B lymphocyte receptor CR2 (Nemerow et al., 1985; 
Tanner et al., 1987) and consists of at least four major EBV-induced glycoproteins, 
gp350/220, gp250/200, gp85, and gp78/55 (Mackett et al., 1990). Gp85 is a relatively 
minor viral protein which is important in fusion between the virus and cell membranes 
(Miller and Hutt-Fletcher, 1988), gp85 and gp3 50/220 are processed through the Golgi 
apparatus and are found on the virus and in the plasma membrane of lytically infected 
cells (Gong and Kieff, 1990; Kieff, 1996). The membrane antigen (MA) glycoprotein is 
encoded by nucleotides 1784-4504 of the BamHI L fragment of the EBV genome 
(Zhang et al., 1991). gp350 is a 907 amino acid protein with 37 putative N-glycosylation 
sites. Both gp350 and gp220 are derived from a single gene by splicing, without a change 
in reading frame (Beisel et al., 1985). The carbohydrate moiety of gp350 was found to 
be made up of both O-linked and N-linked types and to constitute about 50% of the 
molecular mass. The high carbohydrate content of gp350 appears to confer resistance to 
proteolysis (Morgan et al., 1984). The MA is a component of the virus envelope 
(Pearson et al., 1971), and neutralising determinants are included in gp350/220, 
gp250/200, and gp85 (Hoffman et al., 1980; Qualtiere et al., 1982; Stmad et al., 1982).
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The viral capsid antigen is abundantly expressed in cell lines undergoing productive 
infection, and has polypeptide and glycoprotein components ranging in size from 18 to 
200kDa, with a 143-kDa polpeptide (BNRF1 reading frame) (Thorley-Lawson 1982) 
being the major component It may be composed of at least seven proteins (Dillner and 
Kallin 1988), of which the capsid protein encoded by ORF BcLFl(Vroman et a l , 1985) 
and a 36 kDa protein encoded by BGLF2 (Chen et a l , 1991, Seibl and Wolf, 1985) have 
been described in detail Another VCA protein, gpllO, is encoded within the BALF4 
ORF (Takada et a l , 1982) and is one of the most abundant late EBV glycoproteins, 
which is localised to the inner and outer nuclear membrane and to the cytoplasmic 
membranes frequently surrounding enveloped virus (Emirn et a l , 1987, Gong et a l , 
1987, Gong and KiefF, 1990)
Two immunologically dominant VCA proteins with molecular sizes of 18 and 40 kDa 
have recently been identified (van Grunsven et a l , 1993a) Both of these proteins are 
structurally associated with the viral capsid and are recognised by antibodies from almost 
all EBV carriers Sera from most IM patients already contain detectable levels of IgG to 
pi 8 and p40 at early stages of disease, which increase rapidly in titre and remain constant 
following recovery (van Grunsven et a l , 1993) The serological profile against EBV- 
VCA proteins has proved to be useful in the differential diagnosis of EBV-related 
diseases (Ooka et a l , 1991), such as IgA for diagnosis of NPC and elevated IgG titres in 
BL (Desgranges and De The, 1987), oral hairy leukoplakia (Greenspan et a l , 1985), and 
Hodgkin disease (Mueller et a l , 1989) The VCA antigens are gene products whose 
synthesis is blocked by inhibitors of the viral DNA replication Only part of these VCA- 
class antigens may form structural components of the EBV vinon, the major VCA 
antigen components p i8 and p40 belong to this class of structural VCA antigens (van 
Grunsven et a l , 1993a)
The late BCRF1 gene is located in the middle of the EBNA regulatory domain between 
oriP and the Cp, and the protein it encodes has almost 90% collmear identity in amino- 
acid sequence with human IL-10 (Moore et a l , 1990, Vieira et a l , 1991, Touitou et a l ,
1996) BCRF1 also has most of the activities of human IL-10 including negative 
regulation of macrophage and NK cell functions and inhibition of IFN y production
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Therefore, virally expressed IL-10 may have a local effect on these responses to 
reactivated infection.
1.4 EBV and Disease
1.4.1 Self-limiting Disease - Infectious Mononucleosis
The classical clinical syndrome associated with primary EBV infection is infectious 
mononucleosis (IM), commonly known as glandular fever, which is a benign self-limiting 
disease. In most cases the disease runs it’s course within a few weeks. Primary infection 
during early childhood appears to result in mild or no clinically detected symptoms 
(Henle and Henle, 1970). In contrast, infection during or after adolescence can give rise 
to IM in up to half of the infected individuals (Henle and Henle, 1979). Hormonal 
changes and maturation of the immune response are thought to be possible reasons for 
this maturation-related incidence of disease. There is a 30-50 day incubation period, 
followed by a 3-5 day period where mild symptoms are experienced, these include 
headache, malaise and fatigue. In more than 80% of cases a sore throat will occur during 
the first week. Fever with temperatures reaching 39.5°C or higher lasts for about 10 days 
and then falls gradually over an additional 7-10 days. Patients gradually develop 
generalised lymphadenopathy. Splenomegaly is observed in about 50% of patients in the 
second and third weeks. Hepatosplenomegaly, rash and several central nervous system 
syndromes may also occur. Fatal mononucleosis usually occurs in individuals with an 
underlying genetic defect, such as X-linked lymphoproliferative syndrome (Miller, 1990). 
Patients with this disorder suffer from an immune defect that makes them sensitive to 
EBV-induced diseases, most infected men die by the age of 40 (Purtilo, 1991). Patients 
with XPL may develop Burkitt’s lymphoma carrying c-myc translocations (Purtilo, 
1991).
Infectious mononuleosis represents a benign, lymphproliferative disorder with prominent 
expansion of the paracortex of lymphoid tissues by numerous activated B blasts. 
Morphological, molecular and tissue culture studies have shown the proliferation of 
EBV-infected polyclonal blasts, accompanied by the growth of activated T cells 
(Svedmyr and Jondal, 1975; Tosato et al., 1979; Syedmyr et al., 1984; Brown et al.,
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1986; Niedobitek et al., 1992; Anagnostopoulos et al., 1995; Callan et al., 1996; 
Niedobitek et al., 1997). Infected cells are largely B cells which often undergo plasma­
cell differentiation (Anagnostopoulos et al., 1995; Niedobitek et al., 1997). During acute 
infection up to 80% of EBNA-positive cells in peripheral blood may express cytoplasmic 
immunoglobulins (Robinson et al., 1981).
The acute phase of virus infection is characterised by a well-defined serological pattern. 
There is the absence of antibodies to EBNA and the presence of IgM antibodies to 
structural components of the virion, anti-VCA (viral capsid antigen) and anti-MA (anti­
membrane or envelope antigen). Antibodies to early components of the viral replication 
cycle, early antigens (EA) are also readily detected (Henle and Henle, 1979). IgM 
antibodies to VCA evolve quickly with infection, persist for weeks to months, and do not 
reappear. Their detection is presumptive evidence of recent primary infection. (See 
section 1.5 below). Antibodies to EA of the diffuse or restricted types develop in most 
primary infections and wane with time. (Horowitz et al., 1985).
Infectious mononucleosis follows a type III EBV latency pattern of gene expression, 
however a small number of cells also express lytic cycle antigens, such as BZLF1 and 
EA. Plasma cells may sustain full replication of EBV and may represent a cellular source 
of infectious virus in the saliva of patients with IM (IARC Monographs, 1997).
Infectious mononucleosis is a self-limited disease, with few exceptions, however, a 
number of complications may develop depending on the immunopathologic responses to 
the virus. Severe autoimmune haemolysis, airway obstruction from grossly enlarged 
tonsils, splenic rupture, and encephalitis have been observed in otherwise healthy 
patients. Agranulocytosis, aplastic anaemia, and other rare features of acute progressive 
EBV infection can arise in healthy patients. These symptoms indicate a deficiency in 
cellular immunity in the patient (Straus, 1992). Several central nervous system 
syndromes have been described in association with EM. These include asceptic 
meningitis, encephalitis, acute psychosis, coma transverse myelitis, acute cerebellar 
syndrome, and infectious polyneuritis (Grose et al., 1975). This may be partly due to
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invasion and proliferation of EBV-infecting B cells into the central nervous system, 
lymphoid cells harbouring EBV and EBV-specific antibodies have been found in 
cerebrospinal fluid (Schiff et a l., 1982).
Chronic infectious mononucleosis is a rare, heterogeneous, and poorly understood 
syndrome that arises in previously well men and women (Schooley et al., 1986; Straus,
1988). Reactive adenopathy and hepatosplenomegaly, uveitis, pneumonitis and 
polyneuropathy are characteristic of this syndrome. Progressive cellular and humoral 
immune deficiencies evolve in the course of follow-up, it is therefore impossible to 
determine if active infection causes the impairment of the immune system or if the 
infection persists because of immune deficiency (Straus, 1992a). A number of patients 
with this syndrome have been studied, their illnesses lasted two to fourteen years and 
three died during the study period. There exists a second form of chronic IM which is 
less severe, it is often referred to as chronic fatigue syndrome, and is far more common. 
Some patients have elevations of antibody titres to EAs and a few lack antibody to 
EBNA1, however the link with EBV infection has not been confirmed (Straus, 1988). 
The symptoms include fatigue, chronic pharyngitis, tender lymph nodes, headaches, 
myalgia and arthralgias, the symptoms are recurrent and prolonged (Miller, 1990). 
Chronic fatigue syndrome (CFS) may arise in individuals in the absence of an EBV 
infection, it may be due to another herpesvirus or as in many cases there is no virus 
detected. This indicates that EBV is not the causative agent of CFS, but may contribute 
to it’s development in some cases.
1.4.2 Malignant Disease
1.4.2.1 Burkitt’s Lymphoma
Burkitt’s lymphoma (BL) is the most common childhood cancer in certain parts of 
equatorial Africa and Papua New Guinea, with an annual incidence of more than 50 
cases per million children, below the age of sixteen. Burkitt’s lymphoma now accounts 
for 30-70% of childhood cancers in equatorial Africa. The high incidence of BL in these 
locations is associated with geographic and climatic features coincident with haloendemic 
malaria (Burkitt, 1983 and 1969; O’Connor 1970). Burkitt’s lymphoma is a poorly
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differentiated malignant lymphoma in which the tumour cells show little variation in size 
or shape. The tumour cells are monoclonal B lymphocytes and they contain characteristic 
chromosomal translocations (Manolov and Manalova, 1972 ; Manalova et al., 1979) 
(Rowe and Gregory, 1989). In the areas of Africa where BL is endemic, more than 90% 
of the tumours contain EBV DNA and express EBNA (Geser et al., 1983), the number 
of genome copies per cell has been found to range from 10 to 113 (Reedman et al., 
1974; Lindahl et al., 1974). However, in parts of the world where BL is sporadic 
(Western Europe and the Americas), only about 15-20% of BL tumours contain EBV 
DNA. In temperate regions in South America, such as Argentina and Chile, the rate of 
EBV association is lower than in tropical regions in the north of the continent, however, 
this may be accounted for by the differences in climate and socioeconomic 
circumstances. This difference in the presence of EBV DNA in tumours indicates that 
EBV is not essential for formation of the tumour, therefore, EBV may have no direct 
role in the pathogenesis of BL, but may simply increase the risk of development of BL by 
virtue of it’s ability to immortalise B cells (including the cell population that gives rise to 
Burkitt’s lymphoma) (Klein, 1979). This hypothesis is consistent with the lack of 
expression of EBV latent genes (e.g. EBNA2, EBNA3 and LMP) known to be necessary 
for the transformation of B cells (Alfieri et al., 1991; Woisetschlaeger et al., 1991). The 
only latent gene invariably expressed in Burkitt’s lymphoma, EBNA1, has never been 
shown to have transforming functions (Rowe et al., 1987, 1988 and 1992; Sample et al., 
1991; Schaefer et al., 1991). The sporadic BL presents at a slightly later age and 
frequently involves abdominal and lymphoid tissue but rarely involves the jaw, the high 
incidence BL frequently involves the jaw and the abdominal viscera but rarely lymphoid 
tissues. (Magrath et al., 1993). In series of cases of BL in Uganda, 70% of children 
under 5 years of age and 25% of patients over 14 had jaw involvement (Burkitt, 1970a).
Burkitt’s lymphoma is invariably of B cell origin, the presence of surface immunoglobulin 
(Ig), was first shown in 1967 (Klein et al., 1967). The surface Ig is usually IgM, but IgG 
and IgA are occasionally present. The surface antigens expressed are CD 10, CD 19, 
CD20, CD22, CD77 and CD79a (Harris et al., 1994). Burkitt’s Lymphoma cells also 
express low levels of HLA class I adhesion and activation molecules such as CD54, 
CD1 la/18 and CD58 (Masucci etal., 1987; Billaud et a l, 1989; Andersson etal., 1991).
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There are three known co-factors involved in the pathogenesis of high incidence BL, 
these are malaria, chromosome translocation and EBV There are a number of factors 
which suggest that malaria is a co-factor in the development of Burkitt’s lymphoma, 
these include, (a) The incidence of BL correlates within countries and internationally 
with the incidence of malaria and with parasitaemia rates, (b) The age at which peak 
levels of anti-malanal antibodies are acquired (5-8 yr) corresponds to the peak age 
incidence of BL, (c) Individuals m urban areas where malarial transmission rates are 
lower also have lower incidence of BL and (d) There is some evidence for a seasonal 
variation in the onset of BL and for time-space clustering, (Morrow, 1985) It is thought 
that malaria plays it’s part via immunosuppression, resulting m uncontrolled B-cell 
proliferation, which is partly due to EBV Chronic malaria leads to a shift in the helper T 
cell response towards Th2 cells (von der Weid and Langhome, 1993) Th2 cytokines, 
such as IL-10, suppress the humoral arm of the immune response, support the early steps 
of B cell immortalisation by EBV (Burdin et a l , 1993), and suppress CTL function 
Consequently, the number of B lymphocytes latently infected with EBV increases, while 
the ability of T cells to suppress the outgrowth of EBV-infected lymphoblastoid cells is 
impaired (Gunapala et a l , 1990, Moss et a l , 1983, Whittle et a l , 1984, Lam et a l , 
1991) Young children at greatest risk suffer multiple bouts of clinical malaria every year 
and during acute attacks their T-cell immunity to EBV infected B cells is significantly 
impaired (Moss et a l , 1983, Whittle et a l , 1984) It has been proposed that the 
increased frequency of B cell mitosis, arising from the combined effects of malaria and 
EBV infection, increases the chances of random chromosomal aberrations, including the 
specific translocations of BL (Klein, 1983 and 1987) The c-myc protooncogene is 
activated by the chromosomal translocation, this activation is a co-factor m the 
development of BL, shown in studies with transgenic mice Deregulated c-myc alone is 
thought to be insufficient to induce the fully malignant phenotype but it causes a 
prelymphomatous state where abnormal polyclonal proliferation and accumulation of B 
cells at a particular stage of differentiation occurs (Langdon et a l , 1986) The 
translocation is likely to occur at one of the points at which the Ig gene complex is 
genetically unstable, possibly at the pre-B stage during VDJ joining Geographical 
studies of the myc/lg chromosomal breakpoint locations have shown a different pattern 
in every region studied (Magrath et a l , 1993) This suggests that BL consists of several
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subtypes which occur in different proportions in different regions of the world, and that 
these subtypes are environmentally determined
Due to the down-regulation of EBV latent proteins BL cells have an advantage in 
escaping virus-specific immunosurveillance, yet can contribute to the oncogenic process 
All the latent genes may be expressed during the initial infection of the BL progenitor cell 
but are subsequently down-regulated as the growth transforming property of the virus is 
replaced by the activity of deregulated c-myc There is constant expression of EBNA1 
and of the EBERs, this implicates an essential role for these gene products m the 
maintenance of the malignant state of BL cells (Rowe and Gregory, 1989) It is thought 
that EBV may be essential m pathogenesis m some molecular varieties of BL but not 
others
Previous work has shown that endemic tumours, associated with EBV, have 
approximately 75% of tumours in which the breakpoint on chromosome 8 is distant from 
c-myc and this led to the investigation of the possibility that EBNA1 may collaborate 
with the myc/lg translocation in the pathogenesis of BL Specific antisense inhibition of 
EBNA1 m Raji cells has been shown to cause failure in proliferation and cell death, the 
growth inhibition was accompanied by a decrease m both c-myc and (i heavy cham 
expression Transfection of an EBV cell lme with EBNA1 caused increased transcription 
when also transiently transfected with an immunoglobulin enhancer and a part of c-myc 
Electophoresis mobility shift assays have shown that EBNA1 acts directly with a cellular 
protein rather than inducing expression of another gene (Magrath et a l , 1993) This 
evidence suggests that EBNA1 can participate in the deregulation of c-myc , when c-myc 
is juxtaposed to an immunoglobulin enhancer EBV infection of a large number of 
precursor B cells greatly increases the chance that a translocation and EBV infection will 
happen in the same cell, explaining why EBV infection at an early age is associated with 
a higher proportion of EBV-associated BL, and accounts for the risk of children with 
anti-VC A titres above the mean for their age group in Africa (Geser et a l , 1983) The 
combination of EBV and malaria further increases the risk HIV is another environmental 
factor which can influence the occurrence of BL, like malaria, there is evidence that HTV 
impairs cell-mediated immunity against EBV infected B cells (Birx et a l , 1986) HIV
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may contribute by inducing severe immune suppression, leading to a loss of EBV- 
specific T cell immunity, or by chronic stimulation of the B cell system (IARC 
Monographs, 1997).
1.4.2.2 Nasopharyngeal Carcinoma
The etiologic link between nasopharyngeal carcinoma (NPC) and EBV was first 
suggested based on serological evidence (Old et al., 1966). This association was 
subsequently confirmed by EBV nucleic acid hybridisation studies on NPC biopsy 
material and by demonstrating that EBV DNA was present in a majority of NPC tumours 
(zur Hausen et al., 1970; Nonoyama et al., 1973; Wolf et al., 1973; Klein et al., 1974). 
It has been shown by Southern blot hybridisation that EBV DNA in NPC biopsies is 
clonal, arising from a single EBV-infected cell (Raab-Traub and Flynn, 1986). EBV is 
present in the cell at the time of carcinogenic transformation, this suggests that the virus 
contributes to the transformation event. NPC is a rare malignancy in most parts of the 
world, however, it is highly prevalent among southern Chinese (Ho, 1972), this indicates 
that genetic or environmental factors may contribute to the development of NPC. 
Southern chínese are an ethnically distinct population and they may be related to Aluet 
indians, another high-risk group who are ethnically distinct. The Inuits and other natives 
of the Arctic region have high rates of NPC also (Albeck et al., 1992; Nutting et al., 
1993), as do many indigenous peoples of Southeast Asia, including Thais, Vietnamese, 
Malays and Filipinos (Parkin et a l, 1997).
In about half the cases of NPC the presenting sign is a cervical mass resulting from 
spread to regional lymph nodes. Other symptoms may include nasal obstruction, 
postnasal discharge or epistaxis and possibly impairment of hearing, tinnitus or otitis 
media. NPC may metastasise to the skeleton, the spine, the liver, lung and skin as well as 
to the peripheral lymph nodes (Miller, 1990), as a result of metastasis NPC is often 
identified only after dissemination.
EBV infection is an essential step in the progression to malignancy. The nasopharyngeal 
epithelium becomes infected early in life by EBV. BARFO, LMP-2, EBER and EBNA1
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are always expressed in NPC cells, while LMP1 is expressed in a variable proportion of 
tumour cells (Fahraeus et a l , 1988, Young et a l , 1988, Brooks et a l , 1992, Gilligan et 
a l , 1991, Sbih-Lammali et a l , 1996) LMP1 has strong growth stimulating effects in 
vitro and may have similar effects in the nasopharyngeal epithelium As the cells are 
stimulated to divide, EBNA1 ensures that the viral genome will replicate and be 
distributed to progeny cells The early genes BALF5, BZLF1, BMRF1, EA-D and BHRF 
(EA-R) are occasionally detected in a few cells, early protems such as ribonucleotide 
reductase, BZLF1, BMRF1 (EA-D) and BHRF1 (EA-R) can be detected with 
monoclonal antibodies (Luka et a l , 1988, Lung et a l , 1989, Cochet et a l , 1993) To 
reach full malignant potential the dividing nasopharyngeal cells may acquire cellular 
genetic alterations, the nsk for which may be increased by exposure to environmental 
carcinogens such as volatile mtrosamines in salted fish (Liebowitz, 1994)
Ingestion of Cantonese style salted fish, correlates with increased nsk for NPC (Ho, 
1978, Armstrong et a l , 1983, Yu et a l , 1986 and 1988) Carcinogenic volatile 
mtrosamines have been detected in Chinese salted fish, however, their precise role in 
inducing NPC has yet to be determined (Huang et a l , 1981) Studies suggest that age at 
exposure is an important co-determinant of nsk, earlier age at exposure being associated 
with higher nsk for disease (Armstrong et a l , 1983, Nmg et a l , 1990, Yu et a l , 1988, 
Zheng et a l , 1994) Fumes, smoke, dust, formaldehyde, tobacco, alcohol, herbal drugs, 
anti-mosquito coils and Chinese nasal oil are other environmental factors whose influence 
has been assessed m relation to the nsk of NPC development In general it appears that 
each of the above factors may significantly increase the nsk for NPC (Armstrong et a l , 
1983, Blair et a l , 1986, Zhu et a l , 1995, Vaughan et a l , 1996, Zheng et a l , 1994a, 
West et a l , 1993, Yu et a l , 1990) Early evidence for a genetic determinant among 
Chinese was an HLA-associated nsk for NPC (Simons et a l , 1974 and 1976) The 
presence of both A2 and BW46 antigens was associated with a twofold increased nsk for 
NPC among Chinese in Singapore, Malaysia, Hong Kong and Guangzhou (Simons et a l , 
1978, Chan, 1983a) Other HLAs have also been shown to be associated with NPC in 
selected populations Familial aggregation has been reported m diverse populations, 
ranging from high nsk populations such as the southern Chinese to low nsk Caucasians
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This phenomenon can be a result of shared genes, shared environments or both (IARC 
Monographs, 1997)
Early studies have shown that patients frequently possess elevated serum antibodies to 
two EBV lytic cycle antigen complexes, viral capsid antigen (VCA) and early antigen 
(EA) (Henle and Henle 1976, Ho et a l , 1976) Serum detection of these antibodies is a 
routine diagnostic test for NPC in South-east Asia (Yip et a l , 1996) It has been shown 
that the ZEBRA protein can be expressed occasionally in a subpopulation of NPC cells 
(Cochet et a l , 1993), and NPC patients also have serum antibody to ZEBRA (Joab et 
a l , 1991) It was found that detection of antibodies to early lytic antigens (ZEBRA and 
EA) could be of greater prognostic value than those to the late ones (VCA and MA) or 
latent antigens (LMP2, EBNA 1 and 2), and that IgG antibodies may be more prognostic 
than IgA antibodies (Yip et a l , 1996)
1.4.2.3 Hodgkin’s Disease
EBV association with Hodgkin’s disease (HD) was first suggested by serological studies, 
and subsequently analysis of tumour tissue extracts (Weiss et a l , 1987) Studies of over 
1000 patients over a 2 year period showed on average 50% positivity for EBV, by 
various techniques, in the Reed-Stemberg (RS) and Hodgkin cells (Joske and Knecht, 
1993) PCR has been used to detect EBV DNA in HD tissues, showing a high 
percentage of positive cases, however, it has been necessary to use in situ techniques to 
assess the significance of PCR positive results (Pallesen et a l , 1993) Viral replication is 
only seen occasionally in RS cells in HD cases, this shows that in most EBV-positive HD 
cases viral infection is strictly latent (Pallesen et a l , 1991) Type II EBV latency is 
detected in RS cells, they are EBER-positive, EBNA1-positive and LMP1-positive 
(Joske and Knecht, 1993) All cases showing EBER1 expression also demonstrate LMP1 
expression, this occurs only in a proportion of RS cells At the transcriptional level 
LMP1 expression is associated with a high viral burden, this suggests that expression of 
this oncogene is of biological significance (Joske et a l , 1992), however, LMP1 positivity 
does not affect prognosis (Vestlev et a l , 1992, Fellbaum et a l , 1992) It is thought that 
the RS cells have acquired the ability to tolerate high levels of LMP1, the levels
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measured are toxic to normal cells (Hammerschmidt et a l , 1989, Knecht et a l , 1993) 
Previous work has shown there may be geographical vanation in EBV positivity rates 
worldwide, similar to the situation with Burkitt’s lymphoma (Ambinder et a l , 1993, 
Chang et a l , 1993) Up to 50% of cases in western countries and up to 100% in some 
other populations carry the virus (Armstrong et a l , 1992, Wemreb et a l , 1996) Patients 
with IM have a fourfold increase in risk for developing Hodgkin’s disease (Munoz et a l , 
1978) Cases of HD arising in immunosuppressed individuals are almost invariably EBV- 
associated, and regression of EBV-positive cases of HD has been reported after 
restoration of the immune system (Berger and Delecluse, 1993) This provides further 
evidence for an etiological role for EBV in the pathogenesis of Hodgkin’s disease
Hodgkin’s disease has previously been classified as four major types, nodular lymphocyte 
predominant, nodular sclerosis, mixed cellulanty and lymphocyte depleted However, 
there is increasing evidence to suggest that HD is a heterogeneous group of diseases, this 
prompted inclusion of HD in the Revised European-Amencan Lymphoma (REAL) 
classification (Hams et a l , 1994) Hodgkin’s disease usually arises as a unifocal lesion in 
cervical lymph nodes followed by spread of the tumour to adjacent lymph nodes, giving 
rise to enlarged nodes The tumour spreads through the lymphatic channels and other 
organs can become involved, the preferential sites of involvement include the spleen and 
distant nodes As the disease becomes more aggressive other organs are involved, 
including the kidneys and liver (Kaplan, 1980) Much evidence suggests that the risk for 
HD in young adulthood through middle age is associated with higher education, higher 
social class, fewer siblings, less crowded housing and early birth rank These factors lead 
to susceptibility to late infections with the common childhood infections which tend to be 
more severe than those m younger children (IARC Monographs, 1997) Because HD in 
childhood occurs primarily in developing countries, the children at risk would appear to 
be of lower social class and thus are infected earlier by EBV
The role of EBV in Familial Hodgkin’s disease (FHD) has also been studied by Lin, et 
a l , 1996 As with sporadic HD the causes are unclear, HLA phenotype and disease 
susceptibility has been explored, however, this may account for only a fraction of cases 
Environmental factors may also be involved, these require further investigation FHD
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patients were found to have higher geometric mean antibody titres (GMTs) to the viral 
capsid antigen (VCA) and early antigen (EA-D), and 28% had EBER1 expressed in the 
RS cells However, lack of concordance of EBER1 expression and EBV serology m 
FHD cases in the same family suggest that EBV does not play an important role in FHD 
EBV could be important m a subset of FHD with a specific genetic predisposition that is 
not yet identified (Lin et a l , 1996)
1.4.2.4 AIDS-Related EBV Infection
Development of lymphomas is a common occurrence in patients carrying Human 
Immunodeficiency virus (HIV), being 60 times more common than the general 
population (Beral el a l , 1991) AIDS-related lymphomas (ARLs) may show EBV 
infection as do other immunodeficiency-associated lymphomas, suggesting a direct 
oncogenic effect of EBV infection in B cells, when physiological immune regulation and 
natural defence barriers have broken down Four kinds of EBV-positive lymphomas are 
seen in AIDS patients (Anonymous, 1991), these are B cell immunoblastic lymphoma, 
closely resembling PTLs, a small cell, or Burkitt-like lymphoma, primary central nervous 
system (CNS) lymphoma, and Hodgkin’s disease EBV gene expression in these 
lymphomas is the same as non-HIV-associated lesions Burkitt’s lymphoma is EBV- 
positive in 20% of cases (Beral el a l , 1991), and the immunoblastic lymphoma is EBV- 
positive in 50% of cases (Hamilton-Dutoit et a l , 1991) Studies using in situ 
hybridisation have shown that 100% of CNS lesions are EBV-positive, all of these being 
of B cell phenotype (DeAngelis et a l , 1992, Morgello 1992, MacMahon et a l , 1991) A 
number of case studies have shown that 88% of HIV-associated HD patients are EBV- 
positive (Uccim et a l , 1990, Moran et a l , 1992, Audouin et a l , 1992) There tends to 
be less lymphocytic infiltration in HIV-positive cases as compared to HIV-negative 
cases, this is thought to be due to the T-cell depletion and breakdown of cellular 
immunity (Pelstnng et a l , 1991) It has been shown that HIV-positive individuals with 
HD are more likely to have advanced and extra-nodal disease, not to respond to therapy, 
and to die of opportunistic infection than those with HD alone (Ames et a l , 1991, 
Knowles et a l , 1988)
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Most AIDS-related non-Hodgkm’s lymphomas appear to be monoclonal with respect to 
their antigen receptor genes and to the EBV episomes (Ballenm et a l , 1993, Delecluse 
et a l , 1993, Shibata et a l , 1993) However, rare cases may be polyclonal and thus 
resemble post-transplant lymphoproliferative disorder (Delecluse et a l , 1993) AIDS- 
related B-cell lymphomas consistently lack the HIV genome, therefore, a direct 
contribution of HIV to tumongenesis beyond suppression of the immune system is 
unlikely (Knowles, 1993) Disturbances in EBV-specific immunity are a pathogenic 
factor in the development of some EBV-associated, AIDS-related non-Hodgkin’s 
lymphomas As the central nervous system is less accessible for immunosurveillance it is 
particularly susceptible to the development of AIDS-associated lymphomas (MacMahon 
e ta l ,  1991)
The clinical, molecular and viral features of AIDS-related BL suggest a pathogenesis 
similar to that of sporadic BL The primary event appears to be chronic stimulation of the 
immune system, leading to polyclonal B cell hyperplasia, which may be initially dnven by 
HIV infection The low rate of EBV infection in these lymphomas suggests that the 
function of the virus could be substituted by other factors, which as yet remain 
unidentified (IARC Monographs, 1997)
Many AIDS patients develop oral hairy leukoplakia (OHL) tongue lesions, which 
contain a high level of EBV replication (Greenspan et a l , 1985) The lesion usually 
presents as a white patch that often appears corrugated or even hairy, most commonly on 
the lateral margin of the tongue Approximately 20% of otherwise asymptomatic HIV 
patients develop OHL, this increases as the immune status, CD4 cell count and clinical 
condition deteriorate (Greenspan et a l , 1995) A significant proportion of patients with 
OHL and without AIDS subsequently progress to AIDS fairly rapidly (Katz et a l , 1992) 
Oral hairy leukoplakia can be induced to regress by treatment with acyclovir, indicating 
that this lesion is caused by EBV infection (Resmck et a l , 1988)
A combination of Northern blotting and sequencing of clones from a cDNA library, 
constructed using RNA isolated from OHL, has been used to study EBV gene expression
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in this AIDS-associated lesion (Lau et a l , 1993) No expression of EBNA1, EBNA2 or 
EBNA3A RNA was detected on the OHL cDNA library BdRFl, BCRF1, gp350, and 
the BARFO ORF were selected for detailed study as these are genes expressed m the 
EBV productive cycle, there is no detectable latent phase in OHL Analysis of BZLF1 
RNAs from this library have also been studied (Lau et a l , 1992) Five full length cDNAs 
and one partial cDNA covering BdRFl, five cDNAs covering BCRF1, four partial 
cDNAs covering the 3’end of the gp350 gene, one cDNA spanning part of the BKRF1 
ORF, and several cDNAs covering the BARFO ORF were rsolated (Lau et a l , 1993) 
Previously RNAs crossing BARFO have only been reported from latent EBV infections 
in NPC and lymphocytes (Gilligan et a l , 1990, Hitt et a l , 1989, Karran et a l , 1992) 
There were unexpected differences in the relative abundance of cDNA clones isolated, 
this is thought to reflect the abundance of their respective mRNAs
1.4.2.5 Post-Transplant Lymphoproliferative Disease and EBV
In the early 1980’s EBV was first associated with post-transplant lymphomas (Crawford 
et a l , 1980) Lymphoproliferative disease (LPD) is a significant cause of morbidity and 
mortality in these patients as lifelong immunosuppression is essential for graft survival 
Incidences of LPD vary with different types of organ grafts, heart-lung recipients have 
the highest reported incidence at 33% (Randhawa et a l , 1989), while bone marrow 
transplant recrpients have a low rate of incidence The general consensus is that LPD 
development in recipients of solid-organ transplants are of host-ongin, while those 
occurring in bone-marrow transplant patrents are of donor origtn (Zutter et a l , 1988, 
Chadbum et a l , 1995,'Weissman et a l , 1995) Lack of previous exposure to EBV has 
been shown to carry an rncreased risk of LPD development (Ho et a l , 1988) Serological 
data from LPD patrents shows that approxrmately 50% of cases are EBV seronegative at 
the time of transplant and have a recent primary infection just prior to lymphoma 
development (Ho et a l , 1985, Thomas et a l , 1990) The majority of LPD tumours show 
the full latent viral gene expression (EBNA1-6, LMP, TP1 and 2), this implicates EBV 
directly in their aetiology
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The clinical features of LPD can be divided into two types, IM-like illness and 
lymphoma-like presentation The IM-like illness is usually presented by young patients 
within a year of transplant, the symptoms are generalised lymphadenopathy, fever, 
pharyngitis and skm rashes Mortality is only 38% (Armitage et a l , 1991), and 
spontaneous regression may occur Lymphoma-like presentation is usually found m older 
patients, who often develop extranodal disease especially in the gut, central nervous 
system and the transplanted organ, their response to therapy is poor and mortality is 
71% A diffuse polymorphic B cell hyperplasia develops mainly with the primary EBV, 
IM-like type of presentation while a B cell lymphoma tends to occur in the EBV 
seropositive patients with extranodal disease EBV serological testing for antibodies to 
the lytic cycle antigens (IgM and IgG to VCA and IgG to EA) is not diagnostic in LPD 
since the majority of immunosuppressed individuals show a ‘reactivated’ pattern with 
high levels of IgG antibodies to VCA and EA (Crawford and Thomas, 1993)
1.4.2.6 Non-Hodgkin’s lymphomas and other Malignancies
Non-Hodgkin’s lymphomas are a numerous, heterogeneous group of malignancies th a t , 
originate from lymphocytes, they can develop from lymph nodes or other sites, many 
lymphoid neoplasms pass through both solid tumour and circulating (leukaemic) phases 
(IARC Monographs, 1997) Sinonasal T cell lymphoma is the most strongly associated 
with EBV, and the virus is highly prevalent in lymphomatoid granulomatosis EBV is 
almost universally present in brain lymphomas secondary to immunodeficiency The rate 
of detection of EBV is relatively low in B cell lymphomas of the nasopharynx, tonsil and 
tongue Patients with X-linked lymphoprohferative syndrome are at increased risk for 
non-Hodgkin’s lymphoma, these patients have a specific defect in their control of 
infection of EBV In one study EBV was found in all of 82 lymphomas associated with 
this condition (Sullivan and Woda, 1989) Several studies have indicated that EBV is 
associated with about 80% of lymphoepithelial gastric carcinomas (Rowlands et a l , 
1993, Osato and Imai, 1996) Smooth muscle tumours in immunosuppressed transplant 
recipients have frequently been found to contain EBV (McClain et a l , 1995, Lee et a l , 
1995a)
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1.5.1 Serology of EBV Infection
Studies of IM patients have provided the bulk of the information available on primary 
antibody responses The typical antibody pattern for primary EBV infection is 
characterised by IgM and IgG antibodies to virus capsid antigen (VCA), IgG antibodies 
to early antigens (EA) and the absence of antibodies to nuclear antigens (EBNA) (See 
figure 5)
1.5 Immunological Aspects of EBV-Related Disease
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Figure 5: Antibody responses during EBV-induced infectious mononucleosis. (Adapted from
Purtilo and Heinrich, INCSTAR Corp)
A gradual increase in anti-EBNA IgG antibodies occurs during convalescence and after 
four weeks VCA-IgM antibodies disappear A possible explanation for the delayed 
antibody response to EBNA1, is that EBNA1 is protected from certain pathways of 
antigen processing In adults also IgA anti-VCA arise frequently, whereas young children 
develop IgA only in 10-30% of the cases Once infected, IgG antibodies to VCA and 
EBNA1 persist in healthy individuals for life, VCA-IgG is at a lower level than that at 
acute phase Antibodies to EA-D (diffuse EA component) show a transient rise m the 
acute phase and are generally undetectable three to six months after onset Anti-EA-R
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(restricted EA component) antibodies are sometimes present m children younger than 
two years of age and in asymptomatically infected patients IgM antibody to EA can 
reappear during EBV reactivation, there is also an increase in VCA-IgG and a decrease 
m EBNAl-IgG titres, in most cases of reactivation VCA-IgM is not detected The levels 
of each of these antibodies are generally lower in young patients, however, the profile 
does not differ with age The titres of antibody to each antigen and the time taken to 
develop a full spectrum of antibodies vanes between patients See table 4
Ab-Ag Not
infected
Silent
prmary
infection
Past
infection
Re-activation IM BL NPC
IgM-VCA - + - +/- + - -
IgG-VCA - + + ++ ++ ++ ++
IgA-VCA - - - +/- - - +
IgO-EA/D _ +/- +/- + +/- ++
IgA-EA/D * - - +/- * - +
IgG-EA/R - - - +/- +/- ++ -
IgM-EBNA _ + +/- +/- +/- n/d n/d
IgG-EBNA - +/- + +/- - + +
H aerophile - - - +/- + - -
+ positive antibodies, ++ elevated antibodies, - negative antibodies, n/d no data
Table 4: Serological patterns of EBV antibodies in patients with EBV associated
syndromes (Adapted from Lennette, 1991, Purtilo and Hmnchs, INCSTAR Corp)
Neutralising antibodies are detectable dunng the acute phase of IM but only at very low 
titres, which increase to stable levels thereafter (Horowitz et a l , 1975, Lennette et a l , 
1982) Patients in the acute phase show IgG-response to EBNA2 and probably 
EBNA3A, 3B and 3C also Healthy virus earners consistently have antibodies to VCA, 
neutralising anti-gp350 antibodies and antibodies to EBNA1 (Henle et a l , 1987) Only a 
proportion of healthy earners have antibodies to EA or to one or more of the other 
EBNA proteins There is an unusually strong cell-mediated immune response to clinically 
manifested pnmary EBV infection, which plays an important role in the control of 
persistent EBV infection A prospective study of IM patients showed that CTL memory 
increases dunng convalescence and soon reaches a stable steady state (Rickinson et a l , 
1980)
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Many years before the Epstem-Barr virus (EBV) was discovered serodiagnosis of 
infectious mononucleosis (IM) was based on the Paul-Bunnell test (Paul and Bunnell, 
1932) In addition to EBV-specific antibodies, the early phase of IM is characterised by a 
general increase in total IgM, IgG and IgA, which is consistent with virus-dnven 
polyclonal activation of the B cell system The presence of heterophile antibodies in sera 
of IM patients was originally detected by agglutination of sheep, horse or bovine blood 
cells presenting heterophile antigens on their surfaces (heterophile antigens occur in 
unrelated species of animals but have similar serologic properties among them) This was 
later modified with the introduction of guinea pig kidney adsorption of serum to prevent 
interference of Forssman-type antibodies (Davidsohn, 1937) More recently, enzyme- 
linked immunosorbent assay (ELISA) techniques have been introduced, in which reaction 
tubes are coated with purified heterophile antigens Heterophile antibodies are usually 
detected less than one week after onset of IM, peak at two-five weeks and can be 
detected, at low levels, a year after onset of illness (Niederman et a l , 1968 Evans et a l ,
1975) This method is rapid and cost-effective and is still widespread in routine 
diagnosis, however, the test fails (10-15%) in detecting primary EBV-infection, 
particularly with young children (Lenette, 1991) Consequently serological assays have 
been introduced, these assays involve the measurement of the EBV-specific antibody 
response
Primary EBV infections lead to the appearance of antibodies to specific EBV antigens 
which are usually detected by immunofluoresence (IF) staining of EBV infected cells 
(Henle et a l , 1974) Primary infection may or may not be accompanied by clinical signs 
of IM These IF assays are time consuming, difficult to evaluate, can’t be standardised 
exactly and may be hampered by autoantibodies to various cellular antigens which 
emerge in the course of IM in most patients (Sutton et a l , 1974) Humoral responses to 
primary EBV infection are quite rapid, eighty percent of patients have peak titres when 
they consult their doctor The type of infection a patient has can be determined, as the 
level and spectrum of antibodies are sufficiently distinct The serological profile can 
indicate if the patient is still susceptible, has a current primary infection, has had a recent
1.5.2 Historical Aspects of Serodiagnosis
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primary infection (within 2-3 months), had a past infection or may have a reactivated 
EBV infection (Lennette, 1991).
1.5.3 Comparison of Commercially Available Diagnostic Kits
A number of studies have been undertaken to evaluate the specificity and sensitivity of 
the commercially available EBV diagnostic kits. A study undertaken in Germany 
evaluated eleven immunoassays for the detection of IgM antibodies to EBV (Weber et 
al., 1996). The kits evaluated were, Fresenius, BAG, Diamedix, Progen, Viro-Immuno, 
Virotech, Sigma Diagnostics, Viramed, Biotest, Behring and Savyon. An 
immunofluorescence assay was used as the standard as the symptomatology of IM may 
be attributable to other viral infections, i.e. HCMV and HIV. The IFA is the only test 
method for which antibody profiles have been correlated with clinical disease. 
(Wiedbrauk and Bassin, 1993). The results showed that there were great differences in 
the quality of current EBV-IgM-ELISA test kits. The Fresenius and Diamedix ELISAs 
showed the highest correlation with the reference IFA, the Biotest also correlated very 
well while the Virotech assay had very poor sensitivity.
Another study carried out in Sweden evaluated 6 kits that used purified heterophile 
antigen for the rapid diagnosis of IM compared with EBV-specific serology (Elgh and 
Linderholm, 1996). Three latex agglutination-based kits were involved, Monolatex, 
Mono-Latex and Mono-Lex, and three solid-phase-based kits, Mono-Plus, IM-Check 
and Clearview IM. Epstein-Barr virus-specific serologies including detection of VCA 
IgM and IgG and EBNA1 IgG, were used as a reference method. Five of the methods 
utilised purified bovine heterophile antigen, IM-Check was based on horse heterophile 
antigen. IM-Check was the only test which was not recommended for the confirmation 
of EBV-associated IM, the other five tests were recommended. Clearview IM combined 
a high sensitivity and specificity with a very simple one-step solid-phase-based 
procedure. This evaluation indicated that purified heterophile antigen-based rapid tests 
have higher specificity than the whole red blood cell agglutination assays for the 
diagnosis of EBV-induced IM. However, the heterophile antibodies go undetected in 
greater than 50% of children less than seven years old (De Ory, 1991).
A more recent study in Spain tested the reliability of new indirect tests in the diagnosis of 
acute EBV infection (Gutierrez et al., 1997). Mono-Latex, Enzygnost, Biotest
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Diagnostics and the IgG avidity test were evaluated The antibodies to antigen pools of 
virus (Enzygnost) had high reliability, the IgG avidity test is simple and automated in the 
laboratory, and is useful for determining the time since infection from a single sample 
Mono-Latex and Biotest were shown to be lacking in sensitivity, specificity and the 
negative predictive value was low This finding for Mono-Latex and Biotest does not 
correlate with the results from the previous two studies described The reference method 
used and the range of sources of sera used may have implications in the differences in 
results found in both these studies
In China a study was undertaken to evaluate multiple antibodies to EBV as markers for 
detecting patients with EBV-associated nasopharyngeal carcinoma (NPC) (Liu et a l ,
1997) Five serological tests were assessed for their sensitivity for screening and early 
detection of NPC, these included the detection of, (1) VCA using IFA, (2) EBV DNase 
using an activity neutralisation assay (NT), (3) EBV DNase using an ELISA, (4) DNA 
polymerase (DP) using a neutralisation assay, and (5) major DNA binding protein 
(MDBP) using an ELISA It was found that no single test was sufficient for the detection 
of all NPC patients, however the detection of anti-DNase by ELISA was found to be the 
most sensitive method for detection of NPC
1.5.4 Developments in Diagnosis
There is currently work being done to improve existing diagnostic techniques and to 
develop more sensitive and specific diagnostic methods The detection of IgA antibodies 
to viral antigens is also being investigated IgA is the principal antibody in mucous 
secretions i e saliva, intestinal secretions and colostrum (Cooper, 1982) Studies in rats, 
mice and humans suggest that IgA is involved with transport of foreign antigens from the 
circulation into the bile (Russell et a l , 1981) There have been many reports of detection 
of specific IgA antibodies in viral infections, for example, HSV and CMV (Hadar and 
Sarov, 1984, Sarov and Haikm, 1983)
In one case study anti-VCA IgA antibody was detected in the serum of almost 50% of 
IM patients screened using an immunoperoxidase assay (Hadar et a l , 1995) The EBV- 
VCA-specific IgM antibodies were more sensitive (95-98%) and are more valuable for 
early diagnosis of IM, however, the IgA antibodies appear to be more useful as a marker
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for EBV reactivation Serum-specific IgA antibodies to EBV-VCA have a high titre in 
most patients with nasopharyngeal carcinoma also It has also been shown that EBV- 
VCA IgA antibodies in HIV-1 infected homosexual men may serve as an indicator for 
EBV reactivation, which seems to precede changes in the status of HIV-1 infection 
(Margalith et a l , 1990) Similiarly, other work has shown that the inclusion of the 
detection of IgG and IgA antibodies against EBV-VCA in a diagnostic test makes 
possible the diagnosis of chronic EBV infections and reactivations as well as primary 
infection by detection of IgM antibodies (Dopatka and Schuy, 1996) Anti-EA IgA is 
also known to be a highly specific marker for NPC (Henle and Henle, 1976) Work has 
been done on the development of an ELISA-based method for the detection of serum 
and saliva IgA against EA-D (Nadala et a l , 1996) The results indicated that this method 
has potential as it was very specific, however, sensitivity was lower than that found with 
immunoperoxidase assay (IPA) Further work is being done to improve sensitivity 
without the loss of specificity
An ELISA-based test has also been developed for the detection of IgG and IgM 
antibodies to three recombinant EBV antigens for routme diagnosis of EBV primary 
mfectron (Farber et a l , 1993) The early antigens MDBP (truncated) and EA-D were 
used for detecting IgG and IgM antibodies, and EBNA1 (carboxy-half) was used for 
detecting IgG antibodies These recombinant antigens have been proven effective for the 
standardised rapid diagnosis of acute EBV primary infection by ELISA, in comparison 
with the IF technique Using highly purified recombinant EBV polypeptides as antigens 
may solve the problem of autoantigens encountered when using IF A number of groups 
have investigated this possibility (Wolf et a l , 1985, Motz et a l , 1986, Hinderer et a l , 
1988, Gorgievski-Hnsoho et a l , 1990)
The enzyme immunoassay has many potential benefits over the IF A test, including cost 
reduction, time-saving, and greater reproducibility It is necessary to establish 
appropriate levels for determining a positive or negative result in comparison with the 
IFA test It is possible to detect anti-EA antibody by EIA and to differentiate between 
the various EBNA components, with IFA this is not possible It is also possible to detect 
IgM antibodies to EBNA which are not typically sought using the IFA test The 
increased sensitivity provided by the EIA test allows the characterisation of individuals
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who are in transition from acute infection to latent or chronic infection However, it may 
not be possible to correlate levels of antibody detected by IFA with those detected by the 
E IA , at all times This is due to the amount of antigen used to coat the EIA wells as well 
as the selection of specific components of the viral proteins such as EBNA (Purtilo and 
Hinnchs, INC STAR Corp)
ELIS As have been developed using recombinant EBNA1 truncated protein and a p i8- 
VCA synthetic peptide IgG antibodies are measured for the EBNA1 ELISA while both 
IgG and IgM antibodies are measured in the p l8-VCA ELISA (Rosa et a l , 1994, Liu et 
a l , 1994) The VC A IgG test had a sensitivity of 98 2% and specificity of 99%, the 
VCA IgM test had a sensitivity of 96% and specificity o f 98% in comparison to a 
commercial IFA The EBNA1 IgG test showed a sensitivity of 85 9% and a specificity of 
92 5% as compared to EBNA ACIF responses The IgG responses to EBNA1 did not 
cross-react with CMV,HSV land 2,VZV, Toxoplasma or Rheumatoid factor, also, the 
increase of EBNA 1 peptide IgG responses was found to correlate well with the decrease 
of VCA IgM responses
The replicative phase of the EBV life cycle seems to be restricted to epithelial cells of the 
nasopharynx, this results in release of viral particles in the saliva and the surrounding 
tissue (Greenspan et a l , 1985, Young and Sixbey, 1988, Becker et a l , 1991) The IgG 
response against the structural proteins of the virus, that is the major membrane protein 
and the capsid proteins MCP, p l8 and p40, is initiated by encounter with local lymphoid 
tissue In one particular study the antigenic domains o f pi 8 VC A were mapped (van 
Grunsven et a l , 1994) This was done using the Pepscan technique (Geysen et a l , 1984 
and 1987), peptides of these domains were synthesised and their diagnostic relevance 
determined via ELISA A single peptide was synthesised m which all the major epitopes 
of p l8-VCA were combined, (peptide IV) Sera from healthy persons, and patients with 
IM and NPC whose diagnosis was previously determined using a heterophile antibody 
test were used in the evaluation
Peptide IV showed improved reactivity with human antibodies in comparison with the 
individual peptides synthesised, and had a sensitivity of 95% for anti-VCA IgG and IgM 
The specificity was determined using sera from EBV-negative blood donors who had
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antibodies against other herpesviruses, all sera were proved negative for peptide IV. The 
IgG reactivity was detectable in sera from latently infected persons from the US, Hong- 
Kong, and the Netherlands, this shows worldwide conservation of the antibody response 
to the EBV-specific epitopes represented by VCA peptide IV. In general 80-90% of 
NPC patients have been shown to possess anti-VCA IgA antibodies, however, only 61% 
of the NPC sera tested contained anti-VCA peptide IV IgA antibodies. This peptide 
represents an important immunodominant EBV-specific reagent that may allow the 
production of a relatively cheap, reproducible EBV ELISA, however, it’s usefulness in 
NPC diagnosis is limited. Also sensitivity of 95% to IgG and IgM antibodies may not be 
sufficient, and additional EBV markers would be needed for 100% sensitivity.
1.6 Vaccine Development
In 1976 Epstein proposed a case for the development of an EBV vaccine (Epstein,
1976), since then a number of projects have been undertaken to develop and evaluate 
many different candidate vaccines. Killed, inactivated or attenuated virus cannot be used 
as the viral DNA is potentially oncogenic, and EBV is capable of sustaining a persistent 
lifelong latent infection. All vaccine candidates to date have been based on the 
gp3 50/220 subunit of the membrane antigen complex. This protein has been selected as it 
is the major envelope glycoprotein and is a major target of virus neutralising antibodies.
1.6.1 EBV Vaccine Candidate - gp350/220
The membrane antigen complex is involved in mediating virus binding to the B 
lymphocyte receptor CR2 (Nemerow et al., 1985; Tanner et al., 1987) and consists of at 
least four major EBV-induced glycoproteins, gp350/220, gp250/200, gp85, and gp78/55 
(Mackett et al., 1990). During the acute phase of infectious mononucleosis there is an 
antibody response to gp85, however, there is none to gp350/220 (Henle et al., 1979), 
this finding is important as the antibody to this complex is the most potent source of 
neutralisation of the virus. Anti-gp3 50/220 monoclonal antibodies prevent virus infection 
and abolish it’s ability to transform B-cells. It has been suggested that antibody to 
gp3 50/220 binds to productively infected cells, making them susceptible to antibody- 
dependent cellular cytotoxicity (ADCC)-mediated lysis (Patarroyo et al., 1980). T cells 
play an important role in controlling EBV infection, recent studies have shown that T 
cells have a role in inhibiting cells expressing replicative antigens, including gp350/220
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(Bejarano et a l , 1988) If an antigen is found to induce antibodies which can both 
neutralise the virus and inhibit it’s binding to target cell receptors, this antigen or it’s 
active peptide would represent a preferred component of an effective EBV vaccine For 
this reason efforts m the field of vaccine preparation against EBV have been directed 
primarily towards the use of these EBV-induced glycoproteins
A study was carried out to evaluate the degree of conservation of gp3 50/220 between 
B95-8 (type A) and AG876 and P3HR-1 (type B) (Lees et a l , 1993) Twenty four 
amino acid changes exist between the type A and type B strains, 9 of these cluster in the 
region of the protein which is spliced out of gp220 The gp350 molecule has a high 
proportion of senne, threonine, and proline residues, the majority of which are within the 
repeat region This repeat region vanes considerably in length and is the section removed 
from gp220 These facts suggest that this portion of the molecule is not required for 
persistence and replication of fully functional virus
A number of B-cell epitopes have been identified on the gp350 molecule (Pither et al, 
1992a,b) and three non-virus neutralising monoclonal antibody binding sites have been 
mapped by Zhang et a/,1991 Two virus-neutralising epitopes are known to exist but 
their location has not yet been identified (Qualtiere et a l , 1987) It is thought that the 
virus-neutralismg epitopes are discontinuous and conformation dependent, therefore 
native structure is required to elicit a neutralising serum response (Hoffinan et a l , 1980, 
North et a l , 1982, Qualtiere et a l , 1987) The monoclonal antibody 72A1 neutralises 
both B95-8 and P3HR-1 indicating that the epitope is present in both type A and type B 
viruses (Sairenji et a l , 1988), this epitope is thought to be located within the ammo- 
terminal 162 aa (Tanner et a l , 1988) Two T cell specific epitopes have been mapped by 
Wallace et a l , 1991, located between positions aa 61-81 and 163-183 A further study 
has confirmed the action of 72A 1 with type A and B, and shown the conservation of 
several B cell epitopes within the gp3 50/220 molecule of both strains (Lees et a l , 1993) 
The vanant loci within the EBV genome seem to be confined to the latent genes, while 
proteins associated with productive infection are more highly conserved The high level 
of homology between EBV MA genes may be due to structural/functional constraints or 
possibly due to the fact that the virus latently infects B cells and transcnption of most of
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the genome is consequently down regulated, thus reducing the immunologic selection 
pressure usually seen in other viruses Type A is predominant in most parts of the world, 
however, both type A and B seem to have equal oncogenic potential in their association 
with BL and NPC (Young et a l , 1987, Chen et a l , 1992) Therefore, a vaccine based on 
the B95-8 gp350/220 should be equally effective against both types of EBV
There appears to be species-specific variation in the immune response to EBV, as the 
epitopes found using serum from healthy seropositive humans were located toward the 
carboxy terminus of gp350 and were thought to be discontinuous in nature (Pither et a l , 
1992a), while those found after immunisation of rabbits were amino-terminal and 
continuous (Pither et a l , 1992b) This difference in response may also depend on 
whether the individual is naturally infected or vaccinated The molecule’s host cell- 
specific pattern of glycosylation will also influence the accessibility and structure of the 
gp350/220 molecule
1.6.2 Neutralising Antibodies to EBV
Eight monoclonal antibodies have been identified which are capable of neutralising EBV 
strain B95-8 (Qualtiere et a l , 1987), one of these 72A1, an IgG2a class antibody, has 
also been shown to neutralise type B strain P3HR-1 (Sairenji et a l , 1988), both with and 
without complement This antibody completely eliminated infectious virus from 
supernatants of B95-8 cells, however, in the case of P3HR-1, 72A1 never completely 
eliminated infectious virus from the supernatants, even at high MAb concentrations, but 
decreased the virus titre from 1/10 to 1/50 B95-8 EBV possesses larger amounts of 
gp350/300 than gp250/200 on it’s surface, while gp250/200 is more abundant on P3HR- 
1 than gp350/300 (Edson and Thorley-Lawson, 1981, North et a l , 1980) This may 
somewhat explain the difference in the effect of 72A1 on the different strains A previous 
study showed that of eight monoclonal antibodies analysed only four were capable of 
neutralising EBV and one of these four (72A1) could inhibit EBV binding to it’s target 
receptor (le CR2) It is probable that the epitope recognised by 72A1 is the only 
glycoprotein domain with a dual role, in EBV neutralisation and binding to target cell 
receptors (Stocco et a l , 1990) If the epitope recognised by 72 Al could be identified it
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may be possible to develop a vaccine based on this peptide sequence which would both 
neutralise the virus and simultaneously prevent binding of the virus to it’s target 
receptor
The third component of the MA gp85 is encoded by the BXLF2 ORF, this is an 85kD 
glycoprotein found on the envelope of the vinon, as well as the surface of EBV- 
producing cells F2 1 is an IgG2a class antibody against gp85, which can neutralise EBV 
only in the presence of complement gp85 appears to play an important role in the fusion 
of virus envelope to the target cell membrane (Miller and Hutt-Fletcher, 1988) F2 1 
inhibits this fusion but cannot inhibit binding of the virus to it’s target receptor G31 
another anti-gp85 IgG2a antibody can also neutralise the virus and inhibit the fusion 
process The inability of these antibodies to prevent virus attachment indicates that the 
epitopes they recognise play no role in EBV binding
1.6.3 The Cytotoxic T Cell Response to EBV Infection
The study of other viral systems has shown that there exists a central role for CD4+ T 
cells in the induction of specific immune responses to vaccine antigens, this activity has 
the potential to enhance both antibody responses and CD8+ cytotoxic T cell responses to 
a subsequent natural infection (Wallace et a l , 1991) CD4+ T cells recognise foreign 
antigens as small peptides which are generated by processing within antigen-presenting 
cells and are presented at the cell surface as a complex with MHC class II molecules 
(Schwartz 1985), the CD4+ T cell responses of individuals to EBV-vaccination have 
been investigated (Wallace et a l , 1991) The locations of two epitopes were found, as 
described earlier Identifying these epitopes within the primary sequence could facilitate 
effective vaccine design T cell clones with different epitope specificities were found to 
be restricted through different HLA class II antigens, therefore it will be necessary to 
screen T cell clones from a greater number of donors to assess the influence of HLA 
class II polymorphism upon epitope choice To identify an epitope capable of forming 
complexes with several polymorphic HLA-DR molecules would be desirable, as has been 
found in other systems such as HIV and malaria (Simgaglia et a l , 1988, Berzofsky et a l ,
1989)
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In order to study the Epstein-Barr virus a number of animal models have been developed 
Since the early eighties many vaccine trials have been undertaken, in which these animal 
models have played an essential role Mice, rabbits, common marmosets and cottontop 
tamanns have been involved in such trials Cottontop tamanns when challenged with a 
large dose of EBV develop multiple B cell lymphomas within 2-3 weeks, these 
lymphoma cells contain the EBV genome (Cleary et a l , 1985) The tumours are 
progressive and fatal in most cases, but a number of animals survive, the tumours regress 
in these individuals over a period of 8-12 weeks They are completely immune to a 
second challenge with EBV (Finerty et a l , 1988)
Human and tamann EBV infections differ in a number of ways, however, in vivo the B 
cell tumours resemble those in immunosuppressed humans It is also possible to establish 
EBV-transformed lymphoblastoid cell lines (LCLs) from tamann penpheral blood B cells 
(Miller et a l , 1972) EBV does not establish a lifelong latent infection of tamanns at the 
same level that occurs in humans (Finerty et a l , 1988, Niedobitek et a l , 1994), and the 
dose of virus is 50,000 times that estimated to transfer infection between humans An 
infectious mononucleosis-type disease is not established in the tamann model and it has 
not been possible to infect them via the mucosal route This raises the question as to 
whether this is a suitable model for vaccine development, however, the immune 
responses of both the tamanns and humans are similar, each have an effective cellular 
immune response (Finerty et a l , 1988, Rickinson et a l , 1989) Despite the fact that the 
cottontop tamann is less than the ideal model for human infection and disease, the 
induction of lymphoma by a large dose of virus is completely reproducible and could be 
considered as representing a ‘worst-case’ infection and in this respect is a useful measure 
of the efficacy of any expenmental vaccination (Morgan, 1992)
From previous vaccination tnals in tamanns it appears that a cell-mediated immune 
response is essential for protection against further EBV challenge When immunised with 
a gp350 envelope glycoprotein in liposomes the tamanns developed high neutralising 
antibody titres but were not protected, however immunisation with a recombinant
1.6.4 A model of EBV Infection
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vaccinia virus protected them from EBV challenge in the absence of a neutralising 
antibody response (Epstein et al., 1986; Morgan et al., 1988). Similarly, a replication- 
deficient recombinant adenovirus (Ad) used to immunise cottontop tamarins, protected 
animals against further viral challenge without the development of neutralising antibodies 
(Ragot et al., 1993).
1.6.5 Vaccinia Virus - a Vaccine Vector
There have been developments in potential new vaccines based on the expression of 
foreign genes in vaccinia virus, hepatitis B surface antigen, herpes simplex virus type 1 
glycoprotein and influenza virus haemaglutinin (Smith et al., 1983; Moss et al., 1984; 
Paoletti et al., 1984). Vaccinia virus was used successfully in the eradication of smallpox 
world wide, these results prompted the development of a recombinant vaccinia virus 
(Wyeth strain, New York city board of health) expressing EBV gp350 (Mackett and 
Arrand, 1985). The protein possessed the properties of native gp350, it was heavily 
glycosylated and could be detected at the surface of infected cells. When used to 
vaccinate rabbits, they produced antibodies that recognised EBV-containing 
lymphoblastoid cells and neutralised EBV. In the more recent study by Morgan et al., 
1988, a second recombinant vaccinia virus (WR laboratory strain) was constructed again 
expressing EBV gp350. In this case protection against EBV-induced lymphoma in 
cottontop tamarins was obtained with the WR strain but not with the Wyeth strain. This 
difference was thought to be due to the thymidine kinase (TK) negative phenotype of the 
Wyeth strain. A TK-negative virus (vTK-16) was used to produce a gp350 recombinant 
vaccinia virus in the vaccination of common marmosets (Mackett et al., 1996). The 
gp350 gene used was from the M81 strain, which is closer to the wild type strain of FRY  
circulating in the general population than the widely used B95-8 strain. Infection of the 
common marmoset with the M81 strain is followed by responses similar to those 
commonly seen in man, ie. lymphocytosis, heterophile antibody and longterm production 
of antibody to viral antigens (de Thé et al., 1980; Wedderburn et al., 1984). The long­
term EBV-host interactions are established essentially without clinical disease, similar to 
natural infection in the majority of cases. Successful vaccination was reported, that is, 
there was a decrease in virus load compared to controls after oral challenge with EBV. 
Vaccination does not prevent infection but can prevent clinical disease. Further work is
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necessary to improve the safety of vaccination with vaccinia virus for human trials, 
without compromising the efficacy of the vaccine. The first EBV vaccine trial in humans 
using recombinant vaccinia virus was carried out in 1995, the entire gp350/220 gene was 
expressed and resulted in protection against and /or delay of EBV infection by the 
natural route in humans (Gu et al., 1995).
1.6.6 Adenovirus - a Vaccine Vector
Human adenoviruses have considerable potential as expression vectors and live-virus 
vaccines for a wide variety of human and animal diseases. Ad 5 recombinants carrying 
inserts of HSV, VSV or rabies glycoprotein-coding sequences have been shown to raise 
neutralising antobodies in rhesus monkeys, cows, pigs, dogs, foxes, striped skunks, 
raccons, and mice (Graham and Prevec, 1992). The first human use of an Ad vaccine 
vector expressing HBsAg was under taken by Tacket et al., 1992 in a phase I study. 
Ragot et al., 1993 have developed a recombinant adenovirus serotype 5 expressing the 
full length gp3 50/220. The gp3 50/220 gene was cloned into the El A region of the Ad 
genome which encodes the immediate early proteins that trans-activate all other early 
regions, therefore making the mutant replication-defective. It has been shown that even 
without replication such vaccine vectors can induce good humoral immune responses in 
animals (Ballay et al., 1985; Alkhatib and Briedis, 1988; Eloit et al., 1990; Ragot et al., 
1991; Levrero et al., 1991). Recombinant Ad constructs expressing gp350/220 have 
been shown to induce anti-gp350/220 antibodies in rabbits and their sera was EBV- 
neutralising in vitro (Ragot et al., 1990). In this study the ability of one of these 
constructs to protect cottontop tamarins against EBV-induced lymphomas was 
investigated (Ragot et al., 1993). The tamarins were completely protected following 
intramuscular injection, immunisation via the oral route is being investigated as the mode 
of immunisation may result in a different type of immune response. The sera obtained 
from the protected tamarins following intramuscular introduction were not virus- 
neutralising. This reinforces evidence that the cellular immune response plays an 
important role in protection. Previous work has shown the absence of correlation 
between neutralising antibody and protection (Epstein and Achong, 1986). It is not 
necessary for neutralising antibodies to be produced following immunisation in order to 
develop protective immunity. The use of recombinant live viruses as vaccine vectors has
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many advantages, effective T cell antigen presentation, absence of the need for adjuvants 
and low production costs There is the risk of horizontal transmission between humans or 
between humans and other animal species, however, a replication-defective Ad vector 
greatly increases the safety
1.6.7 Varicella-Zoster - a Vaccine Vector
An attenuated strain of vancella-zoster virus (Oka) has been developed for use as a live 
viral vaccine, it has been clinically tested and proven to be both well tolerated and 
effective in preventing chicken pox (Takahashi et a l , 1974) A recombinant varicella 
zoster virus has been produced which expresses the EBV glycoprotein gp3 50/220 (Lowe 
et a l , 1987) Vancella-zoster has been shown to be safe and efficacious in vaccination of 
immunocompromised individuals (Feldman et a l , 1973), an important consideration for 
EBV immunisation This reinforces the potential of this recombinant for use m EBV 
vaccination tnals
1.6.8 Subunit Vaccines
The advantages of using live virus vectors are, the induction of broad ranging immune 
responses, including long term immunological memory, relatively low production costs 
and the potential for use as single dosage oral vaccines There are also a number of 
disadvantages such as possible reversion to pathogenic forms by mutation or 
recombination with wild types, possible alternative host cell tropism and poorly defined 
immunogenic activities Development of a subunit vaccine could overcome a number of 
these disadvantages A subunit vaccine is clearly defined and a pure product which 
contains no genomic matenal or replicative capacity These factors are important when 
considenng health and safety regulations The need to administer a subunit vaccine with 
adjuvant does pose a problem The only adjuvant licensed for general human use is alum 
Alum is a relatively weak adjuvant and is defective in it’s ability to induce appropnate 
cell-mediated immune responses Alternatives have been explored and found effective, 
these include muramyl dipeptide denvatives administered in synthetic oils (Byars et a l ,
1991), and immunostimulating complexes (ISCOMS) (Morein et a l , 1984) These 
adjuvants have been tested in the tamarin model and were found to be excellent 
alternatives to alum (Morgan, 1992) An appropnate adjuvant must be selected before
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subunit vaccine trials can be undertaken in humans. Substantial amounts of gp350 can 
now be produced in conditions compatible with good manufacturing practice and in the 
certain absence of any potentially oncogenic EBV DNA. Biodegradable microparticles as 
controlled antigen delivery systems are an attractive alternative to alum or other 
adjuvants but have yet to be tested in the tamarin lymphoma model (O’Hagan et a l ,
1991). The identification of the neutralising epitopes on the gp350/220 molecule, and the 
subsequent synthetic production of these peptides could provide an alternative subunit 
vaccine. The production of recombinant gp3 50/220 would be eliminated and a number of 
peptides, possibly from the latent antigens of EBV, could be incorporated in order to 
induce a broad immmunological response, T cell epitopes could also be included in this 
type of vaccine.
1.6.9 Vaccines Based on Peptide Epitopes for CTLs
Cytotoxic T-lymphocyte (CTL)-mediated immunity is a specific and potent response to 
EBV infection. The CTL response is directed primarily against latently-infected B cells, 
with EBNA3A, 3B and 3C being the major targets (Murray et a l, 1992; Khanna et a l,
1992). The possibility of priming the T cells by peptide immunisation before infection 
occurs could accelerate the CTL response to primary infection and thus limit subsequent 
colonisation of the B cell pool. This strategy would involve the use of synthetic peptides 
representing the major CTL target epitopes presented by common HLA alleles 
(Rickinson, 1995). A large number of epitopes have now been identified and calculations 
have shown that a polytope vaccine containing only 7 epitopes restricted by HLA A2, 
A3, Al l ,  B7, B8, B35 and B44 would protect >90% of a Caucasian population 
(Suhrbier, 1997). The chance of developing IM after EBV infection is only 50% in 
adolescents, therefore, a few EBV-specific memory CTL might be sufficient to tip the 
balance to asymptomatic seroconversion. EBV vaccines based on CTL induction would 
reduce morbidity rather than prevent infection. It has been shown that only a small 
number of adoptively transferred EBV-specific CTL were sufficient to clear an LPD that 
was X-ray-visible (Rooney et a l, 1995).
EBV infection has been shown to result in significant morbidity and mortality in specific 
high risk populations and the extent of it’s impact remains undetermined. Despite the 
considerable cost involved in vaccination trials and a vaccination program, it appears that
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an EBV-vaccine would be cost-effective EBV has been incriminated in the pathogenesis 
of various malignancies, almost all cases of NPC, 95% of African BL, -33% of BL m the 
United States, ~50% of HD, 11% of spontaneous non-Hodgkin’s lymphomas and about 
33% of non-Hodgkin’s lymphomas in AIDS patients (Evans, 1993) The development of 
an EBV vaccine to prevent IM is considered cost effective and taking into consideration 
the malignant consequences of an EBV infection further reinforces the need for the 
development of such a vaccine
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Expression of EBV recombinant proteins in E  coli is the main part of the subject matter 
of this thesis
Production of recombinant proteins on an industrial scale is essential due to many 
factors The natural supply of a particular protein is too limited to allow widespread use 
This is especially true for proteins used m the pharmaceutical industry, for example 
insulin, factor VIII, and growth factors In some cases the supply exists but it is difficult 
to exploit, or may become limited as demand increases It is also important when using 
proteins in pharmaceuticals or food production, that the products are as safe as possible, 
the absence of pathogens js  crucial If a particular protem is to be used in diagnosis it is 
important that contaminating proteins be removed to eliminate the possibility of cross- 
reactivity, and reduction of specificity
Many hosts for production of heterologous proteins have been exploited, these include 
mammalian cells, insect cells, filamentous fungi, yeast and bacteria (both gram-negative 
and gram-positive) Mammalian cells .are used extensively for the production of human 
proteins, the products retain their native structure and glycosylation is possible In some 
cases this is important for correct protein function Yeast cells also provide the 
advantage of allowing correct foldmg and processing of mammalian proteins Cell culture 
is expensive, yield can be too low, and there may be problems with cross-reactivity if the 
products are needed in diagnosis, for this reason use of a bacterial host can be an 
advantage Escherichia coli remains the organism of first choice for expression of 
heterologous genes as a result of it’s ease of manipulation and the quantity of protein 
obtainable E  coli is genetically and physiologically well defined, it is easily manipulated 
and high-level expression of many heterologous proteins has been achieved It has also 
proven to be easily scaled-up from shake flask to large-scale culture and commercial 
production However, with high-level production often product quality is sacrificed, 
recent advances in heterologous gene expression now allows, in many cases, enhanced 
protem quality in vivo and in vitro (Olins and Lee, 1993) The use of fusion proteins can 
aid maintenance of the correct secondary and tertiary structure of a particular protein as 
well as aid in protein purification GroESL, DnaK, protein disulphide isomerase, and
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1.7 Recombinant Protein Expression in Escherichia coli
prolyl isomerase used singly or in combination may prove useful in enhancing either the 
rate or extent of protein foldmg (Buchner et a l , 1992, Freskgard et a l , 1992) Fusion of 
cytoplasmically expressed heterologous proteins to other proteins can increase their 
solubility and biological activity (Smith, 1992, McCoy and LaVallie, 1992) Thioredoxin 
fusions allow a variety of mammalian proteins that would otherwise form inclusion 
bodies (IBs) to be expressed in „an active and .soluble form, which can be recovered by 
osmotic shock, or heat treatment (LaVallie et a l , 1993)
Escherichia coli expressed recombinant antigens have been used in the development of 
ELISA-based assays for improved diagnosis of virus-associated diseases, two examples 
are hanta virus and dengue virus -In the case of Hanta virus, truncated recombinant 
nucleocapsid protein of five viral serotypes have been expressed in E  coli These proteins 
were purified and successfully screened with sera from patients of each serotype for IgM 
and IgG reactivity (Elgh et a l , 1997) An indirect ELISA has also been developed for 
diagnosis of dengue virus using a recombinant viral envelope B protein, which is 
expressed as a trpE fusion in E  coli This antigen was found to be of equal sensitivity as 
cell culture-derived antigen for both IgM and IgG detection (Simmons et a l , 1998)
1.7.1 The Thiofusion Expression System
The Thiofiision™ Expression System developed by INVITROGEN allows expression 
and purification of large amounts of heterologous protein from E  coli The gene of 
interest is cloned into the multiple cloning site of the pTrxFus cloning vector, and are 
consequently expressed as fusions with the E  coli thioredoxin protein (trxA) (Bayer, 
1968 , Holmgren, 1985) Thioredoxin appears to confer solubility to formerly insoluble 
heterologous proteins, thus avoiding the problem of mclusion bodies (LaVallie et a l ,
1992) Fusion with thioredoxin may confer a unique cellular location allowing easy 
purification by osmotic shock, also the fusion protein may be heat stable allowing 
purification by heat treatment In addition these fusions express at high levels (Lunn et 
a l , 1982 and 1984) The P l promoter from bacteriophage X is used to drive expression 
m pTrxFus This is one of the most efficient promoters for bacterial expression and is 
tightly regulated (Buell and Panayotos, 1986) The bacteriophage X cl repressor binds to 
the operator region in front of the PL promoter and controls the level of transcription 
from the promoter The cl repressor expression is regulated by the trp promoter in the
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E co h  cells (either G1698 or G1724) by trp repressor and attenuation When cells are 
grown in tryptophan-free medium, the cl repressor gene is transcnbed, and the cl 
repressor protein binds to the P l promoter preventing transcription Expression is 
induced by adding tryptophan to the medium, this shuts down cl repressor synthesis, thus 
allowing transcription from the PL promoter Figure 6 shows a schematic diagram of the 
pTrxFus plasmid used in the cloning procedure
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Figure 6: Schematic representation of the
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bases 201-1061 
bases ~1300-1880 
bases 2159-2187 
bases 2709-2726 
bases 2724-3050 
bases 3051-3080 
bases 3081-3112 
bases 3113-3179
Expression of thioredoxin fusions is optimised by varying the growth temperature during 
induction to get the maximum amount of soluble fusion protein The expression
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temperature can range from 15°C to 37°C for thioredoxin fusion proteins (Holmgren, 
1985) There are two host strains, G1698 for expression of fusions below 30°C, and 
G1724 for expression at or above 30°C They differ in their expression of the cl 
repressor The G1698 strain has no ribosome binding site before the cl repressor gene, 
this causes decreased production of cl repressor even in the absence of tryptophan 
G1724 has a good ribosome binding site leading to increased production of cl repressor 
relative to G1698, therefore, regulation is quite tight in G1724 and leaky in G1698 Since 
expression at lower temperatures may increase the solubility of the fusion protein, leaky 
expression may allow more of this soluble fusion protein to be expressed at lower 
temperatures
Thioredoxin fusion proteins may localise to the adhesion zones (See Figure 7) (Lunn et 
a l , 1984), where native thioredoxin normally localises Adhesion zones are sites on the 
cytoplasmic side of the inner membrane If fusions are located at this position they could 
be punfied by osmotic shock (Lunn et a l , 1982) Thioredoxin fusions may also be heat 
stable, and since all will not localize to adhesion zones, heat treatment can provide an 
alternative purification method Most proteins precipitate after 1 minute at 80°C, while 
some thioredoxin fusions are stable for 10 mms at this temperature There is an 
enterokinase cleavage site (Asp-Asp-Asp-Asp-Lys-Xaa) engineered into pTrxFus in a 
30bp spacer between the TrxA gene and the multiple cloning site Enterokinase 
hydrolyses the peptide bond between lysine and the next amino acid, except if the next 
amino acid is prolme The fusion protein must be partially punfied for enterokinase to 
work efficiently
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Figure 7: Schematic representation of the adhesion zones
Mouse brain fascin has been cloned and expressed in this thioredoxin expression system, 
producing mouse fascin as a soluble fusion protein (Edwards et al., 1995). Previous 
study of recombinant fascins was difficult, bacterially expressed fascins were insoluble, 
fusion with thioredoxin overcame this problem. The thioredoxin moiety was cleaved 
using a-chymotrypsin, as fascin is relatively resistant to digestion to a-chymotrypsin. 
Seryl-tRNA synthetase from the extreme halophile Haloarcula marismortui has also 
been cloned into the pTrxFus plasmid for expression in E.coli (Taupin et al., 1997). 
Soluble active recombinant proteins were expressed however the activity level was poor.
1.8 Random Phage Peptide Libraries (RPLs)
Screening of random phage peptide libraries is the second part of the subject matter of 
this thesis.
It was first suggested by Dulbecco in 1982, that immunogenic peptides from well- 
characterised epitopes of pathogenic agents could be fused to the coat proteins of 
bacteriophage. The foreign peptides would be displayed on the surface of the viral 
particles and could be used as the principal components of cell-free vaccines (Dulbecco,
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1982). By 1985 it had shown that filamentous phage could easily be manipulated to 
produce phage displaying ‘phagotopes’ on their surface (Smith, 1985). Random peptide 
libraries (RPLs) can be used to survey tens of millions of short peptides for tight binding 
to an antibody, a receptor or other binding protein. The library consists of a huge mixture 
of filamentous phage clones, each displaying one peptide sequence on the virion surface. 
Fusion phage are filamentous bacteriophage vectors in which foreign antigenic 
determinants are cloned into phage gene III or gene VIII and displayed as part of the 
product of either gene.
Both chemical and biological libraries have been developed. The first chemical libraries 
were linear peptides displayed on glass beads or plastic pins, biological libraries include 
peptide display on surface proteins of E.coli (Little et al., 1993) the ‘peptides on 
plasmids’ approach, and phage display of peptides. In biological approaches, protein and 
peptide variants are expressed physically linked in some way to the genes that encode 
them, therefore, any selection procedure enriching for a particular mutant co-selects for 
it’s DNA sequence. Biological libraries can be endlessly regenerated unlike chemical 
synthetic libraries, however, they are subject to selective pressures independent of those 
imposed in vitro.
1.8.1 Structure and Biology of fd and M13
The filamentous phage infection cycle is initiated by the attachment of pill to the tip of 
the F pilus of the bacteria, followed by internalisation of the single-stranded viral DNA 
(ssDNA). This ‘plus’ strand serves as template for minus-strand synthesis which results 
in a double-stranded replicative form (RF). The RF is the template for mRNA 
transcription, RF replication and production of ssDNA progeny. Progeny virions are 
assembled by extrusion of ssDNA through the bacterial envelope without killing the cell 
or preventing cell division. As it emerges from the cell, the ssDNA acquires it’s 
extracellular sheath of coat proteins from the membrane (Smith and Scott, 1993). The 
pill protein is a 406-amino-acid protein synthesised with an 18-amino-acid leader 
sequence, which is later cleaved off. The protein has two domains of approximately equal 
size; in the viral capsid, the N-terminal region protrudes outwards, while the C-terminal 
domain is buried in the particle.
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1.8.2 Peptide Fusions
Filamentous phage are the preferred vectors for the construction of ‘genetic’ repertoires 
for the following reasons Insertions of foreign sequences at the amino terminus of either 
the pill or the pVIII coat protein are, in general, well tolerated The foreign sequence is 
displayed on the surface of the viral particle (See figure 8) and can bind to molecules 
such as antibodies and receptors (Smith, 1985) Sequences that interfere with the life 
cycle of the virus can be displayed by using the ‘two genes’ or ‘phagemid’ system, where 
chimaenc phage bearing both wildtype and recombinant coat proteins are produced In a 
two-gene system, the fusion protein is supplemented with the corresponding wild-type 
protein, so that the particles bear a mixture of coat proteins, only some displaying the 
foreign domain This system allows fusions that partially impair coat-protein function, 
and for that reason would not be tolerated in one gene systems A phagemid is a plasmid 
containing the intergenic region of filamentous phage in addition to a conventional 
replication origin and an antibiotic resistance gene The mtergemc region contains all the 
cis-acting elements that form the site of initiation of replication and the morphogenetic 
signal, which are required for ssDNA synthesis and packaging mto vinons When a cell 
with a phagemid is superinfected with helper phage that supply all the phage proteins, it 
secretes not only helper phage but also infectious phagemid vinons (Smith, 1991)
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Figure 8: Filamentous bacteriophage displaying peptides fused to (a) the minor viral coat
protein pill and (b) the major coat protein pVIH Only a single copy of pill shown, rather than the 4-5 
copies that are actually present on the vinon (Adapted from Houghten, 1993)
The pill protein from gene III is present in five copies at one end of the phage particle 
coat, while the pVIII protein from gene VIII has approximately 2700 copies on the 
surface of the phage (Scott and Smith 1990) The pill minor capsid protein is used most 
frequently for display of peptides This protein is required for infectivity, and can be seen 
under the electron microscope (EM) as protruding knob-like structures, pill also 
stabilises the phage particle against dissociating agents (Hill and Stockley, 1996)
The major limitation in the use of pill to present peptide sequences is the number of 
fusion proteins that can be displayed on each particle, a maximum of five This may be an 
advantage in selection of peptides which have very high affinity for the ‘selector’ 
molecule as opposed to those with low affinity binding Peptides up to a few hundred 
residues in length can be displayed on pill (Smith, 1991) Alternatively pVIII can be 
used for cloning as there is the potential to present more than 2700 copies of a peptide 
on each phage particle The pVIII is a 50-amino-acid protein with a cleavable 23-amino- 
acid signal sequence The first four or five N-terminal amino acids are found at the 
surface of the particle and it is in this region that insertions have been made Conditions
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for insertion into pVIII are more stnngent than for pill, and only 8-9 amino acids in 
length can be tolerated if present on every pVIII subunit of the capsid (Greenwood et a l , 
1991) (See figure 9)
T y p e  T y p e  T y p e  T y p e  T y p e  T y p e
3 3 3  3 + 3 8 8 8  8 + 8
Figure 9: Classification of phage display vectors. (Adapted from Smith, 1993)
Type 3 a single recombinant gene III bearing a foreign peptide insert
Type 33 2 genes III, one wild type the other an insert bearing recombmant
Type 3+3 2 genes III, one wild type the recombinant gene is on a phagemid
Type 8 a single recombinant gene VIII bearing a foreign peptide insert
Type 88 2 genes VIII, one wild type the other an insert bearing recombmant
Type 8+8 2 genes VIII, one wild type the recombinant gene is on a phagemid
It is possible to select the binding protein or peptides, of a particular ‘selector’ molecule, 
from a mixture of >109 different phage particles (Cortese et a l , 1994) This technique, 
commonly known as biopanmng, was first described in 1985 (Smith, 1985), and has 
since been altered and modified for many different applications (See figure 10 for a 
schematic diagram of this procedure) The original method involved covalent linkage of 
biotin to the target molecule, this is done prior to incubation with the phage library 
Phage able to bind the target are then selected by ‘panning’ the mixture of phage and
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target molecule on a streptavidin-coated dish This exploits the strong biotin-streptavidin 
interaction, retaining the target molecule and consequently the phage bound to it Bound 
phage are then eluted from the complexes and subjected to further rounds of 
amplification in E  coh and biopanmng Usually three rounds of biopanning are necessary 
to isolate binding phage, on subsequent rounds a limited amount of target can be used to 
achieve competition between different clones, this facilitates the isolation of higher- 
affimty peptides Individual clones must be independently assayed, because false positives 
may occur by the selection of clones that bind the support matrices, or streptavidin 
(Adey et a l , 1995) A subtraction step may be used to avoid false positives, this involves 
panning the phage selected from the first round on a streptavidin coated plate m the 
absence of target molecule This should, in theory remove those phage which are not 
specifically selected for by the target molecule
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Repeat twice
I
Coat plate with streptavidin
I
Immobilise biotinylated 
antibody on streptavidin 
coated plate
1
Add phage to the plate 
1
Wash away unbound phage 
1
Elute bound phage 
1
Titer eluate and amplify m E  coli K91Kan
Biotinylate monoclonal antibody
Figure 10: Flow diagram of the biopannmg procedure.
1.8.3 Phage-derived Peptides and their Applications
The first phage display libraries polyvalently displayed random linear peptides with 6 
(Scott and Smith, 1990, Cwirla et a l , 1990) to 38 (Kay et a l , 1993) residues being 
randomised Libraries with longer random regions are incomplete due to the huge 
numbers of individual clones necessary, with several shorter random peptides contained 
within each clone, and may be useful if binding preferences are being sought as opposed 
to an optimum sequence Longer peptides may be capable of assuming a wide variety of 
secondary structure motifs including a-helices, P-turns and mimics of antigenic loops on
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the surface of different proteins A 30 mer library created by Grihalde et a l , 1995, 
without any special constraints, contained a significant percentage of sequences carrying 
two or more Cys residues, and could present ‘looped peptides’ containing a disulphide 
bridge Libraries that are theoretically complete may lack clones that are toxic to the 
host, disrupt protein folding, are proteolytically labile, or are poorly translated, secreted 
and/or processed (Clackson and Wells, 1994)
1.8.3.1 Epitope Mapping
Classical epitope mapping required a set of overlapping synthetic peptides spanning a 
region of the antigen, or a set of deletions obtained by genetic manipulation of the 
antigen-coding gene If a peptide was found to react with the antibody, the epitope was 
declared to be linear or continuous, however, if a peptide could not be identified, the 
epitope was said to be discontinuous A discontinuous epitope is one which is made up 
of amino acids closely related in space but distant in the primary sequence This was an 
oversimplification of the actual situation and it is thought that ‘complete’ epitopes (i e 
all amino acids that make contact with the antigen-binding site) are probably all 
discontinuous to a certain degree
The primary application of phage display libraries has been the identification of B cell 
epitopes and to a lesser extent T cell epitopes There has been much success with linear 
epitopes, however, discontinuous epitopes have proven less amenable to this technology 
An example of the success in identification of an epitope is a study with HIV A 
monoclonal antibody 447-52D raised against the HIV-1 glycoprotein 120 V3 loop has 
been shown to neutralise the virus, as a result this protein (gpl20) has been the focus of 
vaccine studies A 15-mer epitope library was screened with the MAb 447-52D, the 
consensus sequence GPXR was identified in 98% of the isolated clones (Keller et a l ,
1993) The core of the recognised epitope is linear and this is thought to have 
contributed to the success of this study An immunogen was created using one of the 
selected peptides and it was found to elicit an antibody response which neutralised two 
related viral variants A later study focused on the isolation of peptide binders to anti- 
HCV (14-153-462 MAb) and anti-gpl20 V3 loop (1001 MAb) (Gnhalde et a l , 1995)
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Both antibodies detect then respective antigens in western blot suggesting they bind 
linear epitopes A 30 mer phage library was screened with both antibodies, the anti- 
gpl20 antibody selected clones all contained a G-R sequence flanked by two cys 
residues The presence of a disulphide bridge at the base of the loop constrains the 
peptide in a (5-tum allowing binding of the antibody (Ghiara et a l , 1994) This is 
consistent with the other findings of Keller et a l , 1993 The G-R dipeptide is known to 
be part of the highly conserved G-P-G-R-A-F sequence present in many HIV isolates 
Forty clones derived from selection agamst the HCV Ab were isolated and their 
sequence deduced, 22 unique sequences with the consensus R-X-R-R-Q-P were 
identified, which maps to the sequence R-G-R-R-Q-P at aa 59-94 of the HCV core 
protein sequence These results illustrate the accuracy with which epitopes can be 
identified via phage display libraries
Phage borne mimotopes have been isolated that mimic non-peptidic epitopes, two groups 
have isolated phagotopes that react with streptavidin, these molecules are likely to be 
analogues or mimics of biotin, on the basis of competition experiments (Devlin et 
a/,1990, Kay et a l , 1993) Most of the phagotopes isolated display the consensus 
sequence HPQ, and appear to use only a subset of the biotin interaction sites at the 
bindmg pocket Concanavalin A and the carbohydrate binding antibody B3 have also 
been used as selector molecules with phage libraries The lectin Con A naturally binds 
carbohydrates, the common consensus sequence isolated for this protein is YPY (Scott 
et a l , 1992, Oldenburg et a l , 1992) The B3 monoclonal antibody which binds the 
carbohydrate antigen Lewisy, selects for the consensus sequence PWLY (Hoess et a l ,
1993) A recent study involved the analysis of closely related mAbs directed against the 
cell-wall polysaccharide of group A Streptococcus (Harris et a l , 1997) All of the 
antibodies isolated peptides which crossreact, from a panel of phage-displayed libraries 
Competition studies indicated that many of the peptides bind at or near the carbohydrate 
bindmg site The peptides were found to bind the mAbs by different mechanisms than the 
branched tnsacchande epitope, which is the epitope bound by each of the antibodies in 
vivo It has been suggested that the CHO-crossreactmty of Abs produced agamst CHO- 
mimic peptides is determined by factors other than their structural similarity to the 
antigen (Hams et a l , 1997) Previous work has shown that in general the majority of
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anti-CHO Abs use a limited subset of V  genes, indicating that this class of Abs uses a 
restricted structural repertoire (Vargas-Madrazo et a l , 1995) Other peptide mimics for 
non-protein ligands have also been identified, for example, anti-biotin PCAbs (Roberts et 
a l , 1993), and iron oxide (Brown, 1992) In the case of iron oxide the peptides were 
displayed on the surface of bacteria
1.8.3.2 Antibody (Fab) Libraries
Libraries have also been created displaying antibody Fab fragments, the method used is 
known as ‘the combinatorial strategy’ (Huse et a l , 1989) This involves the random 
recombination of light- and heavy-chain fragments (Fabs) expressed in phage X Most 
work in this area is directed toward the cloning of human antibodies as these are the 
most difficult to obtain by other methods and are of therapeutic value Use of phage 
display allows the production of antibodies without immunisation Human antibodies 
have been cloned that bind HIV (Barbas,CF III et a l , 1992a), hepatitis B (Zebedee et 
a l , 1992), respiratory synctial virus (RSV) (Barbas,CF III et a l , 1992b), 
cytomegalovirus, herpes simplex virus types 1 and 2, varicella zoster virus, measles, and 
rubella Single chain antibodies have also been displayed on phage, however, the single 
chain antibodies that have been selected have been found to have very low affinity, and 
only those which dimense on the phage and subsequently in solution are selected 
(Griffiths et a l , 1993) Using a helper phage which is deleted in pm  converts a 
monovalent phagemid system into a multivalent system, aiding the capture of these low 
affinity clones Phage libraries displaying Fab fragments which are monomeric, have 
proven more effective than other antibody libraries m the isolation of high-affimty clones
1.8.3.3 Phage Display of Protein Ligands
In theory, any protein secretable to the penplasmic space of E  coli may be displayed on 
the surface of filamentous phage, especially when using two-gene phagemid systems 
(Barbas, 1993) Human growth hormone (Bass et a l , 1990), trypsin inhibitor (Roberts et 
a l , 1992), ricin B-chain (Swimmer et a l , 1992), and alkaline phosphatase (AP) 
(McCafferty et a l , 1991, Light and Lemer, 1992), have all been expressed It is also 
possible to construct systems expressing two different proteins, for example, the 
expression of (alkaline phosphatase) AP-pVin and Fab-pIII fusions These phage can be 
used directly as immunological reagents (Light and Lemer, 1992) This technology may
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also be used to examine enzyme activities, rapid identification of highly active and 
selective protease substrates for both stromelysin and matrilysin was possible using a 
random hexamer library in the fAFF-1 phage (Smith et al., 1995). This method can be 
used to isolate new substrates for poorly characterised endoproteases.
Human neutrophil elastase (HNE) is an abundant serine protease involved in the 
elimination of pathogens and in connective tissue restructuring. Hereditary reduction of 
the circulating cti antiproteinase inhibitor, the principal physiological inhibitor of HNE, or 
inactivation of oil antiproteinase inhibitor by oxidation results in extensive destruction of 
lung tissue, caused by the uncontrolled elastolytic activity of HNE. For this reason it was 
desirable to identify effective inhibitors of HNE which could be of therapeutic value. A 
library of pill fusion phage displaying 1000 customised protease inhibitor variants 
derived from wild-type bovine pancreatic trypsin inhibitor (BPTI), was created. One 
inhibitor was isolated which was 50-fold more potent than the most potent anti-HNE 
inhibitor (Roberts et al., 1992).
1.8.3.4 Constrained Libraries
Most small peptides that bind specifically to target proteins in vivo are constrained, 
usually by disulphide bridges. ‘Constrained’ peptide libraries have been constructed, in 
which the potential conformation of the displayed peptide is limited by the structural 
constraints built around it, for example, flanking the random sequence by two cysteine 
residues forces the displayed peptide into a loop conformation. This type of library may 
be required to overcome the problem of mimicking discontinuous epitopes with linear, 
unconstrained peptides (Cortese et al., 1994). Constraining the random sequence still 
permits flexibility within the loop, however, constraining into an incorrect conformation 
could also prevent binding of certain selector molecules.
Constrained libraries could prove to be richer sources of mimotopes than linear peptides. 
In one particular study an antibody with a linear epitope selected it’s recognition 
sequence from a linear hexapaptide library but also selected unrelated clones with 
cysteines at the first and sixth positions. This suggests that these were mimotopes 
constrained by a disulphide bond (Matthews and Wells, 1993). The residues of a 
disulphide-close loop (DCL) are only partially constrained by the disulphide bond, the
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larger the loop the less the constraint The amino acid sequence within the loop can also 
impose additional constraint (Cunningham et a l , 1994) Sequences rich in Pro,Val or lie 
are more constrained than are sequences rich in Gly, Ala or Ser The formation of helices 
or the burial of hydrophobic residues can also limit the freedom of the mam chain Linear 
peptides that mimic the binding of a conformational epitope, or protein-protein binding 
have been found but are rare (Ladner, 1995) A constrained peptide (CP) can show 
higher affinity for a target than an unstructured peptide (UP), a ligand that has the shape 
to complement a binding site should have higher affinity than a similar ligand that 
changes shape when it is separated from the target The more tightly constrained a 
peptide segment is the less likely it is to bind any particular target, however, if it does 
bind, it is more likely to be tighter and more specific It is desirable to have varied 
peptides that are constrained in several different frameworks of varying rigidity It has 
also been found that CPs display far more diversity than UPs, and it is thought that 
having 6 optimal ammo acids in a CP, that are correctly positioned can lead to specific 
binding to macromolecular targets (Parmley and Smith 1988)
The first example of the use of phage-displayed peptide libraries to identify a structural 
epitope was by Hoess et a l , 1994, previous to this little success was had in identifying 
conformational epitopes In this study two hexapeptide phage libraries were screened 
with mAb CB5B10, raised against plasminogen activator inhibitor type-l(PAI-l) This 
protein is a member of the senne protease inhibitor (serpin) family and the principal 
physiologic inhibitor of both tissue-type and urokinase-type plasminogen activators (Ny 
et a l , 1986) One of the libraries was contrained to form loops by disulphide bond 
formation between flanking cysteine residues An equal mixture of both libraries was 
used during the biopanmng procedure, the consensus sequence selected matched residues 
115-119 of PAI-1 Only phage from the constrained library were selected by the mAb 
This suggests that constraining the peptide is required for bonding This was investigated 
further by mutating the selected sequence, replacing one of the cysteine residues with a 
senne, thus eliminating the disulphide bond and the loop formation The efficiency of 
capture of the senne-substituted peptide was two orders of magnitude less than that for 
the onginal phage containing the disulphide bond This suggests that the selected peptide 
not only required the appropnate side chains for binding, but that they be held m a loop
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conformation to mimic the structure found in PAI-1 Constraining the peptide confers 
the advantage of restricting the peptide to fewer conformations, allowing the 
determination of more structurally complex epitopes
A study by Felici et a l , 1993, found a mimic for a discontinuous epitope, similarly, both 
a constrained and unconstrained library were used, but not simultaneously The mAb 
1B7 which neutralises Bordetella pertussis by binding the enzymatically active subunit 
SI of the Bordetella pertussis toxin (PTX), was the selecting antibody in this case A 
precise identification of the antigen residues involved in the binding of the mAb 1B7 
could not be obtained although some similar di- or tn-peptide identities could be found in 
the comparison with the sequence of the SI subunit of PTX The original antigen was 
able to compete for antibody binding with the selected phage clones, this indicates that 
binding occurs at the level of the antigen binding site However, in vivo immunisation 
with phage particles did not prove successful in eliciting a protective immune response, 
a more complex and sophisticated library may be required to achieve this goal The 
methods used for selecting mimotopes with mAbs tend to drive selection toward 
structures which show the ‘best fit’ to the ligate, and may not actually correspond to 
efficient imunogens
Japanese encephalitis virus (JEV) has also been the focus for identification of 
conformational epitopes using peptide display technology (Hirabayashi et a l , 1996) 
Synthetic libraries were used with two monoclonal antibodies that recognise 
conformational epitopes on the prM protein of JEV Synthetic libraries can contain the 
20 genetically encoded natural L-anuno acids as well as D-optical isomers and unnatural 
amino acids, giving greater diversity than phage libraries Two consensus sequences were 
identified, but only one was capable of producing antisera, on immunisation, which 
recognised the virus Short peptides have poor immunogenicity and are usually 
conjugated to a earner protein to prepare anti-peptide antisera, this procedure can 
modify the antigenic determinants making it difficult to obtain antibodies which could 
recognise the onginal protein Identification of a specific peptide for a neutralising MAb 
may produce polyclonal antibodies which have virus-neutralising activity
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Phage display has also been used to map the surface of many viral antigens, such as the 
hepatitis B surface antigen (HBsAg) (Chen et a l , 1996) HBsAg is the diagnostic marker 
for Hepatitis B (HBV), which causes major endemic illness throughout the world and is 
associated with a greatly increased frequency of primary hepatoma, a major cancer in the 
world (Hollinger, 1990) HBsAg is the major component of the envelope of the vinon 
and is mainly present in the plasma of HBV-infected patients (Mangold and Streeck,
1993) Four monoclonal antibodies were used in the study, three of which were found to 
bind to distinct discontinuous epitopes between residues 101 and 207 of HBsAg, the 
fourth bound residues 121-124 The data obtained was used to map the surface of the 
antigen and to derive a topological model for the a-carbon trace of the 101-207 region 
of HBsAg This approach would be useful for mapping other proteins, where the crystal 
structure is not available but a set of monoclonal antibodies are accessible A detailed 
picture of the amino acids that make up a particular epitope can be obtained for most 
Ab-Ag interactions via x-ray crystallography (Amit et a l , 1986), chemical modification 
(Jemmerson and Patterson, 1986), or deuterium exchange analysis by nuclear magnetic 
resonance (NMR) (Patterson et a l , 1990) These methods require substantial effort and 
are very difficult technically, the phage display approach has proven a useful alternative 
for epitope identification
1.8.3.5 Identification of Disease-specific Mimotopes using Human Sera
It has been possible to identify mimotopes of pathological antigens using only peptide 
libraries and human sera (Folgon et a l , 1994) In this way, diseases for which the 
aetiological agent is unknown, can be investigated using patient sera, thus improving the 
possibilities for the diagnosis and prognosis of these diseases Identification of disease- 
specific mimotopes could provide a set of novel reagents for the diagnosis of the disease 
In cases where the humoral immune response is protective, the isolated phagotopes 
could also represent a step in the development of acellular vaccines A model system was 
used to investigate the potential of this methodology, sera from both human hepatitis B 
virus envelope protein (HBsAg)-immumsed individuals (positive serum) and non- 
îmmumsed individuals (negative serum) were used This antigen was chosen as it is 
known that immunisation with HBsAg can elicit a protective immune response
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The experimental strategy consisted of the following steps
• Affinity selection of a peptide library with a positive serum,
• Screening of the enriched phage population for epitopes also recognised by a second 
positive serum,
• Further screening of the selected phagotopes using large panels of positive and 
negative sera
Screening the affinity-selected phage with a patient serum different from that used for the 
enrichment allows only those phage displaying epitopes recognised by antibodies of 
‘common’ specificity between the two sera to be identified There should be a high 
percentage of disease-specific phagotopes among the common ones It was not possible 
to subtract completely all the phage which reacted with the sera of healthy individuals, 
this may have been due to a low efficiency of the selection procedure Phage bearing 
HBsAg peptide mimics were identified, and used as immunising agents, which proved to 
be both antigenic and immunogenic mimics of the natural antigen HBsAg This model 
system proves the potential of this simple and inexpensive procedure for ‘footpnnting’ 
the immune response against a particular antigen, even in the absence of any information 
on the aetiological agent, the only requirement being clinically well-charactensed sera 
from patients and normal individuals
1.8.4 Advantages of using a Panel of RPLs
It has been seen that the peptides selected by a given selector molecule are significantly 
influenced by the structural framework within which a random peptide is presented This 
has been further investigated by the construction of a panel of peptide libraries 
comprising a variety of structurally constrained and unconstrained peptides of varying 
length, and screening it with a number of monoclonal antibodies (MAbs) and polyclonal 
antibodies (PCAbs) (Bonnycastle et a l , 1996) High affinity peptides are more likely to 
be found by screening a panel of peptide libraries, since a single library will not provide 
tight-binding peptides for all antibodies, and the preference of an antibody for particular 
constraints is not usually known in advance Eleven libraries were screened with 17 
antibodies, 15 MAbs against peptides, linear and discontinuous epitopes on proteins or 
carbohydrates and 2 PCAbs against proteins of known structure All except 2 MAbs 
isolated binding peptides from several libraries, the 2  which failed to select peptides were
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directed against discontinuous protein epitopes. Only a few of the large fraction of 
antibodies that bind to discontinuous epitopes in polyclonal serum were able to isolate 
weakly binding, cross-reactive peptides, while the less abundant antibodies that recognise 
linear epitopes cross-reacted well with peptides. Many of the antibodies showed 
polyspecificity in their preference for different consensus sequences within and between 
libraries. No library produced the best-binding phage across all of the antibodies, but the 
best-binding phage pools were obtained from a few of the libraries, especially if the 
binding was weak or moderate across the panel. These results were determined using the 
average binding strength of each library as a measure. These values were calculated by 
adding the scores within a library from every screening and dividing by the number of 
screenings performed on the library. All of the libraries had approximately the same 
average binding strength.
This study and previous work have also shown that the majority of anti-protein 
antibodies that cross-react with peptides recognise linear epitopes on their corresponding 
immunogens, and these epitopes usually occur on the folded protein as turns and 
extended loops (Getzoff et al., 1987; Geysen et al., 1987; Tainer et al., 1984). 
Discontinuous epitopes on folded proteins usually bind antibodies over a large shallow 
surface, this may be a reason for their inability to select peptides from a phage library. 
Large shallow binding sites would not allow a peptide to become buried as occurs with 
linear epitopes (Wilson et al., 1994). Discontinuous epitopes may be more successfully 
mimicked by folded proteins than by peptides. A more complex library displaying large 
inserts that are part of a protein having a very stable fold, is likely to be an important 
development. In this way an epitope or mimotope which would better fit the large, 
shallow binding site of a discontinuous epitope may be selected (Bonnycastle et al.,
1996).
1.8.5 Gene-Fragment Libraries
A recent study was carried out to compare the efficiencies of epitope mapping by gene- 
fragment libraries and two random peptide libraries in combination with peptide scan 
(Fack et al., 1997). The gene-fragment libraries were constructed by cloning DNasel 
digested random gene fragments into the 5’ terminus of the pill gene of fd phage. The 
random peptide phage libraries displayed 6 mer and 15 mer peptides at the N-terminus of
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the pill protein Peptide scanning required the synthesis of oligopeptides on activated 
membranes using the SPOTs system (Genosys, Cambridge, England) Four monoclonal 
antibodies were used, all were thought to recognise linear epitopes, shown by 
immunoblot, however, a positive reaction on immunoblots can also be achieved by non­
linear epitopes where the reacting portions are m relatively close proximity Using the 
gene-fragment display system a single round of affinity selection resulted in 65% to 95% 
ELISA-positive clones and in the determination of epitopes recognised by all 4 of the 
MAbs However, after 2-4 rounds of biopanmng with the 6  mer library, only 2 of the 4 
antibodies yielded positive clones and 3 out of 4 antibodies failed with the 15 mer library 
The epitopes were fine mapped by peptide scan, this showed that the minimal epitopes of 
the two antibodies which selected clones from the 6  mer library, MAbGD05 and 
MAbp53-ll, consisted of four and five amino acids respectively The antibodies 
MAb215 and MAbL13F3 failed to yield the epitope sequence from either random 
peptide library For the determination of the MAb215 epitope by gene-fragment phage 
display a minimal overlap size of 17 amino acids was obtained and the peptide scan 
narrowed this region to 11 amino acids This explains why the MAb215 epitope could 
not be found m the 6  mer library Neither the random peptide library or the peptide scan 
succeeded in yielding an epitope sequence for MAbL13F3 The sequence recovered from 
the gene-fragment library was relatively large and it is possible that this antibody 
recognises an epitope larger than the 15 amino acids used in the peptide scan or that the 
antibody recognises structures with a high conformational constraint It was found that in 
general when an antibody produced a positive signal m an immunoblot it also yielded 
positive clones by gene-fragment phage display Antibodies that could not detect their 
antigen by immunoblot, also failed to select positive clones from the gene-fragment 
libraries, these antibodies recognised conformational epitopes
Random peptide libraries cannot contain all possible epitopes and therefore will not yield 
positive clones for all antibodies investigated However, short epitopes can be identified 
in most cases using random peptide libraries It appears that epitopes spanning more than 
six consecutive amino acids can be more reliably detected by gene-fragment libraries, and 
epitopes with particular structural conformations which often escape detection by 
random peptide libraries or peptide scan can be determined
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1.9 Aims of this Thesis
This thesis may generally be divided into two parts Both possess a common theme in 
that each uses recombinant DNA methods to address important aspects related to the 
diagnosis and immune-response to EBV-related disease
In the first part, a number of EBV antigens were cloned into a plasmid for expression in 
Escherichia coh Using the chosen system, which is described m section 17 1, antigens 
are expressed in a soluble form with the E  coh thioredoxin To date these antigens have 
been purified from lysates of mammalian cells in cell culture Expression of these 
antigens in E  coh will allow production of greater quantities of recombinant antigen at a 
lower cost, for the purposes of developing a serology-based method for diagnosing 
EBV-related diseases Serotesting allows the determination of the type of EBV infection 
an individual has at a particular time, 1 e primary, past or reactivated infection
In the second part we have attempted to use phage display technology to identify 
peptides which bind to the EBV neutralising antibody 72A1 To this end, a number of 
random phage libraries were screened with the virus-neutralising anti-gp350 monoclonal 
antibody, 72A l, using different ‘biopannmg’ methods
Successful identification of the epitope or mimotopes of this antibody would have 
potential applications in the area of vaccine development Synthetic peptides with high 
affinity for 72A1 could be produced and used as constituents of a vaccine against EBV- 
related disease
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Chapter 2 
Materials and Methods
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2.1 Biological materials
2.1.1 Antibodies
72A1, F29.167, and F2.1 were supplied by Dr. Andrew Morgan, University of Bristol. 
These antibodies were provided as monoclonal cell line supernatants which were purified 
on a Protein G column then dialysed in PBS, but not exhaustively. They were stored at - 
20°C. Polyclonal anti-gp350/220, MDP 61.1.4.
Monoclonal Antibody
Anti-mouse-alkaline phosphatase (AP) conjugate 
Anti-mouse-horseradish peroxidase (POD) conj.
Anti-fd bacteriophage 
Anti-human-AP conjugate 
Anti-rabbit-AP conjugate 
Anti-human IgG-POD (X-chain specific)
Anti-human IgM-POD ((i-chain specific)
GullSORB
2.1.2 Serum Samples
All anti-EBV IgM-positive sera were supplied by Mrs. Dorothy Wyatt, Regional Virus 
Laboratory, the Royal Hospitals Trust, Belfast. All these sera were shown to be strongly 
positive for anti-EBV IgM by indirect immunofluorescence (Gull Laboratories), after 
removal of rheumatoid factor. They were not tested for blood-borne or other viruses.
Sample no. Patient details
Age Sex 
962/97* 35yrs F
1385/97* 35yrs F
7126/97 18yrs F
7217/97 53yrs F
9217/97 26yrs M
10211/97 26yrs M
12874/97 18yrs M * These are 2 sera from the same patient.
Supplier
Promega 
Boehringer Mannheim 
Sigma 
Boehringer Mannheim 
Boehringer Mannheim 
Dako 
Dako 
Gull Laboratories
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All EBNA IgG-positive and IgG-negative sera, and EB VC A IgM-positive and IgM- 
negative sera, were supplied by Carol Mongan, Virus reference laboratory, UCD, 
Belfield All specimens were from 1997
EBNA IgG-negative
6627 6737 
6769 6891 
6985 6988
EBNA IgG-positive 
7248 7256 7467 
7302 7310 8090 
7 3 4 3  7 3 4 4  8712
7068 7127 7387 7456
8725 8694 7529 7971
EB VCA IgM-negative EB VCA-IgM positive
7523 7266 
7268 7271 
7274 7281 
7291 7296
7611 7617
7739 7837 
8128 8318 
8413 8415
7299 7300 8811
All normal serum were supplied by a Dublin Hospital, July 1998 (samples were taken for 
routine clinical investigations)
7435 7436 7458 7464
7438 7439 7459 7465
7442 7443 7460 7466
7 4 4 7  7 4 4 8  7461 7467
7449 7454 7462
7456 7457 7463
CMV (Cytomegalovirus) positive sera (BIOTRIN, Dublin)
NY1 8638 769/95
NY2 16792 607/95
NY3 69/95 10190
NY4 0124 765/95
NY5 0623
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EBV positive sera (BIOTRIN, Dublin)
MS8 MS9
2664 CAC6385
2656 1318/95
26637 331/95
2.1.3 Oligonucleotides
R&D Systems and Genosys 
EBNA1
Forward primer
5’ CGGGATCCC AGG AGT CCC AGT AGT CAG TCA 3’ 
Reverse primer
5’ CGG GAT CCT AAT ACG ATT GAG GGC GTC TCC 3’
P 1 8 V C A
Forward primer
5’ GTT ATG GAT CCC CGG CTG CCC AAG 3’
Reverse pnmer
5’ GTT TCG GAT CCT CTA CTG TTT CTT 3’
BARFO
Forward pnmer
5’ TGC CAG TGG GAT CCC GGG TAC GCT 3’
Reverse pnmer
5’ TAC GGG GAT CCT AAA GTC GAT GTA 3 ’
Early antigen 
Forward pnmer
5’ CGG GAT CCG GAA ACC ACT CAG ACT CTC 3’ 
Reverse pnmer
5’ CGG GAT CCC GAG AAC ATG GTG TTA AAT 3’
2.1.4 Commmercial Kits and Enzymes
Thiofiision cloning kit Invitrogen
QIAEX Qiagen
Phage libranes New England Biolabs (NEB)
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T7 Sequencing kit Pharmacia
Protein assay dye reagent BIORAD
Supersignal substrate Pierce
All restriction and deglycosylation enzymes were supplied by Boehnnger Mannheim
2.2 Chemical materials
Protein prestained markers 
35S labeled dATP 
dNTPs 
Marvel 
Enterokinase 
Chloroform 
Dimethyl formamide
Sigma Chemical C o ,
NP-40, Urea, Dithiothreitol, Coomassie blue R, BCIP/NBT, Streptavidm, Kanamycin, 
Gelatin, Tetracycline, NZ amine A, Ethanolamine, Biotin-NHS, Liquid Phenol, 
Tryptophan, Nitocellulose, Cassamino acids, Ampicillin, Potassium acetate, Tween-20, 
Thiamine, Sodium bicarbonate, BSA, dialysed BSA, Sodium azide, PEG-8000, Sodium 
iodide, Sigma fast pNPP, Sigma fast OPD, Ammonium sulphate, Sigmacote, Ammonium 
phosphate, Mineral oil, PMSF
Merck,
Bone acid, Ammonium persulphate, Sodium acetate, Magnesium chlonde, Glucose, 
Sodium chlonde, Potassium chlonde, Sodium hydroxide, Sodium dodecylsulphate, 
Calcium chlonde, Glycme, Ammonium chlonde
BDH,
TEMED, Bromophenol blue, Potassium dihydrogen phosphate, Potassium hydrogen 
phosphate, Sodium phosphate, Glycerol, Tns(hydroxymethyl)methylamine, EDTA, 
Magnesium sulphate, Mereaptoethanol, Ethidium bromide, Sucrose, Isoamyl alcohol, 
Hydrochloric acid, Acetic acid, Methanol, Isopropanol
NEB
Amersham 
Pharmacia Biotech 
Premier Beverages 
Bioyme labs ltd 
ROMIL 
Riedel-de-Haen
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Boehringer Mannheim;
Protein-G agarose, Agarose, Low melt agarose, IPTG, Leupeptin.
Oxoid;
Agar technical, Tryptone, Yeast extract.
KODAK;
X-ray film, X-ray film developer, X-ray film fixer.
National diagnostics;
Acrylagel, Bis-acrylagel.
Gibco-BRL;
1Kb DNA ladder, (3-galactosidase (X-gal).
2.3 DNA M anipulation
Solution and reagents as detailed in appendix section I(i).
All centrifugation of microfuge tubes was carried out in a Biofuge 13 from Heraeus 
Instruments, all centrifugation of 50 ml Falcon tubes was carried out in a Labofiige from 
Heraeus Instruments.
2.3.1 Storage of DNA Samples
DNA samples should ideally be stored in TE buffer pH 8.0 at 4°C. The use of EDTA 
chelates heavy metal ions that are needed for DNase activity while storage at pH 8.0 
minimises deamidation.
2.3.2 Equilibration of Phenol
Before use, phenol was equilibrated to pH 8.0 as DNA partitions into the organic phase 
at <pH 7.8
1. Solid phenol was melted at 68°C, and hydroxyquinoline was added to a final 
concentration of 0.1% (acts as an antioxidant, a chelator of metal ions, and an RNase 
inhibitor).
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2 An equal volume of buffer (0 5 M Tns Cl pH 8 ) was added to the liquefied phenol
and stirred for 15 minutes The two phases were then allowed to equilibrate and as
much as possible of the upper aqueous phase was removed
3 The extraction was repeated using equal volumes of 0 1 M Tns Cl pH 8 until the pH 
of the phenol was > 7 8
4 An equal volume of 0 1 M Tns Cl pH 8 and 0 2% P-mercaptoethanol were added to
the phenol, which was then stored at -20°C in the dark
2.3.3 Phenol/Chloroform Extraction
1 An equal volume of phenol/chloroform/isoamylalcohol (25 24 1) was added to the 
DNA solution, mixed by vortexing and centnfuged for 5 min at 13000 rpm
2 The upper aqueous phase was removed, taking care not to take any material from the 
interphase, this was placed in a fresh microfuge tube
3 To this an equal volume of chloroform/isoamylalcohol (24 1) was added, vortexed as 
before and centnfuged for 5 mm at 13000 rpm Again the upper aqueous phase was 
removed to a fresh tube
2.3.4 Sodium acetate/Ethanol Precipitation of DNA
Concentration of nucleic acid samples or changing the buffers in which a sample is
dissolved was achieved by ethanol precipitation
1 One tenth volume of 3 M sodium acetate (pH5 2) was added to the solution of DNA, 
vortexed and 2 volumes of 100% ethanol were added Again this was vortexed, and 
the mix was incubated at -20°C overnight or at -80°C for 30 nun
2 The DNA preps were then centrifuged for 30 min at 13000 rpm at 4°C, the 
supernatant was removed and the pellet was washed with 1 ml 70% ethanol to 
remove excess salts
3 The tube was centnfuged for 5 mm at 13000 rpm, the supernatant was removed and 
the pellet was allowed to dry for approximately 30 min
4 The pellet was resuspended m an appropnate volume of stenle Tns-EDTA (pH8 0) 
(TE)
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2.3.5 Ammonium sulphate/Isopropanol Precipitation of DNA
This method was used for PCR products which were cut from agarose gels and purified 
by the QIAEXII kit
1 To the PCR reaction mix a % volume of 10 M ammonium acetate was added, the
solution was vortexed and an equal volume of 100% isopropanol was added The
solution was vortexed and incubated at -20°C for at least 1 hr or overnight
2 Tubes were centrifuged for 30 min at 13000 rpm at 4°C, the supernatant was
removed and the pellet was washed with 1 ml 70% ethanol, and centrifuged for 5 mm 
at 13000 rpm
3 The supernatant was removed, the pellet was allowed to dry for 30 mm, and was 
then resuspended in an appropriate volume of sterile TE (pH8 0)
Notes
(a) To remove SDS from a sample, the sample can be adjusted to 0 2 M sodium chlonde 
before the addition of ethanol
(b) If the DNA to be precipitated is small l e <200 bp, the sample should also be made 
10 mM in magnesium chlonde before ethanol precipitation
2.3.6 Spectrophotometric Quantification of DNA
In general, for quantification of maxiprep DNA 5 \x\ of DNA was added to 495 (j.1 of 
distilled water Absorbance readings were taken at 260 nm and 280 nm An absorbance 
reading at 260 nm of 1 corresponds to approximately 50 jig/ml of double stranded DNA 
The ratio between the readings at 260 nm and 280 nm provides a measure of the punty 
of the DNA A pure preparation of DNA will have a 260/280 ratio of between 1 8 and 
2 0
2.3.7 Agarose Gel Electrophoresis of DNA
Electrophoresis through agarose gels is the standard method used to separate, identify 
and punfy DNA fragments The technique is simple, rapid to perform, and can be used 
for the isolation of DNA fragments Typically, the following procedure was used 
1 An appropnate quantity of agarose or low melt agarose was added to 100 ml IX TBE 
buffer The amount of agarose depends on the percentage agarose required This was 
decided m relation to the size of the DNA fragments being separated
8 4
2 The mixture was boiled to dissolve the agarose, when cooled sufficiently (~60°C) the 
gel was poured into the mold and the comb inserted
3 The gel was allowed to set before filling the chamber with IX TBE, the comb was 
then removed
4 To a 20 (il sample, 4 pi of sample buffer was added and loaded into the wells made by 
the comb Sample buffer was also added at IX concentration to 300 ng 1Kb DNA 
ladder which was loaded into the first well
5 The gel was run at constant voltage (5 V/cm) for 1-2 hr When complete the gel was 
stained in ethidium bromide (0 5 mg/ml) for 30 min, placed m water to destain for 15 
min and viewed under UV illumination
2.3.8 Isolation of DNA from Agarose Gels
1 Low melting point agarose gels were prepared in IX TAE buffer (gel isolation is not 
earned out in TBE buffer as borate ions are difficult to remove from the resultant 
DNA solution)
2 After electrophoresis, the gels were stained in an ethidium bromide bath and viewed 
under 70% UV illumination The time of exposure to UV light was kept to a 
minimum, as overexposure to UV causes damage to the DNA
3 The DNA band to be isolated was excised from the gel using a scalpel and placed in a 
stenle microfuge tube Excess agarose was cut away to minimise the size of the gel 
slice
2.3.9 QIAEXII Agarose Gel Extraction Protocol (QIAGEN)
1 A 1 5 ml microfuge tube was used for up to 250 mg of agarose The weight of the 
gel slice was determined and 3 volumes of buffer QX1 was added to 1 volume of gel
2 The QIAEX II was resuspended by vortexing for 30 s, and then 10 pi was added to 
the microfuge tube with the gel This was incubated for 10 mm at 50°C to solubilise 
the agarose and bmd the DNA, the tube was vortexed every 2 min to keep the 
QIAEX II in suspension
3 The sample was then centnfiiged for 30 s and the supernatant was removed The 
pellet was washed once with 500 pi of QX1 and twice with 500 pi of buffer PE The 
pellet was air-dned for 15 min until white
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4 Twenty microlitres of sterile distilled water was added to resuspend the pellet, and 
the tube was vortexed, followed by incubation at room temperature for 5 mm
5 The sample was centrifuged for 30 s and the supernatant was carefully removed to a 
fresh tube
6  A further 20 (il of sterile distilled water was added and the pellet was resuspended 
and vortexed The tube was centrifuged and the supernatant removed to the fresh 
tube
2.3.10 Decontamination of Ethidium Bromide Solutions
This method was developed by Lunn and Sansone (1987)
1 Sufficient water was added to reduce the concentration of ethidium bromide to <0 5 
mg/ml
2 A 0 2 volume of fresh 5% hypophosphorus acid and 0 12 volume of fresh 0 5 M 
sodium nitrate was then added The solution was mixed carefully and the pH was 
checked (should be <3)
3 After incubation for 24 hr, a large excess of sodium bicarbonate was added and the 
solution was discarded
2.3.11 Restriction Digestion of DNA
Restriction enzymes bind specifically to and cleave double stranded DNA at specific sites
within or adjacent to a particular sequence known as the recognition site The restriction
enzymes used were supplied with incubation buffers at a concentration of 10X (working
concentration IX)
1 DNA digests were performed by adding 1 unit of enzyme/fig of DNA solution
2 The reaction mix was vortexed briefly and centrifuged, then incubated for 2 hours at
the optimum enzyme temperature (usually between 30°C and 37°C)
3 The final DNA concentration in the digest should be between 100 and 300 ng/ml for 
optimal digestion
2.3.12 Dephosphorylation of Linearised Plasmid DNA
1 To the digested DNA (5 |ig in 20 jxl) 1 ¡il of calf intestine alkaline phosphatase (CEP) 
was added, 15 (j.1 of the 10X enzyme buffer was added and the volume was made up
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to 150 (j.1 with stenle distilled water (CIP was added 1 umt/100 pmoles for cohesive 
termini and 1 umt/2  pmole for blunt termini)
2 The solution was vortexed, centrifuged briefly and incubated for 30 min at 37°C This 
was followed by denaturation by heating to 75°C for 10 min
3 This DNA was cleaned by phenol/chloroform extraction and ethanol precipitation
2.3.13 Ligation of DNA Molecules
Several strategies for ligation of DNA molecules were used depending on the nature of
the termini
(1) Cohesive termini
Ligations of equimolar amounts of vector and insert DNA (<1 |ig) were earned out
overnight at 16°C in a commercial ligation buffer (5 mM ATP) with 10 Weiss units of
ligase/ml After ligation, the samples were heated to 10 min at 70°C to inactivate the 
ligase (this appears to improve transformation efficiencies)
Dunng ligation, T4  DNA ligase will catalyse the formation of a phosphodiester bond 
between adjacent nucleotides only if one contains a 5’ phosphate group and the other 
contains a 3’ hydroxyl group Recirculansation of plasmid DNA can therefore be 
minimised by removing the 5’ phosphate groups by treatment with calf intestinal 
phosphatase enzyme (CIP)
Typical ligation reaction
per 10(0,1 reaction ¡xl
10X enzyme buffer 1
vector DNA (<1 (ig) 2
PCR DNA (<1 (j.g) 2
T4 DNA ligase 1
stenle distilled water 4
8 7
2.3.14 Small scale Preparation of Plasmid DNA (Miniprep)
Solution and reagents as detailed in appendix section I(n).
This is a modification of the methods of Bimboim and Doly (1979) and Ish-Horowicz
and Burke (1981)
Harvesting
1 A single bacterial colony was used to inoculate 5 ml of medium (with appropriate 
antibiotic), and incubated overnight at 30°C/37°C
2 1 5 ml of this culture was poured into a sterile microfiige tube and centrifuged for 30 
s at room temperature, the remainder was stored at 4°C The medium was-removed 
from the tube, leaving the pellet as dry as possible
Lysis
1 The pellet was resuspended thoroughly in 100 (0.1 of solution I by vigorous vortexing 
To this 200 (il of freshly prepared solution II was added, the tube contents were 
mixed by inverting the tube rapidly a number of times 150 (il of ice-cold solution III 
was added and vortexed gently for JO s
2 The lysate was centrifuged for 5 mm at 13000 rpm, and the supernatant was 
transferred to a fresh tube, taking care not to carry over any of the white precipitate
3 An equal volume of phenol/chloroform/isoamyl alcohol (25 24 1) was added, mixed 
by vortexing and centrifuged for 5 min at 13000 rpm
4 The upper aqueous phase was removed to a fresh tube, to which 2 volumes of 100% 
ethanol was added, the solution was vortexed and centrifuged for 5 min at 13000 
rpm
5 The supernatant was discarded, the pellet was washed with 1 ml 70% ethanol, 
centrifuged as before and the supernatant was removed again
6  The pellet was allowed to air-dry, and was then resuspended in 50 (il of TE (pH 8 0), 
1 (J.1 of DNase-free RNase A (20 (ig/ml) was also added, vortexed and stored at 4°C
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2.3.15 Large scale Preparation of Plasmid DNA (M axiprep)
Solution and reagents as detailed in appendix section I(ii).
1. A 400 ml bacterial culture was grown overnight at 37°C with vigorous agitation. The 
culture was centrifuged for 10 min at 7974 g in a Sorvall/Beckman centrifuge at 4°C.
2. The bacterial cell pellet was resuspended in 20 ml solution I. This was chilled on wet 
ice and 40 ml of solution II (fresh) was added, mixed gently but thoroughly and 
incubated on wet ice for 5 min. Twenty millilitres of solution III was added, mixed 
gently but thoroughly until all viscosity was gone, and incubated on ice for 5 min.
3. This supension was centrifuged for 15 min at 13180 g at 4°C, meanwhile 40 ml of 
isopropanol was added to a clean centrifuge bucket. The supernatant was added to 
the isopropanol, without carrying forward any white precipitated material. This was 
done by filtering through muslin gauze, followed by incubation at room temperature 
for 15 min (At this point the pellet could be stored at -20°C overnight).
4. The mixture was centrifuged at 8000 pm for 30 min at 4°C, the supernatant was 
removed and the bucket was inverted on some paper to drain.
5. The pellet was resuspended gently in 4 ml TE pH 8.0, RNase A was added to a final 
concentration of 25 pg/ml, and incubated at 37°C for 1 hr.
6. This was then extracted twice with an equal volume of phenol/ chloroform/ 
isoamylalcohol (25:24.1) and once with chloroform/isoamylalcohol (24.1), taking 
care not to take any interphase material.
7. For each extraction the solution was centrifuged for 5 min at 1912 g at 4°C. 0.4 ml of 
3 M sodium acetate was added, mixed and added 9 ml of 100% ethanol.
8. This was vortexed and incubated at room temperature for 10 min, the DNA was 
pelleted by centrifugation for 30 min at 13000 rpm at 4°C.
9. The pellet was washed in 70% ethanol, centrifuged for 5 min at 13000 rpm at 4°C, 
and resusupend in 1 ml TE pH 8.0.
2.3.16 Polymerase Chain Reaction Protocol (PCR)
The polymerase chain reaction (PCR) involves the amplification of specific DNA
sequences using DNA primers which anneal to the DNA of interest. The primers are
designed so that one anneals to the forward DNA strand and the other anneals to the
reverse strand thus allowing polymerisation of both strands by the enzyme Taq DNA
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polymerase This results in exponential amplification of the sequence of interest The 
standard requirements for a PCR reaction mix are detailed below
per 50(0.1 reaction ni
Stenle ultra pure water 37
1 OX enzyme buffer 5
25 mMMgCl2 2 5
dNTP 10 mM mix 1
Forward pnmer 250 ng/(ol 1
Reverse pnmer 250 ng/(il 1
Taq DNA polymerase 05
Template DNA 1
This reaction mix was overlayed with 50 \x\ stenle mineral oil before placing in the
numcycler
Polymerase Chain Reaction (PCR), standard program, only Ta was varied for each antigen, 
depending on the pnmers Ta is the annealing temperature for the specific primers
Stage no. Step no. Temp. (°C) Time (min) No. of cycles
1 1 94 2
1
2 1 94 1
2 2 Ta 1
2 3 72 1 5
72
24
15 Hold
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2.4 Thiofusion Expression System (Invitrogen)
Solution and reagents as detailed in appendix section II.
2.4.1 Bacterial Strains
E.coli G1724 and G1698 have the following genotype F',X',/acIq,/acPL8,a/w/7C::PtrpC/.
G1724 was used for expression at 30°C and above while G1698 was used for expression
below 30°C. Both strains were maintained on LB agar plates before transformation, after
transformation with cloned plasmid DNA both strains were grown on RMGamp plates or
RMamp liquid media.
2.4.2 Preparation of Chemically Com petent Cells using Calcium chloride
1. G1724/G1698 was streaked on a fresh LB plate and incubated overnight at
37°C/30°C.
2. A single colony was used to inoculate 5 ml SOB, which was incubated overnight 
with vigorous shaking at 37°C.
3. To 20 ml SOB, 500 pi of the overnight culture was added followed by incubation 
with vigorous shaking at 37°C until the OD550nm reached 0.37-0.5. (~2.5 hr). The 
culture was poured into a 50 ml Falcon tube and centriiuged at 2500 rpm at 4°C for 
10 min.
4. The supernatant was removed, the cells were resusupended in 10 ml of cold 100 mM 
CaCl2 by repeated inversion, and left on ice for 20 min. This solution was centrifuged 
for 10 min at 2500 rpm at 4°C, the supernatant was again removed and the cell pellet 
was resuspended in 1 ml cold 100 mM CaCl2 by gently pipetting up and down.
5. These cells could then be stored for ~5 days at 4°C.
2.4.3 Transform ation of Com petent Cells
1. A heating block was equilibrated to 42°C. Two hundred microlitre volumes of the 
competent cells were dispensed into microfuge tubes and kept on ice.
2. A 3-5 pi volume of each ligation reaction was added to a separate tube of competent 
cells and mixed gently with the pipette tip. For control reactions, 10 ng of each 
supercoiled plasmid (pTrx and /or pAL-781) was added to a separate tube of cells.
3. Each tube was incubated on ice for 30 min. The cells were heat shocked for 90 s at 
42°C in a heat block, then placed on ice for 1-2 min.
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4 To each tube 800 jj.1 of room temperature SOC medium was added and incubated 
with agitation at 30°C for 60 min
5 A 200 ¡il volume of each transformation mix was plated on RMG-amp plates and 
incubated at 30°C overnight (may need 2 nights)
2.4.4 Expression and Analysis of Transformants
Ampicillin resistant transformants were picked from the plate and used to inoculate 5 ml
RM medium with 100 (og/ml ampicillin These cultures were incubated overnight at 30°C
with vigorous shaking Plasmid DNA was isolated by mimprep (as described in section
2 3 14) for restriction analysis
2.4.5 Induction of Positive Clones
1 The clone of interest was streaked on an RMG-amp plate and grown at 30°C 
overnight
2 A single colony from the plate was taken to inoculate 5 ml of RM medium with 100 
|j.g/ml ampicillin and incubated at 30°C with shaking overnight
3 Ten millilitres of fresh induction medium was inoculated with 500 |il of the overnight 
culture in a 100ml culture flask and grown at 30°C to an ODssonm of 0 5 (~2 5hr)
4 A 1 ml sample was transferred to a microcentnfuge tube and centrifuged for 5 min at 
maximum speed This was the time zero sample before induction, the supernatant 
was removed the and the cell pellets were stored at -20°C until ready for analysis
5 To the remainder of the culture tryptophan was added to a final concentration of 100 
jig/ml using the 10 mg/ml stock solution (10 (_il of stock per 1 ml of culture).
6 The culture was then mcubated at 37°C with shaking for 4 hr The OD550nm was 
measured after 4 hr and 1 ml samples were taken and treated as for the time zero 
samples
7 At this point the crude samples were then analysed by SDS-PAGE or further 
purification was earned out
8 The cell pellets for each clone were resuspended in 500 |il osmotic shock solution 2 
and kept on ice A hand held somcator with a micro-tip was used to sonicate each 
sample one at a time with three lOsec bursts
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9 The lysates were put m liquid nitrogen after somcation to flash freeze them, tbs was 
followed by quick thawing at 37°C Two further rapid somcation-freeeze-thaw cycles 
were earned out
10 After the last thaw, all samples were centnfuged at 13000 rpm for 5-10 min at 4°C to 
pellet cell debns and insoluble matter The supernatants were transferred into fresh 
tubes and the pellets from the previous step were resuspended in 500 (j.1 of osmotic 
shock solution 2
11 All samples were stored on ice until analysed by SDS-PAGE
2.4.6 SDS Polyacrylamide Gel Electrophoresis (PAGE)
Solution and reagents as detailed in appendix section III
10 ml 10% resolving self ini') 12%fmi) 7 5%(m\)
acrylagel 3 33 4 0 25
bis-acrylagel 1 35 1 62 1 0
1 5 M Tns (pH8 8 ) 25 25 25
ultrapure water 2  62 1 68 3 8
10% SDS 0  10 0  10 0  10
10% APS 0  10 0  10 0  10
TEMED 0 004 0 004 0 004
2 5 ml 5% stacking gel(ml)
acrylanude 0 42
bis-acrylagel 0  168
1 M Tns (pH6  8 ) 0 312
ultrapure water 1 55
10% SDS 0 025
10% APS 0 025
TEMED 0 0025
Preparation of PAGE apparatus
1 Both plates were washed with detergent, nnsed with tap water and with distilled 
water They are then wiped in one direction with tissue soaked with 100% ethanol
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2 The gasket was placed about the ridged plate, the plates were put together and 
secured with clamps Stand in an upright position the resolving gel was poured to 
within 1” of the top of the larger plate and overlayed with 1 0 0% ethanol
3 When set, the ethanol was removed and the stacking gel was poured The comb was 
inserted and allowed to set IX running buffer was poured into the gel box, the 
clamps and gasket were removed and the plates placed in the chamber with the cut 
plate facing inward, making sure to exclude any air bubbles
4 The chamber was filled with running buffer, the samples were loaded and the 
electrodes were attached One gel was run at 30 mAmps for approximately 1 hr
5 When complete the plates were removed, separated and the gel was placed in 
coomassie stain for 30 min, agitating constantly Then the gel was placed in destain, 
with constant agitation, until all background staining was removed The destain was 
changed as it became saturated with stain
2.4.7 Purification by Osmotic Shock
1 The culture was grown, induced and harvested as described in section 2 4 5, (cells 
were not lysed) The O D @ 550 nm was recorded before harvesting the cells, 4 hr 
post induction Fresh cells were used for osmotic shock
2 The cell pellet was resuspended in osmotic shock solution # 1 to an OD550nm of 5 0 
(The ODssonm value recorded before harvesting was used to determine the volume 
required, using the following formula
Vr = (ODssonm of sample/5 0) * Vs,
Vr = volume to resuspend the cell pellet 
Vs = original sample volume
3 The cells were incubated on ice for 10 min, followed by centrifugation for 1 mm at 
4°C, the buffer was then decanted
4 The cell pellet was then resuspended in osmotic shock solution # 2, using the same 
volume as in step 2 , incubated on ice for 10  min and centrifuged for 10 mm @ 4°C
5 The supernatant was transferred to a clean tube, and the pellet was resusupended m 
the same volume of osmotic shock solution # 2
6  These samples could then be frozen at -20°C or run on SDS-PAGE
94
2.4.8 Purification by Heat Treatment
1 The culture was grown, induced and harvested as described in section 2 4 5, cells
were also lysed A heating block was equilibrated to 80°C
2 Fifty microlitres of the lysate was reserved and kept on ice, this is the zero time point 
which is not heat treated Aliquots of 50 |il were placed in microfuge tubes and 
incubated at 80°C for different lengths of time, from 30 s to 10 min
3 The heat treated samples were centrifuged at 3000*g for 15 min @ 4°C, to remove 
precipitated proteins The supernatants were transferred to fresh tubes and stored on 
ice
4 The protein precipitates were solubilised in 50 pi IX sample buffer, 10 [j.1 aliquots of 
the supernatant and solubilised precipitates were analysed by SDS-PAGE
2.4.9 Ammonium sulphate Precipitation of Recombinant Antigens
1 Saturated ammonium sulphate was prepared by adding 400 g ammonium sulphate 
(AS) to 500 ml distilled water, the pH was adjusted to 6  0 This solution was stirred 
for 2 hr at 37°C, until the salt was completely dissolved This solution crystallises at 
room temperature and it was necessary to heat and stir before each use
2 A small scale precipitation was earned out first with 500 jj.1 aliquots of partially 
punfied recombinant protein The saturated AS was added dropwise to the 
percentage required for a 1ml solution, and the volume was made up to 1 ml with 
PBS (a range of percentages were tned)
3 The samples were then stored on ice for 15-60 mm, gently mixed at 10 min intervals 
and centrifuged at 13000 rpm for 10 min The supernatants were removed to a fresh 
tube and the pellets were resuspended in 1 ml PBS
4 Dialysis tubing was boiled for 10 mins in 1 mM EDTA, nnsed thoroughly with
distilled water, and stored at 4°C
5 The samples were dialysed in ~3 L stenle PBS at 4°C overnight, with stimng
6  The dialysis tubing was cut in ~10 cm pieces, a clip was put at one end the sample 
was pipetted into the tubing, all air bubbles were excluded and another clip was used 
to seal the tubing This was then submerged in the container of PBS and attached to 
the side of the container with a piece of thread
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7 The fluid was removed on the following day to a fresh tube for each sample and a 
fraction of the sample was analysed by SDS PAGE
8 A second AS precipitation was then earned out as described on the chosen sample 
The percentage AS before which the recombinant protem precipitates from the 
solution is the sample chosen, a higher range of AS percentages are used in the 
second cut to precipitate the recombinant protein from any remaining proteins in the 
sample
9 The samples were dialysed after the second precipitation step and again a fraction is 
analysed by SDS PAGE
10  When both AS percentages are chosen a large scale punfication is earned out with 8 
ml of partially punfied recombinant antigen The procedure is similar to that 
desenbed above with larger volumes
2.4.10 Western Blot Analysis of Recombinant Antigens
Solution and reagents as detailed in appendix section IV
1 An SDS-PAGE gel was run as desenbed, with pre-stained markers The sponges and 
12 sheets of 3 MM filter paper were soaked in transfer buffer The filters were cut to 
the size of the gel as was the nitrocellulose
2 Two sponges were placed on each of the 4 gnds and 3 pieces of filter paper on each 
of these Each of the gels was put on one of the stacks of filters The nitrocellulose 
which had been wet with transfer buffer was put on top of the gel Ensunng there 
were no bubbles between any of the layers
3 The second stack was placed on top of each of the membranes, and put in the 
blotting apparatus with the gel on the side of the negative (black) electrode and the 
mtocellulose on the positive (red) side The cooling water was set flowing through 
and the apparatus was connected to the power pack The voltage was set constant at 
30 volts for 1 hr, this was then increased to 60 volts for the second hour
4 The apparatus was then taken apart and the nitrocellulose was placed in TBS bnefly 
followed by blocking buffer for 1 hr The membrane was then incubated in serum 
overnight at 4°C (The serum was diluted 1/100 in blocking buffer)
5 The filter was washed twice m TBST (0 l%(v/v) Tween-20) for 10 min and once in 
blocking buffer for 15 mm Meanwhile the secondary antibody was diluted 1/5000
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also in blocking buffer This was an anti-human alkaline phosphatase conjugated 
antibody
6  The filter was then incubated in secondary antibody for 1 hr at room temperature, 
followed by washing three times with TBST for 10 min each In a clean container 
BCIP/NBT substrate was used to cover the filter and the container was placed in the 
dark at room temperature for 30 min The filter was then rinsed in distilled water to 
stop the reaction and placed in cling film to store
2.4.11 Protein Purification using Phenyl Arsine Oxide (PAO) Agarose
Solution and reagents as detailed in appendix section V
1 A 0  5 ml volume of PAO resin was packed into a 2 5 ml sterile syringe, which was 
plugged at the end with glass wool The upper layer of 50% ethanol was removed a 
cap was put on the end of the syringe
2 The resin was resuspended in 1 ml of running buffer with 3 mM P-mercaptoethanol 
(P-mer), the resin was allowed to settle by gravity and the buffer was decanted by 
removing the cap and allowing the buffer to flow through
3 A 2 ml volume of this buffer was then added to the column, and the column was 
allowed to rock gently for 1 hr at room temperature, parafilm was used to seal the top 
of the column This incubation was done to activate the column The supernatant was 
then decanted as before
4 The resm was resuspended in 1 5 ml of running buffer (without P-mer), again the 
resin was allowed to settle and the supernatant was decanted, this step was repeated 
twice
5 A 1 ml volume of the cell lysate (containing the soluble recombinant protein and 
soluble E  coli proteins), was added to the column and rocked at room temperature for 
1 hr
6  The bottom of the column was opened and the lysate was allowed to flow through, 
this sample was collected in a microfuge tube and stored for SDS PAGE analysis
7 The resm was washed twice with 1 ml running buffer with 0 25 mM P-mer, the flow 
through was collected and stored
8 The recombinant protein was eluted using 1 ml running buffer with 500 mM P-mer, 
the flow through was collected and stored for analysis
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9 A 10 |il volume of each fraction was used for SDS PAGE analysis as described in 
section 2 4 6  The final eluate was assayed for protein concentration using the BCA 
protein assay as per manufacturers instructions, PIERCE product no 23225
10 The purified protein was stored in glycerol (15%), with leupeptin (2 (ig/ml) and 
PMSF (17 4 mg/ml, lOOmM)
2.4.12 ELISA Analysis of Recombinant Antigens with Human Serum
Solution and reagents as detailed in appendix section VI
1 Each protein was diluted to 10 (ig/ml (recombinant protein, not total protein) in 
coating buffer, each well was coated with 100  (xl of these solutions, the microtitre 
plate was incubated overnight at 4°C
2 The coating solution was removed and 200 |il blocking buffer was added to each well, 
the plate was incubated for 2 hr at 37 °C
3 The blocking buffer was removed and 100 ja.1 of serum was added to each well, and 
the plate was incubated for 2 hr at room temperature (Sera were diluted 1/100 in 
TBS, 5 % FCS, 0 05 % NaN3 and 0 05 % Tween)
4 The serum was removed and the wells were washed six times with TBST (0 1 % 
Tween) The secondary antibody [anti-human Ig-AP (1/5000), anti-human IgG-AP 
(1/6000), or anti-human IgM-AP (1/1000)] was diluted in blotto (5%)
5 A 100 |il volume of the diluted secondary antibody was added to each well and the 
plate was incubated for 1 hr at room temperature
6  The secondary antibody was removed and the wells were washed six times with 
TBST (0 1% Tween), 200 jj.1 of substrate was added, the plate was incubated for 30 
min at room temperature in the dark (The substrate was prepared as per 
manufacturers instructions - Sigma fast OPD substrate)
7 The optical density was measured at a wavelength of 414 nm
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2.5 Phage Display Libraries (NEB)
Solution and reagents as detailed m appendix section VII
2.5.1 ER2537 E.coli Strain Maintenance
ER2537 is an F+, recA+ strain
All cultures for M l3 propagation must be inoculated from colonies grown on media 
selective for presence of the F-factor The F-factor of ER2537 contains a portion of the 
proline biosynthetic operon that complements a corresponding chromosomal deletion, so 
these cells can be selected by plating in the absence of exogenous proline, le Minimal 
medium Thiamine must be included in the medium as ER2537 is auxotrophic for 
thiamine
ER2537 was streaked out from the glycerol stock provided onto a minimal plate, 
inverted and incubated at 37°C for 24 hr The plate was stored wrapped in parafilm at 
4°C for up to 1 month
2.5.2 Phage Titering
1 A single colony of ER2537 was used to inoculate 10 ml of LB and incubated with 
shaking at 37°C until OD6oonm ~0 5
2 Melted top agarose was dispensed into 3 ml aliquots and stored at 45°C until ready 
for use One LB/IPTG/Xgal plate was prewarmed for each expected dilution Ten­
fold serial dilutions of phage were made in LB, for amplified phage culture 
supernatants this was 108- 1 0u, for unamplified biopannmg eluates the dilutions were
10M04
3 When the culture had reached mid-log phase 200 jo.1 was dispensed into microfiige 
tubes for each phage dilution To these, 10 ¡il of each dilution was added, vortexed 
quickly and incubated at room temperature for 1-5 mm
4 The infected cells were transferred to a culture tube containing the top agarose, 
vortexed quickly and immediately poured onto a pre-warmed LB/IPTG/Xgal plate
5 The plates were allowed to cool, inverted and incubated overnight at 37°C Plaques 
were counted the following day
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2.5.3 Biopanning Procedure A
1. The monoclonal antibody 72A1 was diluted to 100 [ig/ml in 0.1 M NaHCC>3 (pH 
8.6), 1 ml of this solution was added to each plate (35 mm diameter), and swirled 
until the surface was completely wet. The plate was incubated overnight at 4°C with 
gentle agitation in a humidified container.
2. The next day 10 ml LB was inoculated with a single colony of ER2537, when 
amplifying the eluate on the same day a 20 ml culture was also inoculated with 
ER2537. Both cultures were incubated at 37°C with vigorous shaking.
3. The coating solution was poured off the plate and the plate was slapped face down to 
remove any residual solution. The plate was filled with blocking buffer and incubated 
for 1 hr at 4°C.
4. The blocking solution was then discarded and the plate was washed 6 times with 
TBST (0.1%(v/v) Tween-20). 4*1010 phage were diluted with 1ml TBST (0.1%), 
this was added to the washed plate which was then rocked gently for lhr at room 
temperature.
5. The non-binding phage were discarded by pouring off and slapping the plate face 
down, the plate was then washed 10 times with TBST(0.1%). (A clean section of 
paper towel was used at each wash.)
6. The bound phage were eluted with 1ml of elution buffer (0.2 M glycine-HCl pH2.2, 
1 mg/ml BSA), the plate was rocked gently for 10 min at room temperature, the 
eluate was pipetted into a microfuge tube and neutralised with 150 (il 1 M Tris-HCl 
(pH9.1), 1 (il of the eluate was titered as described above.
7. The remainder was amplified, as follows. The eluate was added to 20 ml ER2537 
culture at OD6oonm~0.5, incubated at 37°C with vigorous shaking for 4.5 hr.
8. The culture was transferred to a centrifuge tube and centrifuged for 10 min at 11950 
g at 4°C, the supernatant was transferred to a fresh tube and re-centrifuged for 2 min. 
The upper 80% of the supernatant was pipetted to a fresh tube to which 1/6 volume 
of PEG/NaCl was added. The phage were allowed to precipitate at 4°C for 1 hr, or 
overnight.
9. The PEG precipitation was centrifuged for 15 min at 11950 g at 4°C, the supernatant 
was decanted and the tube was re-spun briefly the residual supernatant was removed.
10. The pellet was resuspended in 1ml TBS, this solution was microcentrifuged for 5 min 
at 4°C, to pellet residual cells. The supernatant was re-precipitated with 1/6 volume
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of PEG/NaCl by incubation on ice for 15-60 min The tube was microcentnfuged for 
10 min at 4°C, the supernatant was discarded and the tube was re-spun briefly to 
remove residual supernatant
11 The pellet was resuspended in 200 |il TBS, 0 02% NaN3, microcentnfuged for 1 min 
and the supernatant transferred to a fresh tube This amplified elute was titered as 
descnbed above A plate was coated as before for the second round of panning
12 The blue plaques which resulted after titenng were counted and the phage titer was 
determined this value was used to calculate the phage input volume required for the 
second round, 1-2 * 1 0 11 pfu were required
13 The second and third round of biopanmng were earned out as for the first round, the 
Tween-20 concentration was raised to 0 5%(v/v) for all washes and dilutions m these 
rounds
14 When the third round unamphfied eluate was titered the blue plaques were selected 
for phage punfication and sequencing
2.5.4 Plaque Amplification
1 An overnight culture of ER2537 m LB was incubated at 37°C with vigorous shaking
2 This culture was diluted 1/100 in LB, dispensed in 1 ml aliquots into culture tubes, 
and inoculated with a single blue plaque picked from a third round titer plate (The 
plates should not be incubated for longer than 18 hr as deletions may occur) The 
tubes were incubated at 37°C for 4 5-5 hr with vigorous shaking
3 The culture was then transferred to a microfuge tube and centnfiiged for 30 s at 
13000 rpm, the supernatant was removed to a fresh tube and recentnfuged, the upper 
80% of this supernatant was transferred to a fresh tube
2.5.5 Rapid Purification of Sequencing Template
1 To prepare template for sequencing 750 |il of the phage-contaimng supernatant was 
transferred to a fresh microfuge tube
2 To this 300 (J.1 of PEG/NaCl was added, mixed by inversion and let stand at room 
temperature for lOmin This was then centnfuged for 10 nun at 13000 rpm and the 
supernatant removed
101
3 The pellet was thoroughly resuspended in 100 (il of iodide buffer and 250 (0.1 of 100% 
ethanol was added After incubation for 10 nun at room temperature the solution was 
centrifuged for 10  mm at 13000 rpm
4 The supernatant was discarded and the pellet was washed with 70% ethanol,
centrifuged as before for 2 min The supernatant was removed and the pellet was
allowed to dry
5 The pellet was resuspended in 20 |jl of sterile TE pH 8 0 10 (il of this template was 
used for manual Sanger dideoxy sequencmg with35 S
2.5.6 Biopanning Procedure B (solution binding with Protein G capture)
1 A single colony of ER2537 was used to inoculate 10 ml LB, when amplifying the
eluate on the same day a 20 ml culture was also inoculated with ER2537 Both
cultures were incubated at 37°C with vigorous shaking
2 A 75 [il volume of protein A (50% aqueous suspension) was pipetted into a 
microfuge tube, to this 1 ml TBST (0 1% Tween-20) was added The resin was 
suspended by gently tapping the tube, the resin was the pelleted by centrifugation at 
low speed for 30 s - 1  min
3 The supernatant was removed and the pellet was resuspended m 1ml blocking buffer, 
incubated at 4°C for 1 hr The solution was mixed every 10mm to keep the resin m 
suspension
4 Four*1010 phage and 300 ng of antibody (72A1) were mixed together to a final 
volume of 200 |il of with TBST (0 1%), and incubated at room temperature for 20 
min
5 The resm was pelleted by centrifugation and washed 4 times with TBST (0 1%), 
pelleting each time by centrifugation for 1 mm The phage-antibody mix was added 
to the resin, mixed gently and incubated at room temperature for 15 min, the 
contents were mixed occasionally
6  The resin was pelleted, the supernatant discarded, and the resm was washed 10 times 
with 1 ml TBST (0 1%) The bound phage were eluted by suspending the pellet in 1 
ml elution buffer and incubating for 10 min at room temperature
7 This mixture was centrifuged for 1 min at 13000 rpm and the supernatant was 
carefully to a fresh tube, this was then neutralised with 150 |il 1 M Tns-HCl, pH 9 1
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8 One microlitre of the eluate was titered as described in section II(u) and the 
remainder was amplified as described for procedure A
9 The second and third round of biopanmng was earned out as above with the Tween- 
20 concentration raised to 0 5%(v/v) for all washes and dilutions
10 Plaque amplification and punfication of sequencing templates was earned out as 
desenbed above
2.5.7 Preparation of Phage for Assay via ELISA and DOT Blot
1 A single colony of ER2537 was used to inoculate 5 ml LB and incubated at 37°C 
overnight with vigorous shaking This culture was diluted 1/100 in 20 ml of LB for 
each clone to be charactensed
2 Five microlitres of phage supernatant (from the plaque amplification procedure) was 
added to each culture and incubated at 37°C with vigorous shaking for 4 5 hr The 
culture was transferred to a centnfuge tube and spun for 10 min at 11950 at 4°C, the 
supernatant was transferred to a fresh tube and re-centnfiiged bnefly
3 The upper 18 ml was removed to a fresh tube and 3 ml PEG/NaCl was added to 
precipitate the phage, this was done at 4°C for 1 hr, or overnight This solution was 
then centnfuged for 15 min at 11950 g at 4°C, the supernatant was removed and the 
tube was re-spun bnefly, the residual supernatant was removed
4 The pellet was then resuspended in 1ml TBS and transferred to a microfuge tube and 
spun for 5 min at 4°C The supernatant was re-precipitated m a fresh tube with 1/6 
volume PEG/NaCl incubated on ice for 15 min
5 The solution was centnfuged for 10 mm at 4°C, the supernatant was discarded, the 
tube was re-spun bnefly and the residual supernatant removed
6  The pellet was resuspended in 50 jj.1 TBS and titered as desenbed previously
2.5.8 Phage ELISA
1 The selector antibody, 72A l, was diluted to 10 ¡j.g/ml in 0 1 M NaHCOs (p H8 6 ), 
200 (il aliquots were loaded into the appropnate number of wells on a 96 well titer 
plate (Costar microtiter plate) The plate was incubated overnight at 4°C with 
agitation m a humidified container
2 The following day the coating solution was removed and the wells were blocked with 
200 j j .1 of blocking buffer (PBS 2% marvel) for 2 hr at 37°C
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3 Each phage preparation was diluted to 100 |il with PBS and added to the ELISA 
plate the plate was incubated at room temperature for 2 hr This solution was then 
removed and the wells were washed 6  times with TBST (0 5% Tween-20)
4 The primary antibody, rabbit anti-bactenophage antibody, was diluted 1 /1 0 0 0  in 
blocking buffer, 2 0 0  jil of this solution was added to each of the wells and the plate 
was incubated for 2  hr at room temperature
5 The wells were then washed 6  times with TBST as before, the secondary antibody, 
anti-rabbit-alkalme phosphatase conjugate, was diluted 1/1500 in blocking buffer, 
200 |il of this solution was added to each of the wells The plate was incubated at 
room temperature for 1 hr, and the washing step was repeated
6  The substrate pNPP was prepared as per manufacturers instructions, 100 |xl of this 
substrate was added to each well and the plate was incubated in the dark for 30 mm 
at room temperature
7 Where the solution became yellow a positive result was recorded, if no colour change 
occurred a negative result was recorded, the colour intensity was not recorded
2.5.9 Phage DOT Blot
1 Phage were prepared as for ELISA, and the volume of each sample was made up to 
200 [il with stenle PBS A DOT blotting apparatus was used, this was connected to a 
vacuum pump
2 The nitrocellulose was cut to the size of the blotter and placed between the 
perforated mat and the cover of the blotter A vacuum was drawn and the blotter was 
tightened The vacuum was turned off and the samples were loaded into the wells, 
allowed to stand for lhr and then a vacuum was drawn for 1 hr
3 The nitrocellulose was removed and placed m a clean tray to which blocking buffer 
(as for plaque lift) was added This was incubated with agitation for 1 hr at room 
temperature, then washed for 10mm with TNT A, 10 min with TNT B and 10 min 
with TNT A, constantly agitating
4 The primary antibody (72A1) was diluted 1/1000 to a concentration of 1 jig/ml m 
blocking buffer with sodium azide (0 05% NaN3) The nitrocellulose was covered 
with this solution and incubated for lhr at room temperature with agitation
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5 The filter was then washed as before with TNT A and TNT B The secondary 
antibody (anti-mouse-POD conjugate) was diluted 1/750 in blocking buffer without 
sodium azide, the filter was covered with this solution and incubated for lhr at room 
temperature with agitation
6  The filter was washed again as before and then covered with substrate
(Supersignal® substrate PIERCE product no 34080, prepared as per manufacturers 
instructions) and incubated for 10 min
7 The filter was wrapped m clingfilm taking care to exclude any air bubbles, exposed to
X-ray film for 30 s, 1 mm and overnight The film was developed as descnbed in
section 2 7 4
2.5.10 Deglycosylation of gp350/220
1 A 100 (xl aliquot of gp3 50/220 (concentration unknown) was placed in a 
microcentnfuge tube, 1 jj.1 of 10% SDS was added, the tube was vortexed and 
centrifuged briefly This mix was incubated for 10  mm at 100°C to denature
2 After boiling the tube was centrifuged briefly and 1 (il of NP40 was added, the tube 
was vortexed briefly and centrifuged
3 Two tubes were prepared with the following reagents, A as a control (no
deglycosylation enzymes), B with deglycosylases
Reagents A(nl) BGil)
O-glycosidase - 1
N-glycosidase - 5
Neuraminidase - 5
PMSF (17 4 mg/ml) 5 5
gp350/220 (denatured) 30 30
Deglycosylation buffer 65 54
Total volume 10 0 100
4 Each reaction tube was vortexed briefly and centrifuged, the reaction mixes 
were mcubated for 18 hr at 37°C
5 The tubes were centrifuged and 10 ¡¿1 aliquots were taken for analysis on SDS PAGE
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followed by Western blot analysis, as described in sections 2 4 6  and 2 4 8 The 
remainder was stored at 4°C
2.6 Protocols for the 15mer Phage Library
Solution and reagents as detailed m appendix section VIII
The 15mer library displays a 15mer peptide on each of the 5 pill proteins of the fUSE5 
filamentous phage The library consists of 1 1*1012 clones and the concentration of 
phage is 1*1014 vinon/ml This library was gift from Dr Conley
2.6.1 Bacterial Strains
E  coli K91 andK91KAN
K91and K91KAN are standard E  coli strains for propagating most filamentous phage
strains They have ~5 F pili/cell (as opposed to 0 5/cell in most male strains) and give
excellent, large plaques with wild-type filamentous phage K91KAN also carries the 
kanamycin resistance gene Both strains are grown on LB agar with or without 
kanamycm as appropnate
2.6.2 Preparation of Terrific Broth Cultures
A single colony of K91KAN cells was used to inoculate 5 ml NZY (100 (ig/ml 
kanamycm) and incubated at 37°C with vigorous agitation overnight Of this culture 100  
|il was used to inoculate 10 ml terrific broth in a 125 ml flask The culture was incubated 
at 37°C with vigorous shaking When the O D 6oonm of 1/10 dilution ~ 0 1-0 2 the shaking 
was slowed down to allow any sheared F pill to regenerate The cells are then ready for 
use within an hour
2.6.3 Titering of Plaque Forming Units (pfu)
1 A single colony of K91KAN was used to inoculate 10 ml NZY (kan), the culture was 
incubated at 37°C with vigorous shaking until the O D 6oonm ~ 0 2 (~4hr)
2 The TB soft agar was melted and 3 ml aliquots were put in glass tubes, these were 
stored in an oven at 55°C
3 The phage were diluted appropriately m TBS/gelatin and 400(il of the K91KAN 
culture was added to each dilution This solution was mixed and added to a tube of
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soft-agar, the tube was vortexed and immediately poured onto an NZY(kan) plate 
with 40 jig/ml tetracycline and 100 |ig/ml kanamycm)
4 The soft agar was spread evenly over the plate, the agar was allowed to solidify and 
the plates were incubated at 37°C overnight
2.6.4 Titering of Transducing Units (TUs)
1 Terrific broth cultures of K91KAN were prepared as described in section 2 6  2, and 
the eluate or amplified phage were diluted with TBS/gelatin A range of dilutions 
were covered to ensure a particle concentration of 3*105 vmons/ml - 3*106 
vinons/ml
2 Ten microlitres of each dilution was placed m a sterile 10 ml tube, to each of these 
samples 10 ¡j.1 of the K91KAN terrific broth culture was added The two were mixed 
thoroughly and incubated at room temperature for 10 mm to allow the phage to infect 
the concentrated cells
3 After incubation 1 ml of NZY (0 2 |xg/ml tetracycline) was added to each tube and 
they were incubated at 37°C for 40 mm with agitation
4 Two hundred microlitre aliquots of the infected cells were then spread on NZY plates 
containing 40 |o,g/ml tetracycline and 100 (ig/ml kanamycm the plates were incubated 
overnight at 37°C
2.6.5 Biopanning
1 Forty micrograms of the monoclonal antibody (72A1) was added to a sihcomsed 
microfuge tube, 4 4 (il of LM NaHC03 was added to this, and the volume was made 
up to 24 |il with sterile distilled water
2 One milligram of biotm-NHS was dissolved in 2 ml 2 mM NaOAc (pH6 ), 20 (il of 
this solution was added to the monoclonal antibody solution and incubated for 2  hr at 
room temperature
3 Five hundred microlitres 1 M ethanolamine was added and incubated for 2 hr at room 
temperature (the ethanolamine reacts with any residual biotin) Twenty microlitres 50 
mg/ml dialysed BSA and 1 ml TBS were added, and the mix was concentrated on a 
Centncon ultrafilter (Amicon) with a 30-kD cut-off
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4 The retentate was washed twice with 2 ml TBS and once with TBS/0 02% NaN3 
The retentate was then collected and stored in a 0 5 ml microfuge tube and stored at 
4°C The volume was measured and the concentration of biotinylated antibody was 
calculated
5 Nine hundred microlitres of distilled water and 100 (il 1 M NaHC0 3  were added to a 
petn dish (35 mm diameter), 10  jig streptavidin was added and the plate was agitated 
to mix the contents The plate was put in a humidified box and incubated overnight at 
4°C with agitation
6  This solution was then discarded and replaced with blocking buffer, the plate was 
incubated for at least lhr at 4°C The blocking buffer was then returned to it’s 
container (can be re-used until microbial growth becomes evident) and stored at 4°C, 
the plate was washed 6  times with TBS/Tween
7 Five micrograms of biotinylated antibody was added to the dish, and it was allowed 
to rock at 4°C for 2 hr, in a humidified contamer Four microlitres of 10 mM biotin- 
NHS (filter-stenlised) was added to the plate and it was allowed to rock for a further 
hour at 4°C
8 The dish was then washed 6  times with TBS/Tween, then 400 (il TBS/Tween was 
added to the plate and 4 (il 10 mM biotin-NHS was added Five microlitres of the 
original 15mer library was added to this solution The dish was incubated at 4°C m a 
humidified container for 4hr
9 The phage were poured out of the dish, and the dish was slapped face down to 
remove any residual liquid The dish was washed 10 times with TBS/Tween , a clean 
paper towel was used after each wash
10 Four hundred microlitres of elution buffer was added to the dish, and incubated at 
room temperatures for 10 mm The eluate was pipetted into a microfuge tube 
containing 75 (il 1M TnsHCl pH 9 1 One microlitre of the eluate was used for 
titering and the remainder was amplified in K91KAN E  coll
11 The first elauate was concentrated on a Centncon 30-kD ultrafilter and washed once 
with TBS The retentate was back centrifuged into a collection tube and transferred 
to a microfuge tube A further 50 (il of TBS was added to the membrane to wash, 
again this was back centrifuged and transferred to the microfuge tube giving a final 
volume of 100 (¿1 (This step was not necessary for the second and third eluate)
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12 K91Kan terrific broth cells were prepared as described above, 100 (il of these cells 
were mixed with 1 00  (il of eluate, the solution was stirred gently with a pipette tip 
and allowed to react for 10-30min at room temperature This was then added to 20 
ml of pre-warmed NZY medium with 0 2 jig/ml tetracycline in a 125 1 flask
13 The culture was incubated at 37°C for 30-60 nun, 20 |il of 20 mg/ml tetracycline was 
added to the flask (2 0  (il was removed at this point) and the culture was incubated at 
37°C with vigorous shaking overnight
14 The 20 [il sample taken was diluted 10' 1 for the first eluate and 10' 1 and 10'2 for the 
second and third eluate, and was subsequently plated on NZYtet,kan The plates were 
incubated overnight at 37°C, and the colonies were counted on the following day
15 The 20 ml overnight culture was centrifuged at 2987 g for 10mm at 4°C, the 
supernatant was removed to a clean tube and re-centnfuged at 11950 g for 10 mm at 
4°C This supernatant was added to a tube with 3 ml PEG/NaCl, the contents were 
mixed by inverting ~100 times and was mcubated at 4°C for at least 4hr, or 
overnight
16 This solution was then centrifuged at 11950 g for 15 min at 4°C, the supernatant was 
discarded and the centrifugation was repeated, any remaining fluid was then 
removed The pellet was then resuspended in 1ml TBS, the tube was centrifuged 
briefly and the solution was transferred to a microfuge tube which was centrifuged 
for 1mm to remove any insoluble matter
17 The supernatant was added to a tube with 150 j j .1 PEG/NaCl, mixed by -100  
inversions, and incubated at 4°C for at least 1 hr The tube was centrifuged at high 
speed for 10 min at room temperature, the supernatant was removed and the tube 
recentnfuged, the remaining fluid was removed
1 8  The phage pellet was resuspended in 200 j j .1 TBS (0 02% NaN3) The tube was 
centrifuged for 1 mm to remove any insoluble matter and the supernatant was 
transferred to a fresh tube
19 For the second and third round of biopanmng the antibody (72A l) was pre-reacted 
with the phage and then panned on the sterptavidin coated plate The petn dish was 
coated as before with streptavidin, 1 00  (il of phage from the amplified eluate was 
added to 100 nmoles of the biotinylated MAb in a microfuge tube, this mixture was 
allowed to react overnight at 4°C
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20 Four hundred microlitres of TBS/Tween was added to the phage/antibody solution 
and immediately added to the streptavidin coated dish (had been blocked and 
washed) The dish was allowed to rock gently for 10 mm at room temperature
21 The washing and elution were earned out as desenbed for round one This was 
followed by titenng and amplification of the second eluate The procedure for round 
three was similar to that for round two but the amount of biotinylated antibody used 
was reduced to 0 1 nM
2.6.6 Small-scale Propagation and Processing of Phage
1 NZY with 20 mg/ml tetracycline was aliquoted in 1 7 ml portion into culture tubes 
Single colonies were isolated from a third round titer plate and used to inoculate the 
media, these cultures were incubated overnight with vigorous shaking at 37°C
2 The cultures were poured into a microfuge tube and centnfuged for 30 s to pellet the 
cells 1ml of the supernatant was transferred to a fresh tube with 150 |xl PEG/NaCl 
The solution was mixed by -100 inversions and incubated at 4°C for at least 4 hr, or 
overnight
3 This was then centnfuged at 13000 rpm for 15 min at 4°C, the supernatant was 
discarded and the tube was recentnfuged and any residual fluid was removed
4 The pellet was dissolved in 500 (¿1 TBS by vigorous vortexmg
2.6.7 Preparation of Sequencing Template
1 To 200 jil of phage (prepared as in section III(iv)), 200 |il of phenol was added, the 
tube was vortexed for 2 0  s, allowed to stand for 2 0  mm, vortexed for a further 2 0  s 
and centnfuged for 5 mm at 13000 rpm
2 The upper aqueous phase was removed to a fresh tube, an equal volume of 
phenol/chloroform/isoamylalcohol (25 24 1) was added, the tube was vortexed for 
20 s and centnfuged for 5 mm at 13000 rpm
3 Again the upper aqueous phase was removed to a fresh tube, an equal volume of 
chloroform/isoamylalcohol (24 1) was added The tube was vortexed for 20 s and 
centnfuged for 5 nun at 13000 rpm, the upper aqueous phase (-150 jil) was removed 
to a tube containing 250 jj.1 TE
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4 Forty microhtres of 3 M NaOAc and 1ml ethanol were added, and the tube was 
incubated for 1 hr on ice to allow the DNA to precipitate The tube was centrifuged 
for 30 mm at 13000 rpm, the supernatant was removed and the pellet was washed 
with 1 ml 70% ethanol
5 The tube was centrifuged for 5 mm at 13000 rpm, the supernatant was removed and 
the tube was recentnfuged Remaining fluid was removed and the pellet was 
resuspended in 7 jxl stenle distilled water
2.6.8 Immunological Screening of Plaques or Colonies
1 Plates with either plaque forming units or transducing units were incubated at 37°C 
overnight If colonies were being screened the plates were placed at 4°C for 2  hr 
before lifting
2 Nitrocellulose membrane was cut to the size of the petn dish and given orientation 
marks corresponding to marks on the plates The filter was placed face down on the 
colonies or plaques, then lifted straight off and placed in a 1 L beaker of TNT (7 5 
ml/filter)
3 BSA, gp350/220, 72A1 and the secondary antibody were all dotted on to a piece of 
mtocellulose and washed and mcubated as for the plaque/colony lift BSA was the 
negative control, gp350/220, 72A1 and the secondary antibody were all positive 
controls A range of concentrations were used
4 The beaker was covered with cling film and agitated for 30 mm at room temperature 
The TNT was replaced by a fresh aliquot and mcubated for a further 30 mm
5 This wash was then removed and blocking buffer (with NaNs) was added, the beaker 
was agitated at room temperature for 30 min
6  The primary antibody (72A l) was diluted to 0 45 (j,g/ml in blocking buffer (with 
NaN3), the blocking buffer was poured off and the primary antibody was added (7 5 
ml/filter) The filters were incubated in this solution for 2 hr at room temperature 
with agitation
7 The filters were then washed 3 times for 10 min each with TNTA, TNTB, and 
TNTA The secondary antibody (anti-mouse alkaline phosphatase conjugate) was 
diluted 1/5000 with blocking buffer (without NaNs) (7 5 ml/filter) This was 
incubated for lhr at room temperature with agitation
i l l
8 The filters were washed as before and each was placed in a clean container Each 
filter was covered with BCIP/NBT substrate and incubated in the dark for 30 min, 
then analysed for positive reactions which appear as purple spots on the filter
2.7 Sequencing (T7 Sequencing Kit- Pharmacia Biotech)
Solution and reagents as detailed in appendix section IX 
Notes
(1) The heating block was set at 60°C
(2) 1 5 ml microfuge tubes were used for initial primer annealing and labelling
(3) 0 5 ml tubes were used for termination reactions 
(3) S35 was taken from the freezer 30 min before use
Dilutions of T7 DNA polymerase
no of templates polymerase dilution buffer(^l) total volume(|il)
2 1 4 5
3 1 5 6 75
4 2 8 10
5 25 10 12
6 3 12 15
7 3 5 14 17
8 4 16 20
9 45 18 22
10 5 20 25
The primer was diluted to 2 5 |iM
The template was prepared as in section 2 5 5 or section 2 6 6
2.7.1 Sequencing Reactions
1 To 10 \i\ of template (phage DNA), 2 jj.1 of diluted primer was added in a microfuge 
tube, 2 (il of annealing buffer was then added, the tube was vortexed, centrifuged 
briefly, then incubated at 60°C for 10 mm and allowed to stand at room temperature 
for at least 10 min, then centrifuged briefly
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2 To this mix, 3 (j.1 labeling mix (dATP), 1 |il labeled dATP (S35) and 2 jxl diluted T7 
DNA polymerase were added These were mixed gently by pipetting and incubated at 
room temperature for 5 mm
3 Four tubes were labeled A,C,G,T for each template, 2 5 jj.1 of each of the “read short 
mixes” were added to their corresponding tube and incubated for l mm at 37°C
4 To each of the 4 pre-warmed sequencing mixes, 4 5 (j.1 of the labeling reaction was 
added, mixed by gentle pipetting, and incubated at 37°C for 5 mm
5 Five microlitres of stop solution was added and mixed gently
6 Four microlitres of each reaction was added to a fresh tube, incubated at 75-80°C for 
2 nun, and immediately loaded on the sequencing gel The remainder of the unheated 
reactions was stored at -20°C
2.7.2 Preparation of the Sequencing Apparatus
The plates were washed m detergent to remove all traces of gel, rinsed thoroughly with 
tap water followed by ultra pure water, wiped dry with clean dry tissue removing all 
tissue and dust 10% SDS was poured onto each plate and rubbed vigorously with clean 
tissue, another clean dry tissue was used to remove the detergent 100% ethanol was 
poured onto the plates and wiped in one direction along the entire length of the plate 
until dry again The large plate was silicomsed using “sigmacote”, of which a few drops 
were applied at one end and wiped along the plate in one direction The plates were then 
clamped together with the spacers along each side
2.7.3 Casting the Gel
1 Starting with a clean dry casting tray a paper sealing strip was placed into the castmg 
tray To 20 ml of gel mix, 250 {j.1 10% APS and 100 (il TEMED was added This gel 
solution was poured quickly onto the sealing strip and the plates were placed on top 
and clamped into the tray When set (tip to check), the mam gel was poured at 45° 
angle using a 50 ml synnge slowly and constantly
2 The comb was inserted blunt end first and the gel was allow to set, at least 3 hrs Two 
litres of lx  TBE was prepared from the lOx stock with ultra pure water The comb 
was removed and inserted with the sharp tooth edge toward the gel, the wells were 
washed thoroughly with a synnge and fine needle Four hundred millilitres of buffer 
was poured in the bottom reservoir and the IPC chamber was filled The gel was
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prerun for 45 min at least, using sample dye in a few wells to ensure the samples 
would run correctly
3 After a gradual increase of power over a 10 mm period the gel was run at 1700 volts 
for 3 25 hr for the Conley library, and 2 75 hr for the NEB library (due to the required 
length of the sequence to be read)
2.7.4 Drying and Developing
1 The plates were separated and 3MM filter paper (cut to size) was placed on top of the 
gel, avoiding bubbles The paper was lifted gently taking the gel with the paper This 
was then covered with cling film and placed on top of another sheet of 3MM filter 
paper in the gel dryer, with the cling film facing up
2 The gel was dried at 80°C for 1-2 hr When dry the gel was placed in a cassette and in 
the dark room the cling film was removed and a sheet of X-ray film was placed on the 
gel The cassette was sealed shut and the gel was exposed to the film for 48 hr
3 The film was removed from the cassette in the dark, placed in developer for 5 mm, 
water for 1 mm, and fixer for 3 mm The film was then dried for ~ 30 s (when 
developing, the film was agitated continuously m each of the solutions)
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Development of recombinant EBV antigens as reagents for 
serodiagnosis of EBV-related disease.
Chapter 3
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3.1 Introduction 1
Serological testing is of paramount importance in the diagnosis of EBV-related disease 
As discussed in section 1 5, the Paul-Bunnell heterophile antibody test has been the 
method of predominant use to date (Paul and Bunnell, 4932, Elgh and Linderholm, 
1996) A number of ELISA methods have been developed, mainly using cell-culture 
denved antigens The performance of these diagnostic kits vanes (Weber et a l , 1996, 
Gutierrez et a l , 1997), (see section 15 3), and large-scale production of antigens from 
cell culture is expensive Expression of EBV antigens in Escherichia coli would allow 
the large-scale production of recombinant antigens in large quantities at a lower cost 
The Thiofusion expression system was chosen (see section 1 8) as it permits the high 
level expression of soluble recombinant protein, and provides a convenient method of 
punfication (Lunn et a l , 1982 and 1984,LaVallie et a l , 1992)
Three EBV antigens were chosen for expression, EBNA1, pl8VCA and diffuse early 
antigen (EA-D) (sections 1 3 2, 1 3 3, 1 5 1) The BARFO ORF was also cloned, and the 
gene product expressed in E  coli The antibody profile of an individual (IgG and IgM), 
to these antigens, is an excellent indication of the type of EBV infection the individual 
has at a particular time (discussed in section 1 5 1, see table 4)
In summary, the open reading frame (ORF) DNA sequence encoding each antigen was 
cloned into the E  coli expression vector pTrxFus, and the recombinant proteins were 
expressed as fusions with thioredoxin These proteins were partially purified and 
analysed for reactivity against a panel of serum by Western blot and ELISA The sera 
tested had been previously charactensed as IM-positive, VCA-positive or -negative, 
EBNA-positive or -negative, CMV-positive, EBV-positive or normal, by alternative 
methods
The sera were partially charactensed using the novel antigens by ELISA, and compared 
with the profiles determined by alternative commercially available diagnostic kits The 
assays used were as follows
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• BIOTEST, Anti-EBV Recombinant EBNA IgG ELISA
• Gull, EBVCAIgM ELISA
• Baxter Bartels, CMV IgM EIA and EBV IgM EIA
• ORGANON TEKNIKA, Monosticon Dn-DOT test (heterophile antibody test)
• Gull, Anti-VC A IgM IF A
3.2 Sub-cloning of Antigen coding DNA sequence
3.2.1 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) was used to specifically amplify each ORF from 
the cDNA previously cloned into either a pGEM7zf vector (BKRF1), or the pBR322 
vector (BFRF3 and BARFO) The EA-D gene BMRF1 was amplified from genomic 
DNA isolated from the Raji cell line (Burkitt Lymphoma EBV-positive cell line) The 
PCR primers were designed to incorporate a restriction enzyme site at the 5’end, to aid 
sub-cloning into the pTrxFus vector In this regard, BamHl was chosen for each cloning 
experiment as using this site simplified the in-frame cloning of each PCR product and 
obviated the need for a double digestion The PCR program for each amplification was 
as follows (Table 5), the single variable was the annealing temperature (Ta), which was 
determined from Tm, the melting temperature of each primer [Tm = 2(T+A) + 4(G+C)]
Stage no. Step no. Temp. (°C) Time (min) No. of cycles
1 1 94 2 -
1
2 1 94 1 -
2 2 Ta 1 -
2 3 72 1 5 -
24
3 1 72 5 -
1
4 1 15 Hold
Table 5: Polymerase Chain Reaction (PCR), standard program, only Ta was varied for each
antigen, depending on the primers.
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Primers were designed incorporating a BamHI site at the 5’ end of each, the forward 
primer was designed such that a truncated form of EBNA1 was amplified from the 
BKRF1 ORF in p7CMVEl, which contains the complete EBNA1 ORF. Figure 12 shows 
a schematic representation of the EBNA1 protein and the gly-ala repeat which is 
excluded from the truncated protein. The primers were designed so that the cloned 
product was in the correct translational reading frame with the thioredoxin gene of 
pTrxFus. The annealing temperature was 61°C. The truncated form, 829 bases, encodes 
a protein approximately 29 kd which in fusion with thioredoxin forms a protein 41 kd in 
size. The deleted portion of BKRF1 has homology to cellular DNA (Heller et al., 1982), 
antibodies to the protein encoded by this part of the gene also react with cellular proteins 
(Dillner et al., 1984; Luka et al., 1984).
EBNA1
3.2.1.1 EBNA1
1 90 346 641
90 - 346 gly - ala repeat
region targeted for expression
Figure 12: Schematic representation of the EBNA1 protein.
Forward primer
5’ CGGGATCCC AGG AGT CCC AGT AGT CAG TCA 3’
Reverse primer
5’ CGGjGATCCT AAT ACG ATT GAG GGC GTC TCC 3’
BamHI sites underlined above.
Following PCR, an amplified product of the expected size was detected and there were no 
non-specific amplified products. (Figure 13)
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1 2 3 4 5
Figure 13: Amplification of 829 bases of the BKRF1 ORF by PCR. PCR products were
electrophoresed through a 1% agarose gel Lanel- DNA ladder, lanes 2,3 and 4 - 3 jj.1 of a 50 |il PCR 
reaction, lane 5 - PCR negative control (no template)
3.2.1.2 pl8VCA
The viral capsid antigen, pl8VCA, is encoded by the EBV BFRF3 ORF, which was present 
on a larger genomic BamHl DNA fragment cloned mto pBR322, pBRBamHI F Primers 
were designed to amplify the complete pl8VCA gene, again BamHI sites were incorporated 
mto the pnmers to facilitate cloning mto the BamHI site of pTrxFus The first codon of 
BFRF3 was changed from a methionine to aspartic acid (GAC) so as to remove the 
possibility o f internal translation initiation during the rProtem production An annealing 
temperature of 44°C was used The amplified product was 528 bases and encoded an 18 kd 
protem which when fused with thioredoxm was 30 kd
Forward primer
5’ GTT ATGGATCCC CGG CTG CCC AAG3’
Reverse primer
5’ GTT TCG GAT CCT CTA CTG TTT CTT 3’
BamHI sites are underlined
Following PCR, an amplified product of the expected size was detected and there were no 
non-specific amplified products (Figure 14)
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Figure 14: Amplification of the BFRF3 ORF by PCR. PCR products were electrophoresed
through a 1% agarose gel Lane 2 - DNA ladder, lanes 1,3 and 4 - 3 |al of a 50 jjI PCR reaction
3.2.1.3 Early antigen-D
The gene for the EA-D protein BMRF1 was amplified by PCR from purified genomic Raji 
DNA The primers have a BamHl site incorporated and were designed to permit 
amplification of the whole BMRF1 ORF The first codon of BMRF1 was changed from a 
methionine to an aspartic acid (GAC) so as to remove the possibility of internal translation 
initiation during the rProtein production The annealing temperature used was 65°C The 
PCR product was 1234 bases in length and encoded a 44 kd protein, the fusion protein was 
predicted to be 56 kd in size
Forward primer
5’ CGGGATCCG GAA ACC ACT CAG ACT CTC 3’
Reverse primer
5’ CGG GAT CCC GAG AAC ATG GTG TTA AAT 3’
BamHl sites are underlined
Following PCR, an amplified product of the expected size was detected (Figure 15), there 
was another non-specific product amplified at approximately 2 4 Kb The complete PCR
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reaction was run on a low melt agarose gel and the required fragment, BMRF1 was excised 
for purification by the QIAEXII agarose gel extraction procedure (sections 2 3 8 and 2 3 9), 
therefore no nonspecific fragments were present during ligation
I 5 Kb
BMRFl - 1255 bp
1 2 3 4 5
Figure 15: Amplification of the BM R Fl ORF by PCR. PCR products were electrophoresed
through a 1% agarose gel Lanel - DNA ladder, lanes 2,3,4 and 5 - 3 jj.1 of a 50 jj.1 PCR reaction
The BARFO primers allowed amplification of the entire BARFO ORF from pBRBamHI A, a 
pBR322 plasmid with the EBV BamHI A fragment cloned The first codon of BARFO was 
changed from methionine to aspartic acid (GAC) so as to remove the possibility of internal 
translation initiation during the rProtein production The annealing temperature was 45°C 
The PCR product was 1479 bases in length and encoded a 52 kd protein, 64 kd when fused 
with thioredoxin A BamHI site was incorporated to aid cloning, as for each of the genes 
amplified
Forward primer
5’ TGC CAG TGG GAT CCC GGG TAC GCT 3’
Reverse primer
5’ TAC GGGGATCCT AAA GTC GAT GTA 3’
BamHI sites are underlined
Following PCR, an amplified product of the expected size was detected and there were no 
non-specific amplified products (Figure 16)
3.2.1.4 BARFO
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Figure 16: Amplification of the BARFO ORF by PCR. PCR products were electrophoresed
through a 1% agarose gel Lanes 1, 2, and 3 - 3 nl o f a 50 jj.1 PCR reaction, lane 4 - DNA ladder
1 2  3  4
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3.2.2 Ligation and Transformation
Using the Thiofusion system the cloning plasmid pTrxFus was used, figures 17-and 15 show 
a schematic representation of the cloning vector pTrxFus and the multiple cloning site of the 
plasmid
—- x —_
c  S E « o  — ' O.C co.o u <o <
ATG Thioredoxin EK
V1 0-140426
Figure 17: r Schematic representation of the pTrxFus plasmid.
ampicillm ORF bases 201-1061
ColEl origin bases -1300-1880
PL promoter bases 2159-2187
ribosome binding site, bases 2709-2726
thioredoxin ORF bases 2724-3050
enterokinase cleavage site bases 3051-3080
multiple cloning site bases 3081-3112
aspA transcription terminator bases 3113-3179
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Smal AccI
Kpnl BamHI Xbal Sail PstI
5 ’ GAT GAC GAT GAC AAG GTA CCC GGG GAT CCT CTA GAG TCG ACC TGC AGT 3 ’
3 ’ CTACTG CTACTGTTC CAT GGG CCC CTA GGA  GAT CTC AGC TGG ACG TCA 5’
Asp Asp Asp Asp Lys Val Pro Gly Asp Pro Leu Glu Ser Thr Cys Ser 
Enterokmase cleavage 
site
Figure 18: The multiple cloning site of pTrxFus. The base pair sequence is presented m groups
of three so as to highlight the translational ORF which runs through the polylinker.
Reaction mixes were extracted once with phenol/chloroform and the DNA was 
precipitated with ammonium acetate and isopropanol (sections 2 3 3 and 2 3 5) The 
purified DNA fragments were analysed on 1% agarose gels to ensure that the product 
had been recovered after the procedure and was suitable for restriction digestion and 
cloning The purified PCR product and the vector DNA were digested with BamHI as 
described in section 2 3 11, cleaned by phenol/chloroform extraction and precipitated 
with sodium acetate and ethanol, as described in sections 2 3 3 and 2 3 4
Phosphatase treatment of the vector DNA was earned out after restnction with BamHI to 
prevent re-circulansation of the plasmid (section 2 3 12) The ligation reactions were 
performed as desenbed in section 2 3 13 As the concentration of each was not determined 
exactly after digestion and purification, the ratio of vector DNA to insert DNA was vaned 
for a number of reactions Control reactions were also performed to ensure the ligation and 
the phosphatase treatment occurred These reactions were analysed by agarose gel 
electrophoresis Ligated products were then transformed into competent E coh  G1724 
(sections 2 4 2 and 2 4 3), which allows inducible expression of the fusion protein at 30°C 
(The alternative host strain G1698 was not required, this strain is used if the induction 
temperature is lower than 30°C, due to expression of insoluble recombinant protein at 30°C) 
Figure 19 below shows a schematic representation of each of the recombinant plasmids after 
ligation
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Figure 19: Schematic maps of each recombinant plasmid. A  - pTrxEBNAl, B  - pTrxpl8VCA, C -
pTrxEA, and D  - pTrxBARFO Plasmid sizes are indicated at the centre of each diagram
Figure 20 shows DNA agarose gel analysis o f each of the recombinant plasmids after 
ligation
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Figure 20: Agarose gel showing each of the plasmids with the insert ligated. Lanes 1-5 - pTrxFus,
pTrxpl8VCA, pTrxEBNAl, pTrxBARFO and pTrxEA respectively
3.2.3 Restriction Analysis
Two restriction enzymes were used for the analysis of each plasmid, to verify that selected 
clones had the correct insert in the correct orientation The BamHl digest indicated if the 
insert was of the correct size The second enzyme chosen for each differentiated between 
clones containing the insert m the rightward orientation or the leftward orientation, due to 
differences in the fragment sizes Table 6 below shows a list of the expected fragment sizes
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Plasmid Enzyme Predicted fragment sizes bp (correct orientation)
pTrxFus BamHl 3600
pTrxFus Smal 3600
pTrxFus Rsal 2266, 676, 309, 287, 37, 10,
pTrxEBNAl BamHl 3600, 829
pTrxEBNAl Smal 4214, 155, 59
pTrxpl8 BamHl 3600, 528
pTrxpl8 Rsal 2266, 676, 391, 309, 287, 182, 10,
pTrxEA BamHl 3600,1234
pTrxEA Smal 3877, 950,
pTrxBARFO BamHl 3600, 1479
pTrxBARFO Smal 4012, 575, 196, 182, 89, 6
Table 6: Restriction Analysis, predicted fragment sizes from recombinant plasmids.
Differences in the banding pattern, which can be observed on an agarose gel are highlighted m bold type
The patterns observed on agarose gel electrophoresis were as predicted for a number of 
clones, those showing the required pattern were chosen for growth and mduction 
Figures 21 to 23 show the restriction analysis of the four clones that were chosen for 
expression The banding patterns were as predicted in table 6 In figure 21 a BamHl 
digest shows the insert re-excised from the clomng vector, this digest showed that the 
insert was of the correct size Further restriction analysis showed that the insert was in 
the correct orientation for expression of the fusion protem (figures 22 and 23)
1 2 7
3 6K b
1479 bp 
1234 bp
Figure 21: DNA agarose gel analysis of B am H l digest of each recombinant plasmid. Lane 1 -
DNA ladder, lane 2 - pTrxpl8, lane 3 - pTrxEBNAl, lane 4 - pTrxBARFO, lane 5 - pTrxEA
1 2 3 4 5
3600 b p - 
3877 bp ' 
950 bp. - ,V
4214 bp 
‘ 4012 bp
575 bp
Figure 22: DNA agarose gel analysis of Sm al digest of each recombinant plasmid, on a 1.5%
agarose geL Lane 1 - DNA ladder, lanes 2-5 - Smal digest o f pTrxFus, pTrxEA, pTrxEBNAl and 
pTrxBARFO respectively
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Figure 23: DNA agarose gel analysis of R sal digest o fp T rxp l8 , on a 2% agarose gel. Lane 1 -
DNA ladder, lane 2 - pTrxpl8 cut with Rsal
3.3 Expression of Recombinant Protein
3.3.1 Growth and Induction
A number- of clones containing the correct inserts were grown and induced to express 
each particular protein Ten mililitre cultures of each were grown and induced as 
described in section 2 4 5 After harvesting of the cells a crude sample of each was 
analysed by SDS-PAGE This was done by resuspending the cell pellet from 0 5 ml of 
culture,- 4 hours post-induction, in 50 [il sample buffer (appendix section III)- and 
electrophoresis on a 10% SDS-PAGE gel
Clones showing the highest levels of mduction of recombinant protein were separated 
into soluble and insoluble fractions by repeated somcation and freeze-thaw cycles 
(section 2 4 5) It was found that all recombinant protems were soluble when-expressed 
at 30°C, therefore it was not necessary to use the G1698 E  coli strain for induction at 
lower temperatures In summary, novel bands corresponding to theappropnate predicted 
molecular weights of each protem were found by SDS-PAGE
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45 kD
29 kD
rVCApl8
1 2  3 4 5 6 7  8 9
Figure 24: Expression o f soluble recom b in an t p 18 VC A in  E  colL Soluble and insoluble
fractions o f Trx and rVCApl8 after three rounds of somcation, freeze-thaw cycles Lane 1 - Protein 
markers, lanes 2,3 - Trx soluble fraction, insoluble fraction, lanes 4,5 - rVCApl8 soluble fraction, 
insoluble fraction Lanes 6,7 and 8,9 show soluble and insoluble fractions of two more rVCApl8 clones
Three individual clones o f rVCAplS were analysed for soluble expression of the fusion 
protein, figure 24 shows that upon induction at 30°C each expressed a soluble protein 
Thioredoxin was used as positive control to show that the cell lysis was effective in 
separating the cell contents into a soluble and an insoluble fraction, and that thioredoxin 
itself was soluble when expression was induced at 30°C
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rBARFO — ►
1 2
Figure 25: Soluble fraction of rBARFO, after three rounds of sonication and freeze-thaw.
Lane 1 - rBARFO soluble fraction, lane 2 - protein markers
Similar to rVCApl8, rBARFO was also found to be soluble when expression was 
induced at 30°C As can be seen in figure 25 the level of expression for this clone was 
quite high However, it was found subsequently that expression of the rBARFO fusion 
protein on a large scale (400 ml culture) was not possible When plasmid DNA was 
analysed it could be seen that the insert was still present, but the fusion protein was not 
expressed under the conditions used for each of the other fusions, on a larger scale 
Expression was never recovered and B ARFO clones were subsequently abandoned
Variations on cell preparation were earned out by either omitting sonication or freeze- 
thaw, and/or varying the length of the sonication time As desenbed in section 2 4 5 the 
cells were sonicated for 3*10 s bursts, followed by rapid freeze-thaw, this was repeated 
twice Figures 26 and 27 show the effect of increasing the sonication time, on the level of 
soluble fusion protein released from the cells, without freeze-thaw, for both Trx and 
rEBNAl, to investigate these parameters For both rTrx and rEBNAl the level of
soluble recombinant protein released gradually increased with increase in somcation time, 
reaching a peak at 150 s
175 kD 
83 kD 
62 kD 
47 5 kD
32 5 kD 
25 kD 
16 5 kD 
Trx
1 2 3 5 6 7
Figure 26: Effects of increasing somcation time without freeze-thaw, on Trx. Lanes 1-6 - 30 s,
60 s, 90 s, 120 s, 150 s, 180 s somcation, lane 7 - protein markers
Figure 27: Effects of increasing sonication time without freeze-thaw, on rEBNAl. Lane 1 -
Protein markers, lanes 2-5 - 30 s, 60 s, 90 s, 120 s, 150 s somcation
It was found that the freeze-thaw cycles could be omitted without any loss in protein 
yield, and that the optimum somcation time was 150-180 s
1 3 2
Figure 28 shows two clones of rEA expressed in the soluble form, released after 150 s 
somcation The level of expression of this protein is considerably lower than that of each 
of the other recombinants
1 2 3 4 5  6 7 8 9  10
Figure 28: Crude preparations and the soluble fraction after somcation of both Trx and rEA.
The soluble fraction was isolated after 150 s somcation without freeze-thaw Lane 1 - protein markers, 
lanes 2,3 - Trx crude sample, soluble fraction, lanes 4,5 and 6,7 - crude and soluble fraction samples of 
rEA clones lanes 8,9 - rEA with the EA gene in the reverse orientation, crude and soluble fraction
It can be seen m lanes 8 and 9 that when the BMRF1 ORF was cloned in the reverse 
orientation that no fusion protein was expressed
1 3 3
3.3.2 Purification of Recombinant Proteins
Using the Thiofiision expression system, the fusion protein may be located at the 
adhesion zones (Lunn et a l , 1982) (sites on the cytoplasmic side of the inner membrane 
which are osmotically sensitive, where native thioredxoin localises) In this case the 
protein could be purified by osmotic shock Alternatively, as thiordoxin is a heat stable 
protem (Holmgren, 1985), and this stability may be conferred to the fusion protein, this 
would allow purification by heat treatment at 80°C
3.3.2.1 Osmotic Shock
The rVCApl8 and rEA were tested for purification by osmotic shock (section 2 4 7) In 
brief, this involved incubation of the cells in a TE buffer with a high sucrose 
concentration, followed by incubation m a TE buffer without sucrose, thus causing the 
cells to burst
62 kD
1 2 3 4 5
Figure 29: Purification o f Trx and rEA by osmotic shock. Lane 1 - Trx shockate, lane 2 - Trx
pellet, lane 3 - rEA shockate, lane 4 - rEA pellet, lane 5 - protein markers
1 3 4
rVCAp!8 _►  IM t mm ' -** <___  32 5 kD
Figure 30: Purification of rVCApl8 by osmotic shock. Lane 1 - rVCApl8 soluble fraction after
somcation, lane 2 - rVCApl8 pellet after osmotic shock, lane 3 - rVCApl8 shockate, lane 4 - protein 
markers
Figure 29 shows Trx released into the shockate after osmotic shock, however both rEA 
(lane 4, figure 29), and rVCApl8 (lane 2, figure 30) remamed in the pellet fraction The 
result was similar for all other recombinants, with the recombinant protein remaining in 
the pellet fraction Unlike native thioredoxin it would appear that the fusion proteins are 
not localised at the adhesion zones Therefore, osmotic shock could not be used as a 
method of purification of the thioredoxin fusions
3.3.2.2 Heat Treatment
The rVCApl8 was also chosen for purification by heat treatment (section 2 4 8) as this 
clone showed the highest level of expression of recombinant protein In summary, this 
method involved heating the soluble fraction of the cell lysate to 80 °C Samples were 
removed over a time course of 10 mm, each sample was centrifuged to separate the 
precipitated proteins and both fractions were analysed by SDS-PAGE Most proteins 
precipitate after 1 mm at 80 °C , while some thioredoxin fusions are stable for 10 mm at 
this temperature (Holmgren, 1985)
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Figure 31: Purification of Trx and rVCApl8 by heat treatment at 80 °C. Lane 1 - Protein
markers, lane 2 - crude Trx, lanes 3 , 4 - 1  min HT pellet, supernatant, lanes 5,6 - 2 mm HT pellet 
supernatant, lanes 7,8 - 5 nun HT pellet, supernatant, lanes 9,10 -10  min HT pellet supernatant Lane 
11, rVCApl8 crude, lanes 12,13 - 1 min HT pellet, supernatant, lanes 14,15 - 2 min HT pellet 
supernatant, lanes 16,17 - 5 mm HT pellet, supernatant, lanes 18,19 - 10 mm HT pellet supernatant, 
lane 20 - protein markers
Thioredoxin could be seen to remain in the soluble fraction after mcubation at 80°C for 
up to 10 nun (Figure 31, lanes 4,6,8 and 10) There was some loss to the pellet fraction 
after 5 mm (Figure 31, lane 7) Heat treatment of rVCApl8, showed that after mcubation 
at 80°C for 10 mm some of the fusion protein was separated from the remainder of the 
cellular protein, however a substantial amount of the recombmant protein is precipitated 
also (Figure 31, lanes 18 and 19) At shorter mcubation times of 5 - 3 mm there is also a 
high quantity of the recombmant protein m the pellet (Figure 32, lanes 8-10, pellet) and 
some of the native cellular proteins remaining m the supernatant (Figure 32, lanes 12-14, 
supernatant)
rVCApl8 
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Figure 32: Purification of Trx and rVCApl8 by heat treatment at 80 °C. Lane 1 - Protein
markers, lane 2 - crude Trx, lanes 3,4 - 5 mm, 8 nun HT pellet, lanes 5,6 - 5 nun , 8 nun HT 
supernatant Lane 7 - crude rVCApl8, lanes 8 -11, - 5, 7, 8, 10 nun HT rVCApl8 pellet, lanes 12-15 - 
5, 7, 8,10 mm HT rVCApl8 supernatant, lane 16 - protein markers
A 10 min incubation at 80°C was required to remove the majority of native E coh  
proteins resulting in substantial loss of recombinant protein Heat treatment was not used 
to purify the other recombinant proteins, the level of purity obtamed was not considered 
sufficient to compensate for the level of recombinant protein lost
3.3.2.3 Ammonium Sulphate Precipitation
Ammonium sulphate precipitation is used extensively as the first stage in protein 
purification This method involves precipitation of particular proteins using varying
concentrations of ammonium sulphate (AS) In this case, the first stage mvolves the
precipitation of the majority of the cellular proteins without precipitating recombinant 
protein The highest percentage AS at which the recombinant protein remains soluble is 
first determined This soluble fraction is then used for further precipitation at higher 
concentrations of AS During this stage the recombinant protein is precipitated from
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the remaining native cellular proteins Large-scale, 400 ml cultures were grown and 
induced for purification by this method
Figure 33: Ammonium sulphate (AS) precipitation of rVCApl8 - 1st cut. Lane 1 - Protein
markers, lanes 2,3 - supernatant (S), pellet (P) 20% AS, lanes 4,5 - S,P 25% AS, lanes 6,7 - S,P 28% 
AS, lanes 8,9 - S,P 30% AS, lanes 10,11 32% AS, lane 12 - S 35% AS, lane 13 protein markers
Figure 34: Ammonium Sulphate precipitation of rEBNAl - 1st and 2nd cut Lane 1 Protein
markers, lane 2 - crude sample rEBNAl, lanes 3 - supernatant 35% AS, 1st cut, lanes 4,5 - supernatant, 
pellet 48% AS, 2nd cut
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At 28% AS it can be seen that rVCApl8 was completely precipitated (Figure 33 lane 7) 
As there was a very low level of native protems m this fraction, it was decided not to 
proceed with a second ammonium sulphate cut, and to use resolubilised pellet after the 
28% AS cut for further analysis of the recombinant pl8VCA Figure 34 shows the 
products of two AS cuts with rEBNAl, after the first cut with 35% AS, rEBNAl was in 
the soluble fraction (Figure 34, lane 3), a considerable amount of native protems were 
precipitated After the second cut at 48% AS, rEBNAl was precipitated (lane 5), some 
E coh protems remained rEA was also purified by AS (not shown), this fusion protein 
was precipitated at 35% AS After AS precipitation there was still a substantial amount 
of contaminating protem m each-sample, which could cause non-specific signals in 
Western Blotting or ELISA analysis of sera Many human sera are likely to contain 
antibodies to E coh antigens, therefore it was important to minimise the level of native 
protein remaining in each protem preparation
3.3.2.4 Phenylarsine Oxide (PAO) Agarose
In order to further reduce the level of background protems an alternative method of 
purification was chosen A specifically activated resin was used, this resm is an agarose- 
based support covalently modified with phenylarsine oxide (PAO) (Sigma catalogue 
1998), which is especially designed-for the affinity purification of protems containing 
vicinal dithiols, this includes thioredoxin and thioredoxin fusions These protems 
reversibly bind the phenylarsine oxide m the ‘Thiobond’ resm through these dithiols 
Other protems are washed away, and the purified thioredoxin fusion protem is eluted 
using p-mercaptoethanol (P-mer) The conditions for purification were set according to 
those required for the purification of thioredoxin usmg this method, this involved 
considerable optimisation and variation from the manufacturers instructions (section 
2 4 11) The concentration of P-mer used for column equilibration, washing and elution 
had to be altered A number of variations of P-mer concentration m the buffers for each 
stage were earned out (data not shown) Ultimately all of the recombinant protems were 
punfied by this method, using the same conditions The column was equilibrated with 
3mM P-mer, washed with 0 25 mM P-mer and fusion protems were eluted with 500mM 
p-mer
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Figure 35: Purification of Trx using PAO agarose. Lane 1 - Protein markers, Lane 2 - Trx
soluble fraction after somcation, lane 3 - flow through, lanes 4,5 - wash with 0 25 mM p-mer, lane 6,7 
elution with 250 mM P-mer, lanes 8,9 elution with 500 mM p-mer
Although the recombinant was released with 250 mM P-mer (figure 35, lanes 6 and 7), 
there was some protein remaining which was subsequently released using 500 mM P-mer 
(figure 35, lanes 8 and 9) There was no mcrease m the background proteins, therefore it 
was suitable to use 500 mM p-mer for elution as just one wash was required for 
complete elution
1 4 0
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Figure 36: Purification of rEBNAl using PAO agarose. Lanel - Protein markers, lane 2-
rEBNAl soluble fraction after somcation, lane 3 - flow through, lanes 4,5 - wash with 0 25 mM p-mer, 
lane 6,7 elution with 500 mM p-mer
As can be seen m figure 36 lane 6, there are two native E  coll proteins which are also 
eluted, at ~ 20 kD and at -100 kD There does not appear to be any native thioredoxin 
present
Figure 37: Purification of rVCApl8 and rEA using PAO agarose. Lane 1 - rVCApl8 soluble
fraction after somcation, lane 2 - flow through, lanes 3,4 wash with 0 25 mM p-mer, lanes 5,6 - elution 
with 500 mM p-mer Lane 7 - rEA soluble fraction after somcation, lane 8 - flow through, lanes 9,10 - 
wash with 0 25 mM P-mer, lanes 11,12- elution with 500 mM p-mer
1 4 1
It can be seen that the flow through and the washes for both rVCApl8 and rEA contain 
recombinant protein (Figure 37 lanes 2,3,8 and 9) This may be due to the agarose 
binding capacity being reached, the columns could be reused up to 4 times but with each 
use the agarose binding capacity decreased (not shown) Figures 35 - 37 show that each 
of the proteins appears to have been punfied to a greater extent than by ammonium 
sulphate precipitation, l e a reduction in the degree of background protein present In 
this way the background reactivity with human serum can be minimised This level of 
purification is likely to be required if the recombinant antigens are to be used effectively 
as diagnostic reagents However, it was not possible to completely remove all E  coh 
proteins even when using a thioredoxin selective purification method
3.3.2.5 Protein Assay and Densitometry
After purification each protein preparation was dialysed exhaustively against PBS pH 
7 4, to remove the remaining P-mer These samples were assayed by the BCA assay as 
described m the manufacturers instructions (PIERCE product no 23225) As there were 
other cellular proteins still present, densitometry was earned out in order to quantify the 
amount of recombinant protein in each preparation This involved running a sample of 
each on SDS-PAGE beside a set of standards of known concentration The SDS-PAGE 
gels used for densitometry are shown in figures 38 and 39
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Figure 38: SDS-PAGE gel analysis of protein standards and rVCApl8 and rEBNAl
(purified using PAO agarose) for densitometry. Lanes 1-6 - BSA-NIP- 1, 2, 3, 4, 5 and 6 jag
respectively, lane 7 - rVCApl8 uninduced, lanes 8,9 - rVCApl8 induced, lane 10 - rEBNAl
1 2  3 4 5 6 7 8 9  10
Figure 39: SDS-PAGE gel analysis of protein standards and rEBNAl and rEA (purified
using PAO agarose) for densitometry. Lanes 1-6 - BSA-NIP-1, 2, 3, 4, 5 and 6 p.g respectively, lane 7 
- rEBNAl uninduced, lane 8 - rEBNAl induced, lanes 10,11 - rEA induced.
To use dilutions of these samples may have proven more accurate, however as the BCA 
assay earned out on each of the recombinants showed the level of total protein 
concentration to fall within the level of protein standards used the results the neat
samples were used for densitometry It can be seen in lane 7, figure 38, and in lane 7 
figure 39, that there is a low level of fusion protein present m the umnduced samples of 
rVCApl8 and rEBNAl, this was also the case for rEA This leaky expression was not 
apparent before purification by PAO agarose as the level o f E  coh protems present 
masked the fusion protein when analysed on SDS-PAGE These unmduced samples 
could not be used as negative controls for ELISA analysis, it was therefore necessary to 
prepare a negative control sample from G1724 cells without any plasmid DNA (Trx‘ 
G1724), thus eliminating any possible expression of recombinant protem The Trx'G1724 
cellular proteins were purified by PAO agarose under the same conditions also
A BCA assay was earned out to determine the total protem concentration, the 
densitometry reading for each recombinant was compared to that of each of the protein 
standards, and the concentration was determined using this ratio and the protem assay 
results Table 7A shows the concentration of each protem and the total protein 
concentration of each punfied sample
rProtein rProtein conc 
(jxg/ml)
Total Protem 
conc (|ig/ml)
Native E  coh protein 
conc (jig/ml)
rEBNAl 215 362 147
rVCApI8 178 328 150
rEA 420 628 208
Table 7A: Protein Concentration of each Recombinant Protein, as determined by the BCA
assay and densitometry, (rProtein - recombinant protein).
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rProtem rProtein Cone 
(mg/ 400ml)
Total Protein Cone, 
(mg/ 400ml)
% Purity 
(rProtein/Total 
protein)
rEBNAl 1 720 2 797 61 5
rVCApl8 1 424 2 624 54 3
rEA 3 360 5 024 66 9
Table 7B: Approximate concentration of each of the recombinant proteins, after affinity
purification using PAO agarose.
The yield of total protein (Table 7A, column 3) represents the total protein remaining 
after purification using PAO agarose
Western blotting analysis using pre-charactensed sera was used to confirm the 
antigenicity of three recombinant antigens - rVCApl8, rEBNAl, rEA (described below 
in section 3 4 2)
3.4 Antigenicity of rProteins
3.4.1 Serum Characterisation
Human antisera were donated from a number of different sources (see section 2 12) for 
analysis using the recombinant antigens Each of these serum samples had previously 
been characterised (prior to receiving the serum samples) for anti-EBV antibodies using 
a commercially available kit, as listed in section 3 1 The sera from randomly chosen 
normal individuals had not previously been characterised with respect to anti-EBV 
antibodies
3.4.1.1 Infectious Mononucleosis Sera
The IM+ sera were tested using an anti-EBV capsid IgM indirect immunofluoresence 
assay (IFA) The sera are pretreated with GullSORB to remove IgG antibodies thus 
preventing IgG/rheumatoid factor complexes from forming and preventing interference
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from IgG during the test procedure The assay is earned out using Gull slides coated 
with EBV capsid antigen gpl25, punfied from the EBV-positive P3HR-1 cell line
3.4.1.2 Viral Capsid Antigen (VCA) -Positive and -Negative sera
These sera were tested using the Gull EB VC A IgM ELISA (Gull product no EBE150) 
In this assay punfied EBV VCA gpl25 from the EBV-positive P3HR-1 cell line, is used 
to coat a 96-well plate The serum is pre-treated with a PBS based diluent containing 
goat anti-human IgG This absorbent prevents IgG/rheumatoid factor complexes from 
forming and prevents interfenng competition from IgG dunng the test procedure 
(Rheumatoid factor is an IgM type antibody which reacts with IgG antibodies to form 
immune complexes) The conjugate used m this test kit is anti-human IgM alkaline 
phosphatase A negative control serum, positive control serum, and a reference serum 
are included to aid interpretation of the ELISA results The reference serum is minimally 
reactive for this kit, this control sample is set up in tnplicate for each test run Optical 
Density (OD) readings for test samples which are greater than the mean OD of the 3 
reference samples, are considered positive
3.4.1.3 EBNA -Positive and -Negative Sera
The Biotest anti-EBV Recombinant EBNA IgG ELISA was used for charactensation of 
these sera A recombinant EBNA1 (46 kD), consisting of the C-termmal part of the 
native EBNA1 (47 2%), is used to coat the ELISA plate A goat anti-human IgG 
peroxidase conjugate is used for detection Specimens are considered positive m this test 
when the OD is greater than the mean of the negative controls plus a factor of 0 150
3.4.1.4 EBV-Positive Sera and CMV-Positive Sera
The EBV-positive sera were charactensed using the Baxter Bartels EBV IgM EIA The 
antigen used m this assay is EBV VCA gpl25 punfied from P3HR-1 cells Patient serum 
is diluted with a specimen diluent which contains an absorbent to remove IgG, thus 
preventing IgG/rheumatoid factor complexes forming and also preventing interfenng 
competition from IgG dunng the test procedure The conjugate used is anti-human IgM
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alkaline phosphatase, and both positive and negative control specimens were included
The CMV-positive sera were characterised using the Baxter Bartels, CMV IgM EIA
\
This kit consisted of EIA wells coated with purified CMV antigen (AD strain) As for
the EBV IgM EIA the specimen diluent contained an-absorbent for the removal of IgG
\
An anti-human alkaline phosphatase conjugate is also used for detection
3.4.1.5 Heterophile Antibody Test
A number of the IM-positive sera, normal sera and VCA-positive sera were selected for 
testing using the Organon Teknika, Monosticon DRI-DOT Infectious Mononucleosis 
diagnostic kit This is a 2-minute disposable hemagglutination slide test for the 
qualitative determination of IM antibody This test is based on the Paul-Bunnell 
heterophile antibody test as described in section 15 2 In addition to EBV-specific 
antibodies, the early phase of IM is charactensed by a general mcrease m total IgM, IgG 
and IgA, which is consistent with virus-driven polyclonal activation of the B cell system 
The presence of heterophile antibodies m sera of IM patients was originally detected by 
agglutination of sheep, horse or bovine blood cells presenting heterophile antigens on 
their surfaces Heterophile antibodies are usually detected less than one week after onset 
of IM, peak at two-five weeks and can be detected, at low levels, a year after onset of 
illness (Niederman et a l , 1968, Evans et a l , 1975) A combmation of horse erythrocytes 
and sheep erythrocytes are used and guinea pig antigen is included to neutralise 
Forssman antibody (forssman antibody is a heterophile antibody that reacts with 
Forssman antigen, a heterophile antigen, which occurs in a wide variety of unrelated
animals), which may influence the result Horse erythrocytes have been shown to be
\
more sensitive than sheep erythrocytes for detection of IM antibody (Lee et a l , 1968) 
This test was earned out by the author, the serum and test reagent were incubated at 
room temperature for 2 mm with gentle rocking (as per instructions) Agglutination 
mdicates a positive result, lack of agglutination indicates a negative result The level of 
agglutination detected is relative to the amount of heterophile antibody present This test 
may be used quantitatively also See figure 40 and table 8 for the results obtained with 
the sera tested
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Sample no. Type Result Comments
7127/97 IM + - no agglutination
9217/97 IM + ++ slight agglutination
12847/97 IM + +++ strong agglutination
6370/98 IM + - no agglutination
6925/98 IM + + very slight agglutination
7083/98 LM + + very slight agglutination
12755/98 IM + + very slight agglutination
15941/98 IM + - agglutination
9244/98 IM + ++ slight agglutination
11531/98 IM + - no agglutination
12707/98 IM + +++ strong agglutination
14769/98 IM + - no agglutination
15038/98 IM + +++ strong agglutination
15386/98 IM + + very slight agglutination
7435 Normal - no agglutination
7436 Normal - no agglutination
7438 Normal - no agglutination
7439 Normal - no agglutination
7442 Normal - no agglutination
7443 Normal - no agglutination
8413 VCA + - no agglutination
8415 VCA + ++ slight agglutination
7611 VCA + +++ strong agglutination
Table 8: Monosticon DRI-DOT results from a selection of sera.
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Figure 40: Photograph of the Monosticon DRI-DOT test cards after serum was added. 1- No
agglutination with serum no 8413, 2 - Slight agglutination with serum no 8415, 3 - Strong 
agglutination with serum no 7611 Each of these sera were characterised as VCA-positive using the 
Gull EB VCA IgM ELISA
1 4 9
These results show inconsistencies between the IM sera tested using the Gull anti-VC A 
IgM EFA test and the Monosticon test Only 9 of 14 IM-positive sera give a positive 
result using this method The level of agglutination was also variable, ranging from 
immediate strong agglutination to very slight agglutination after 2 mm All the normal 
sera were negative as expected and 2 of 3 VCA-positive sera were positive Some VCA- 
positive sera would be expected to give a positive result using this test also as the 
presence of anti-VCA IgM antibodies is usually indicative of infectious mononucleosis
3.4.2 Western Blot Analysis with IM Sera and Normal Sera
3.4.2.1 rVCApl8
Prior to purification of the recombinant proteins with PAO agarose, western blot analysis 
was earned out for rVCApl8, using the soluble fraction after cell lysis This was done to 
ensure immunoreactivity of the recombinant antigen before more complete punfication of 
the protein on a larger scale A number of IM-positive sera were chosen for this analysis 
The procedure was as desenbed in section 2 4 10 An anti-human Ig alkaline phosphatase 
conjugate was used for detection Each of the sera could be seen to have some degree of 
reactivity to the recombinant rVCApl8 (See figure 41) There was no antibody response 
to Thioredoxin expressed from pTrxFus, this showed that the response to the fusion 
protein was specific for the pl8VCA moiety Therefore, it was not considered necessary 
to cleave the thioredoxin moiety from the recombinant fusion proteins using 
enterokinase The level of non-specific anti-Ecoli antibodies was different for each 
serum sample (see higher molecular weight bands in figure 41, lanes 9,10 and 11) The 
degree of background reactivity was considerably lower than the signal found with 
rVCApl8 However, in an alternative assay such as ELISA or DOT blot this background 
signal could result in false-positive interpretation of results
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Figure 41: Western blot analysis of Trx and rVCApl8 after sonication , with six IM-positive
sera. Lane 1 - protein markers, lanes2,3 - Trx, rVCApl8 probed with serum 962, lanes 4,5 - Trx, 
rVCApl8 probed with serum 10211, lanes 6,7 - Trx, rVCApl8 probed with serum 9217, lanes 8,9 - 
rVCApl8, Trx probed with serum 7217, lanes 10.11 - rVCAp!8. Trx probed with serum 7126, lanes 
12,13 - Trx, rVCApl8 probed with serum 12874 (10 (¿1 of each protein preparation was loaded, the sera 
were diluted 1/100 in BLOTTO)
Those found to give the strongest signal were further analysed in a repeat experiment 
The protein preparation was diluted in the range 1 2 to 1 64 in PBS to find the limiting 
dilution for detection using serum diluted 1/100 As can be seen in figures 42 and 43 the 
limiting dilution ranged between 1 2 and 1 32 for two particular sera
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Figure 42: Detection of rVCApl8 by western blotting, with IM-positive serum 10211. Lane 1
- Protein markers, lanes 2-8 - rVCApl8 neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64.
32.5 kD 
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Figure 43: Detection of rVCApl8 by western blotting, with IM-positive serum 7126. Lane 1
Protein markers, lanes 2-8 - rVCApl8 neat, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64.
3.4.2.2 Blotting of all Proteins after Purification using PAO agarose
The three recombinant antigens were combined in equal concentrations, using the protein 
concentrations determined by B C A  assay and densitometry (1 (ig o f each rProtein was 
loaded per lane). The sample was run on a 10% SDS-PAGE gel for western blotting 
with a number o f IM-positive sera and Normal sera. In this case two secondary
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antibodies were used, an anti-human IgM peroxidase conjugate, and an anti-human IgG 
peroxidase conjugate. As discussed earlier, it is important to establish whether the 
antibody reaction is IgG or IgM, in order to determine the type o f infection or the stage 
o f disease. Table 9 below shows the expected IgG and IgM Ab responses to each o f the 
recombinant antigens o f normal (EBV+) and IM+ sera.
Serum
type
IgM
VCA
IgG
VCA
IgM
EBNA
IgG
EBNA
IgG
EA
Normal - + +/- + +/-
(EBV+)
IM+ + ++ +/- - +
Table 9: Predicted IgG and IgM Ab responses of normal (EBV+) and IM+ sera. [+ denotes
positive; - denotes negative; ++ denotes elevated positive]
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Figure 44: Detection of IgG Ab response to the 3 recombinant EBV antigens. Lanes 1-10 were
probed with 10 different IM-positive sera (7083, 10035, 10188, 12344, 14769, 12755, 9244, 16874, 
14495, 12344) lanes 11-20 were probed with 10 different normal sera (7458, 7459, 7460, 7461, 7462, 
7463, 7464, 7465, 7466, 7467) lane 21 - protein markers.
rEBN A 
rVCApl8
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As can be seen in figure 44, almost all the normal sera (except 7458 and 7462) showed 
an IgG response to rV C A pl8, and a small number showed slight reactivity with rEBNAl 
(7459 and 7463) and rEA (7459 and 7461). The IM+ sera showed no response to 
rEBNAl or rEA, and only a few sera were seen to be reactive with rVCApl8 (10188, 
16874, 14495).
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Figure 45: Detection of IgM Ab response to the 3 recombinant EBV antigens. Lane 1 - protein
markers, lanes 2-11 were probed with 10 different IM-positive sera (7083, 10035, 10188, 12344, 14769, 
12755, 16874, 9244, 14495, 12344) lanes 12-21 were probed with 10 different normal sera (7458,7459, 
7460, 7461, 7462, 7463, 7464, 7465, 7466, 7467).
Figure 45 shows the strong IgM response o f the IM+ sera to rVCApl8 in the majority o f 
the sera tested (12344 shows a weak response, lanes 5 and 11, 10188 shows no 
response, lane 4). Three IM+ sera showed an IgM response to rEA (7083, 10035 and 
9244, lanes 2,3 and 9 respectively), and as expected there was no IgM response to 
rEBNAl with any IM+ serum. There was no IgM responses to any o f the recombinant 
proteins for the normal sera with the exception o f 7465, lane 19, which showed an anti- 
rVCApl8 IgM response. IgM+ VC A, IgM- EBNA1 is the typical response for patients 
with IM as described earlier (see able 19). IgM- VCA, IgM- EBNA1 is the typical 
response for sera from EBV+ individuals without IM. All the normal sera tested appear 
to be EBV+ as determined by the detection o f IgG antibody response to rVCApl8 by 
western blot (shown in figure 44).
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3.4.3 ELISA using Recombinant EBV Antigens
ELISA analysis of all sera was earned out as described m section 2 4 12, the procedure 
was adapted from a number of protocols and optimised for use with these recombinant 
EBV antigens and human serum (Crowther 1995) The wells were coated with 10 |ig/ml 
of recombinant protein, and an equivalent amount of background protein was loaded for 
each antigen This was determined using the concentration values obtained by BC A assay 
and densitometry The E  coh G1724 strain, without plasmid, was grown and induced in 
an identical manner to that of each of the recombinants The cells were harvested and 
purification was earned out using the PAO agarose also In this way the background 
proteins expressed in each of the recombinants, which are not removed dunng 
punfication, would be present and could be used to control for background in ELISA 
assays As the concentration of background proteins vanes for each recombinant, it was 
necessary to add the required amount of G1724 extract to each sample to make the 
concentration uniform throughout An equivalent concentration of G1724 was used to 
coat wells as a negative control, and the total protein concentration was increased by 10 
(ig/ml (the concentration of each rProtein) using BSA Table 10 below shows the 
volumes of each protein required per ml of sample preparation, to give a recProtem 
concentration of 10 (ig/ml and a background protein concentration of 8 4 [ig/ml (the 
rVCApl8 extract had the highest background protein concentration of 8 4 (ig/ml, 
therefore the background protein concentration of each sample was increased to this 
level) Table 11 shows the assays earned out with each of the recombinant antigens and 
the types of sera tested
Protein type recProtein conc. 
(Hg/ml)
Volume of purified 
protein (p.I/ml)
Volume of G1724 
extract (p.l/ml)
G1724 347 - 24
rEBNAl 215 46 5 3 8
rVCApl8 178 56 -
rEA 420 24 10
Table 10; Details of sample preparation for ELISA assay.
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Serum type rEBNA rVCApl8 rEA Anti-IgG Anti-IgM
IM  + + + + + +
Normal + + + + +
VCA +/- nd + nd nd +
EBNA +/- + nd nd + nd
EBV + nd + nd nd +
CMV + nd + nd nd +
Table 11: The ELISA assays which were carried out [(+) - indicates that the antigen was
tested, and the antibody type tested for, IgG/IgM, (nd) - not done ]
The expected serological profiles of normal (EBV+)and IM+ sera were specifically 
outlined in table 9 In general, IM+ sera would be expected to be anti-pl8VCA IgG and 
IgM-positive, anti-EBNAl IgG and IgM-negative and anti-EA-D IgG-positive Normal 
sera may either be EBV-positive or -negative, however as 90% of the population are 
EBV-positive the expected profile would be as follows - anti-pl8VCA IgG-positive, 
IgM-negative, anti-EBNAl IgG-positive, IgM-negative and anti-EA-D IgG- 
positive/negative Figures A - J show the results obtained from the ELISAs earned, out 
with each of the recombinant antigens as detailed in table 11 The values used for 
graphing are averages of tnplicate OD readings at 414 ran
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Figure A
Anti-p18VCA IgM Responses of VCA-/+ Sera,
Normal Sera and IM+ Sera
Figure B
Anti-p18VCA IgG Responses of Normal Sera and 
IM+ Sera
(0
In figure A the anti-rVCApl8 IgM response is shown for four serum types. The IgM 
response is the first to develop at the early stages of IM, and peaks within the first 1-2 
weeks (see figure 6), after which the level of IgM antibodies drops to zero after 
approximately 4 weeks. All but a few IM+ sera show an elevated level of anti-VCA IgM 
antibodies, all the normal sera show a low level of IgM antibodies to the recombinant 
pl8VCA. These results correlate favorably with the results obtained by western blot
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(section 3 4 2 2), none of the normal sera tested by western blot had shown the presence 
of IgM antibodies to the recombinant antigens (figure 45, lanes 12-21) The majority of 
the IM+ sera showed a strong signal by western blot (figure 45, lanes 2-11) and by 
ELISA However, one serum (12344) had a very low western blot signal, but the 
response by ELISA was high, OD @ 414nm 0 616 Other sera with OD readings of 
approximately 0 6 had shown a stronger signal by western blot (figure 45, lanes 3 and 6) 
As expected the VCA+ sera gave a high IgM response, while the VC A- showed a low 
IgM response It is likely, although it cannot be confirmed (information not available), 
that the VCA+ sera were taken from patients with an IM first infection, as there is an 
IgM response to pl8VCA
The anti-rVCApl8 IgG responses of both normal and IM+ sera can be seen in figure B 
The IgG response of the IM+ sera was lower than expected, the anti-pl8VCA IgG 
antibody is normally elevated in IM+ patients However, as can be seen in figure 6 
(section 1 5 1) it may take up to 4 weeks for the IgG titer to reach a peak If these serum 
samples were taken when the first onset of symptoms had shown then it would be 
expected that the IgG titer to pl8VCA would be positive but still at a low level The 
majority of normal sera had a low level, but positive IgG response, this indicates that 
these normal sera were most likely EBV+ The IgM ELISA results and the IgG ELISA 
results correlate well with the western blot results for the normal and IM+ sera (section 
3 4 2 2) However, 1 IM+ sera (10188) shows a very low ELISA result (OD @ 414nm = 
0 058), while the western blot signal is quite strong (figure 44, lane 3)
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Figure C
Anti-EBNA1 IgG Responses of EBNA -/+ Sera,
Normal Sera and IM+ Sera
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Figure D
Anti-EBNA1 IgM Responses of Normal Sera and IM+ 
Sera
« Serum sample
Figure C shows the IgG responses to rEBNA. In general, both the EBNA+ and normal 
sera showed a higher anti-EBNA IgG response than that of the EBNA- and IM+ sera. 
Some of the normal sera showed a very low response comparable to EBNA- and EM+ 
sera. Two of 3 normal sera with a low anti-EBNA response also had very low anti-VCA
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IgG and IgM responses, this may indicate that these samples were taken from patients 
who were EBV-negative The other sample showed an elevated anti-VCA IgG response 
and a low anti-VCA IgM response, this patient may be in the final stages of IM (this 
cannot be confirmed as the health status of these patients is not known) The anti- 
rEBNA IgG response of the IM+ sera was low, as expected, with OD readings 
comparable to those of the EBNA- sera All the sera tested by western blot showed 
antibody responses which correlated well with the ELISA results
The anti-EBNAl IgM responses of both the normal and IM+ sera were very low as 
might be expected, there were only 2 EM+ sera which gave a higher OD reading (figure 
D) In comparison with the anti-pl8VCA IgM readings, the absolute OD values, are 
comparable to the VCA- sera with the lowest level of response Two IM+ sera (16874 
and 14495) showed a high OD reading by ELISA (0 606 and 0 547 respectively), 
however there was no signal for either by western blot (figure 45, lanes 8 and 10 
respectively)
Figure E
Anti-EA IgG Responses of Normal Sera and IM+ 
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Figure F
Anti-EA IgM Responses of Normal Sera and IM+
Sera
♦  Serum sample
ce
E
The trend of the anti-EA IgG responses for normal and IM+ sera (figure E) are very 
similar, there is a substantial overlap in the responses for both serotypes The normal sera 
may either have a positive or negative response while the IM+ sera would be expected to 
have a positive IgG response to EA However, as for the anti-pl8VCA IgG response it 
takes up to 3-4 weeks for the anti-EA IgG response to reach a peak before decreasing 
again to zero at about 5-6 weeks If these samples were taken within the first or second 
week after the onset of symptoms one would expect these low level anti-EA IgG 
responses
The anti-EA IgM responses were generally very low for both IM+ sera and normal sera, 
which is expected in most cases (figure F) A number of the IM+ sera gave a higher 
response to that of the normal sera, however, in comparison with the level of the IgM 
response to pl8VCA these values were very low Generally it is the IgG response to EA 
which is of significance in diagnosis of IM, while the anti-EA IgA response has been 
shown to be of significance in the diagnosis of NPC (Henle and Henle, 1976, Nadala et 
a l , 1996) The western blot results and ELISA results for all sera compare favorably for 
both IgG and IgM responses
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Figure G shows the general profile of IgG responses of the normal sera tested by ELISA, 
to each of the recombinant antigens As stated earlier, normal sera may have a positive 
IgG response to each of these antigens, if they are EBV+ In the cases of patients who 
are EBV-negative there would be a negative response, however these cases are relatively 
rare The majority of the normal sera tested show a low level IgG response to each of the 
antigens, which may be due to the background proteins present in each preparation, as 
these recombinant proteins were not purified to homogeneity
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Figure H
Anti-p18VCA/EBNA1 /EA-D IgM Responses of 
Normal Sera
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The IgM profile o f the normal sera (figure H) was also as might be predicted, in general 
the level o f IgM antibodies in serum o f patients without an active infection is very low.
Figure I
Anti-p18VCA/EBNA1/EA-D IgG Responses of IM+ 
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Figure I shows the IgG profile o f IM+ sera tested by ELISA with each recombinant 
antigen. The mean OD values for anti-pl8VCA and anti-EA IgG were higher than that o f 
the anti-EBNA IgG. In general the IgG responses are low, due to the fact that these
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samples were probably taken at early onset of symptoms before the anti-pl8VCA and 
anti-EA IgG responses have elevated
Figure J
Anti-p18VCA/EBNA1/EA-D IgM Responses of IM+ 
Sera
♦  Serum sample
The IgM profile for the IM+ sera was as might be expected, IM+ sera are anti-pl8VCA 
IgM-positive, anti-EBNA IgM-negative and anti-EA IgM-negative This trend can 
clearly be seen in figure J There was a low level response to EBNA and EA, it is 
possible that this may be due to the background proteins present in each protein 
preparation
3.4.4 Establishment of an ELISA Reference Value
The western blot results from section 3 4 2 2 were used for comparison with ELISA 
results in order to establish a baseline OD value An OD value above this reference point 
would mdicate a positive result, and any OD reading below would be considered 
negative Ten normal sera and 9 IM positive sera were compared for both IgG responses 
and IgM responses The following table shows ELISA vs Western blot results for each of 
the chosen sera
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Serum rVCApl8 rVCApl8 rEBNAl rEBNAl rEA rEA
ELISA IgG W B IgG ELISA IgG W B IgG ELISA IgG W B IgG
IM  +
7083 0 334 + 0.292 - 0.279 +
10035 0 - 0 - 0 137 +
10188 0 058 ++ 0 - 0 +
12344 0 127 + 0 043 - 0 092 -
14769 0.124 + 0 - 0 089 -
12755 0.122 - 0 039 - 0 107 -
16874 0 095 - 0 052 - 0 070 +
9244 1 516 +++ 0 158 - 0.157 -
14495
Normal
0 621 ++ 0 179 - 0 486 +
7458 0 110 + 0 186 - 0 119 +
7459 0 287 ++ 0 273 + 0 057 +
7460 0 748 +++ 0 171 - 0 070 -
7461 0 262 ++ 0.302 + 0 +
7462 0 + 0 146 - 0 -
7463 0 216 ++ 0 498 ++ 0 -
7464 0 315 ++ 0 268 + 0 018 +
7465 0 213 +++ 0 244 + 0 -
7466 0 224 ++ 0 237 + 0 015 -
7467 0 453 ++ 0 539 + 0 -
Table 12: ELISA vs W estern Blot anti-IgG results of 9 IM+ sera and 10 normal sera. WB -
western blot The number of (+) denotes the level o f intensity of the western blot signal The values in 
bold denote the highest ELISA value for which the corresponding WB result was negative and the next 
highest ELISA result for which the corresponding WB result was positive, for each recombinant protein
For rV C A pl8 any OD reading greater than 0 124 (serum 14769) was a positive result, for 
rEBNAl an OD reading greater than 0 302 (serum 7461) indicates a positive result and 
for rEA an OD reading above 0 279 (serum 7083) was positive Combining these data a 
minimum value can be obtained above which is designated a positive result for any of the 
three recombinant proteins An OD reading @ 414nm greater than or equal to 0 302 
would indicate a positive IgG reaction to the particular protein being assayed
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Serum rVCApl8  
ELISA IgM
rVCApl8  
W B IgM
rEBNAl 
ELISA IgM
rEBNAl 
W B IgM
rEA 
ELISA IgM
rEA 
W B IgM
IM +
7083 1.148 +++ 0.101 - 0.062 ++
10035 0.630 ++ 0.150 - 0.236 +++
10188 0.201 + 0.044 - 0.012 -
12344 0.616 + 0.201 - 0.013 -
14769 0.594 ++ 0.182 - 0.077 -
12755 0.711 ++ 0.150 - 0.022 -
16874 0.942 +++ - - 0.044 -
9244 0.773 +++ 0.202 - 0.52 ++
14495 0.893 +++ 0.547 - 0.298 -
Normal
7458 0.009 - 0.016 - 0 -
7459 0.276 + 0.016 - 0.080 -
7460 0.330 + 0.203 - 0.349 +
7461 0.072 - 0.017 - 0 -
7462 0.051 - 0.017 - 0.013 -
7463 0.185 + 0.348 - 0.001 -
7464 0.143 - 0.005 - 0.032 -
7465 0.159 + 0.015 - 0 -
7466 0.065 - 0.088 - 0.022 -
7467 0.187 + 0.103 - 0 -
Table 13: ELISA vs Western Blot anti-IgM results of 9 IM+ sera and 10 normal sera. WB -
western blot. The number of (+) denotes the level o f intensity of the western blot signal. The values in 
bold denote the highest ELISA value for which the corresponding WB result was negative and the next 
highest ELISA result for which the corresponding WB result was positive, for each recombinant protein.
For anti-IgM ELISA results any value greater than 0.159 (serum 7465) was positive for 
rV C A pl8, for rEBNAl all the western blot results were negative yet an OD reading up to 
0.547 was found for one particular serum (14495). This would indicate that any OD 
reading equal or less than 0.547 may be considered negative. This reading was not used 
for establishment o f a cut-off point as there were no other sera negative by western blot 
which had a comparable OD reading by ELISA. For rEA any OD reading above 0.349 
was positive (serum 7460). Combining these results, a minimum OD reading @ 414nm 
o f 0.349 or lower would indicate a negative result. As no rEBNAl IgM-positive sera
1 6 6
were found it cannot conclusively be stated that any reading above this value would be 
positive
Serum
Normal
IgG Response 
P18VCA EBNA1 EA-D
IgM Response 
P18VCA EBNA1 EA-D
7435 + + - - - n/d
7436 + + + - - n/d
7438 + + - - - n/d
7439 + + + - - n/d
7442 + + + - - n/d
7443 + + - n/d n/d n/d
7447 - + + - - n/d
7448 + + - - - n/d
7449 - + - n/d n/d n/d
7454 + + + - - n/d
7456 + + - n/d n/d n/d
7457 - + - n/d n/d n/d
7458 - - - - - -
7459 - - - - - -
7460 + - - - - +
7461 - + - - - -
7462 - - - - - -
7463 - + - - - -
7464 + - - - - -
7465 - - - - - -
7466 - - - - - -
7467 + + _ _ _ _
Table 14: IgG and IgM responses of normal sera to each of the recombinant antigens based
on the reference value determined, (n/d - not done)
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Serum
IM+
7083
10035
10188
12344
14769
12755
16874
9244
14495
15941
13307
12707
15038
15386
11531
6370
6925
9336
12468
12726
IgG Response
P18VCA EBNA1 EA-D
+
+
+ +
+
+
n/d
+
+
IgM Response
P18VCA EBNA1 EA-D
+
+
+
+
+
n/d
+
+
+
+
+
+
+
+
+
+
+
+
n/d
n/d
n/d
n/d
+
n/d
+ +
Table 15: IgG and IgM responses of IM+ sera to each of the recombinant antigens based on
the reference value determined.
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Serum EBNA IgG Response Serum EBNA IgG Response
EBNA- EBNA+
6985 + 7467 -
6627 - 8090 +
8694 - 7343 +
7127 - 7256 +
6988 - 7387 +
7068 - 7344 -
6737 - 7248 +
6891 - 7529 +
8725 - 7310 +
6769 + 7456 _
Table 16: IgG response of EBNA-/+ sera to rEBNAl based on the reference value
determined.
1 6 9
Serum VCA IgM Response Serum VCA IeM Response
VCA- VCA+
7523 - 8415 +
7268 - 8411 +
7274 - 7611 +
7291 - 7617 +
7299 - 7739 -
7300 - 7837 +
7266 - 8128 +
7271 - 8318 +
7281 - 8413 +
CMV+ EBV+
NY1 - MS8 +
NY2 - MS9 +
NY3 - CAC6385 +
NY4 - 1318/95 -
NY 5 - 26637 +
10190 + 2664 -
607/95 + 2656 -
8638 - 331/95 +
16792 -
69/95 -
0124 +
1623 +
765/95
769/95
Table 17: IgM response of VCA-/+, CMV+ and EBV+ sera to rVCApl8 based on the
reference value determined.
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3.4.5 Cross-Reactivity Testing
In order to check for cross-reactivity with serum from patients with a different type of 
viral infection, a number of CMV-positive sera were tested with each of the recombinant 
EBV antigens by ELISA (see figure K) A number of EBV+ sera were also tested at this 
point Sera which gave a positive result were then analysed by western blot also to 
determine if the positive reaction was due to reaction with the particular antigen or due 
to a high background reaction
Figure K
Anti-p18VCA IgM Responses of EBV+ Sera and 
CMV+ Sera
0 Serum sample
+>
fflLU
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Of 8 EBV positive sera tested 5 showed a positive IgM response to pl8VCA, 4 of 14 
CMV-positive sera were also positive, by ELISA The three EBV+ sera showing a 
negative anti-pl8VCA IgM response (according to the reference point established in 
section 3 4 4) showed ELISA OD values of 0 225, 0 074, and 0 105, considerably lower 
than the cut-off point of 0 349 The four CMV+ sera showing a positive result were 
tested by western blot for IgM responses to each of the recombinant antigens
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CMV Ab status + + + + + +
rVC Ap 18 ELISA IgM/IgG + + + + - - + +
62 kD
Figure 46: Western blot analysis of purified recombinant proteins with CMV-positive sera
and IM positive sera, probed with anti-human IgM POD conjugate. Lane 1 - protein markers, lanes 
2-7 were probed with 6 CMV-positive sera ( 10190, 607/95, 0124, 0623, NY1 and NY2 respectively), 
lanes 8,9 were probed with 2 IM-positive sera (7083 and 16874).
Two of the CMV+ sera showed a very strong IgM response to rVCApl8 (sera 0124 and 
0623, lanes 3 and 4, figure 46) which compares on intensity to the response o f the 
positive control EM+ sera (7083 and 16874, lanes 8 and 9). The ELISA reading for these 
sera were 1.127 and 0.798 respectively. It cannot be determined from this result whether 
the reaction is due to EBV-specific antibodies or cross-reactivity o f CMV-specific 
antibodies with the EBV recombinant antigens.
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3.5.1 Purification of the Fusion Proteins
A number of problems were encountered during purification of the recombinant antigens 
by osmotic shock, heat treatment and ammonium sulphate precipitation (sections 3 3 2 1, 
3 3 2 2 and 3 3 2 3 respectively) Initially it was thought that osmotic shock would prove 
a convenient method of purification Native thioredoxm is normally localised at the 
adhesion zones (Bayers patches), osmoticaJly sensitive cellular compartments on the 
cytoplasmic side of the inner membrane However, this did not appear to be the case for 
the thioredoxm fusion proteins, the recombinant proteins were not released to the 
shockate after osmotic shock treatment Therefore, osmotic shock could not be used as a 
method of purification of the thioredoxm fusions, unlike thioredoxm Heat treatment did 
allow the purification of the recombinant fusion proteins, however there were substantial 
losses After 2 mm incubation @ 80°C a substantial amount of both the native proteins 
and the fusion protem was precipitated, a 10 mm mcubation time was required to 
precipitate the majority of the E coli proteins This resulted in the majority of the fusion 
protein being precipitated also, leaving a small amount of soluble fusion protem There 
was also native cellular protem remaining Using ammonium sulphate precipitation there 
were no significant losses of fusion protem but the remaimng E coli protems resulted in 
cross-reactivity in western blotting (data not shown), which could significantly interfere 
with ELISA assay or dot blot analysis of the recombinant antigens Filtration through a 
centrifugal device with a 50 kD/100 kD cut-off was attempted after ammonium sulphate 
precipitation, to separate the residual cellular protems, however it was found that all 
proteins were retained on the filter (data not shown) Affinity purification with PAO 
agarose was a compromise between loss of recombinant fusion protein and elimination of 
cellular E coli protems Under the conditions used there was a limit to the amount of 
thioredoxm fusion protem which bound the column, a substantial amount of the fusion 
protein washed through the column, however this method did successfully eliminate the 
majonty of the native E  coli protems
There was no reactivity observed when western blotting was earned out with thioredoxm 
and a number of IM+ sera (section 3 4 2 1,figure 41), therefore it was not necessary to 
cleave the thioredoxm moiety using enterokmase This could be done after punfication
3.5 Discussion
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with PAO agarose, however it is possible that thioredoxin lends stability to the fusion 
protein As this cleavage was not essential it was preferred not to further manipulate the 
recombinant proteins which could result m further losses in yield This could also result 
m degradation due to incubation at 37°C, possibly for a number of hours, dependmg on 
the nature of the fusion protein The digestion conditions would also have had to be 
optimised for each protein, possibly without advantage gain with regard to the usefulness 
of the recombinant protein as a diagnostic reagent
In order to punfy the proteins to homogeneity subclonmg may be required A number of 
clomng vectors are available which also allow the expression of fusion proteins in E coll 
This original Thiofusion system has recently been improved to allow easier sub-clomng 
and simplified purification The vector used for expression contains a modified 
thioredoxin gene that allows purification of fusion proteins on metal-chelating resins 
(Invitrogen catalog 1998) A number of other examples include Gluthathione-S- 
Transferase (GST) (Wang et a l , 1997, Bettadapura et a l , 1998), Maltose Binding 
Protein (MBP) (di Guan et a l , 1987) and Chitin Binding Domain (CBD) (Chong et a l , 
1997, Rozynek et a l , 1997), fusions These fusion proteins allow purification by affinity 
column, which would be more specific than the phenylarsine oxide (PAO) agarose 
column used for thioredoxin purification, this may also improve the yield of recombinant 
protein For example using a column with maltose as affinity tag in the case of MBP 
Alternatively, the existing system may be used with further purification of the proteins 
already partially purified by PAO agarose High performance liquid chromatography 
(HPLC), is a possible purification alternative, which allows complete purification to 
homogeneity (Oliver 1989), reverse-phase HPLC may be appropriate for the purification 
of these recombinant proteins However, this method is very expensive in comparison to 
those used to date
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3.5.2 Loss of Expression of rBARFO
As the BARFQ ORF encodes a novel EBV protein which may be of value in the 
diagnosis of NPC, it was chosen for expression in E  coh using the Thiofusion expression 
system Initial expression of the rBARFO fusion protein was quite strong, however, it 
was found that the selected clones could not be induced to express this fusion protein on 
a larger scale (400 ml culture) Restriction analysis was earned out on punfied plasmid 
DNA, which showed that the insert (of the conect size) was still present and in the 
correct onentation Freshly prepared competent E coh  cells (G1724 strain) were 
transformed with the recombinant plasmid Induction of both small and large scale 
cultures showed that there was no fusion protein expressed It is possible that there was 
a deletion mutation within the DNA sequence of the BARFO ORF at some stage dunng 
propagation If the mutation was only one base it could not be detected by restnction 
analysis unless it occurred at one of the chosen restnction sites This may have caused a 
frameshift in the DNA sequence which would result in the gene being out of frame thus 
preventing translation of the fusion protein If this were the case there would be no 
visible expression of rBARFO However, as this protein was expressed dunng the initial 
growth and induction it does not seem likely It is also possible that the mRNA was 
unstable, or the fusion protein itself was unstable Mutation or instability might have 
caused a loss of expression due to selection against rProtem expressing cells In order to 
regam expression of this fusion protein, it would be necessary to re-amplify the BARFO 
ORF, possibly changing one or both pnmers The new PCR product would then be 
ligated with the pTrxFus vector as before and selected clones analysed for fusion protein 
expression Clomng in an alternative vector may also be necessary
3.5.3 Background ELISA Signal
When the three proteins were combined and analysed by western blot there was no 
apparent non-specific signal detected (figures 63 and 64), however ELISA analysis did 
result in significant background signals possibly due to the difference m the mode of 
antigen presentation and assay conditions The conditions were vaned (method of 
immobilisation, blocking buffer, washing stnngency, number of washes, antigen 
concentration, secondary antibody concentration and serum dilution factor) m order to 
minimise the background signal but a low level remained consistently (data not shown)
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The E.coli G1724 PAO purified cell extract used in ELISA reactions to evaluate the 
background signal could be pre-incubated with the diluted serum before addition to the 
antigen coated wells. In this way the signal obtained (optical density reading @ 414nm) 
would not require manipulation to account for reactivity o f serum antibodies with native 
E.coli proteins. Further purification (as discussed in section 3.5.1) might also 
significantly reduce the background signal by removal o f the native cellular proteins.
The recombinant protein concentration used for coating the ELISA wells was 10 (ig/ml 
and the concentration o f background proteins was 8.4 pg/ml, therefore the concentration 
of the specific protein being analysed was only a little greater than the background 
protein. The level o f reactivity to the native proteins was higher than expected, being 
greater for anti-human IgG than anti-human IgM. This would be expected as IgM 
antibodies are only present at elevated levels in the initial stages o f an infection. 
Assuming the serum samples tested were from patients without any other infection (apart 
from EBV in the cases o f ‘IM+’, ‘EBV+’ and ‘VCA+’ sera) their non-specific IgM 
antibody levels should be very low. It is possible that a low level o f IgG antibodies to a 
number o f E.coli proteins present in the G1724 extract and the recombinant protein 
preparations, could produce a signal which would significantly amplify the apparent anti- 
EBV antibody response.
Five percent foetal calf serum (FCS) was used as diluent for the serum sample. The 
antibodies present in the FCS could bind the E.coli proteins thus reducing the level o f 
human antibodies reacting with the bacterial proteins. However, the difference in 
background signal did not vary significantly from that obtained when using 5% B SA  as 
diluent. Changing the blocking buffer from 5% BLOTTO to 5% BSA, and increasing the 
concentration o f Tween (0.1%) in the washing buffer also aided the reduction in the 
background signal.
Initially an anti-thiorexdoin (a-Trx) antibody was used to immobilise the fusion proteins, 
however it was found that the anti-thioredoxin antibody was reacting with the human 
serum and gave a significant reaction with the blocking buffer also (data not shown).
Coating with a-Trx, without the addition of recombinant protem, followed by incubation 
with serum gave an OD reading which compared with that obtained when recombinant 
protem or thioredoxin was also added It is not certain why this occurred, but may be 
due to the presence of contaminating antibodies in the a-Trx antibody preparation It 
was necessary to directly immobilise the recombinant antigen preparation on the ELISA 
plate Altering the antigen concentration and the secondary antibody concentration did 
not cause a reduction in the background signal (data not shown), the net difference 
between the recombinant antigen OD reading and that of the G1724 cell extract 
remained constant In order to confirm the data obtained, it would be necessary to use 
fully purified recombinant proteins to eliminate the existence of non-specific interactions 
due to the presence of E  coh proteins
3.5.4 Reference Point for Evaluation of ELISA Data
The establishment of a reference point was essential in evaluation of the ELISA data All 
of the sera tested had been characterised by an alternative EBV diagnostic method, 
except for the normal sera (serum samples for routine clinical investigations) which had 
not been assayed for anti-EBV antibodies As all the methods used were different it was 
necessary to establish another specific method of evaluation of a number of sera of 
different types for direct comparison with the ELISA data A number of normal sera and 
IM+ sera were chosen for western blot analysis The lowest OD reading by ELISA 
above which there was no negative result by western blot was the chosen reference pomt 
for negative/positive ELISA results There were a number of sera with ELISA OD 
readings lower than the reference point, which showed a positive western blot result 
One figure was chosen for IgG responses and one for IgM responses
There were a number of ways in which such a reference pomt could be determined All 
of the sera analysed could be tested using one specific EBV diagnostic method, whose 
results are considered conclusive Immunofluoresence assay (IFA) is often the chosen 
method for comparison with new screening methods (Wiedbrauk and Bassin, 1993) IFA 
is the standard method for detection of anti-VC A antibodies, however it is a difficult 
assay to standardise, time-consuming and not suitable for large scale screemng
177
Heterophile antibody testing could also be used but this test is not reliable for the testing 
of serum from children (Lennette et a l , 1991) Therefore the results could not be 
considered 100% reliable as the age of the patients whose serum was used was not 
known in the majority of cases
The difficulty m determining conclusive results with EBV testing is that only a very small 
percentage of the population are EBV negative It would be necessary to use sera from 
candidates who are seronegative for EBV and those who are conclusively IM+ 
(diagnosed by a number of tests and displaying the relevant symptoms) in order to 
determine the limitations of these novel recombmant EBV antigens Very young infants 
are the only reliable source of EBV-negative serum
To confirm the effectiveness of these antigens for diagnosis of IM or other EBV-related 
diseases it would be necessary to screen a larger panel o f serum samples m parallel with 
commercial kits Analysis by western blot and an alternative anti-EBV ELISA could be 
used to determine the sensitivity and specificity of this method Commercial ELISAs 
have proven to provide a reproducible method for the serological diagnosis of infectious 
mononucleosis, however, the different tests can show considerable variation in 
performance based on the different methods and reagents used, specifically the different 
antigens used (Weber et a l , 1996, Gutiérrez et a l , 1997, Mitchell et a l , 1998)
3.5.5 Antibody profiles using the recombinant EBV antigens
Using the reference point determined by comparison of western blot results and ELISA 
results, each of the serum samples were designated positive or negative for the 
recombmant antigens tested For the majority of the samples the results were similar to 
those expected As patient age, history and symptoms (if present) were not known it was
i
difficult to critically assess the possible reasons for any deviations from the expécted 
profile j
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The normal sera tested had not previously been tested for anti-EBV antibodies. The 
Monosticon DRI-DOT (Heterophile antibody) test was used to assess a number o f the 
samples, all proved negative for the presence o f heterophile antibody. Only one normal 
serum, 7460, showed a positive IgM response to EA there was no response to any o f the 
recombinant antigens for the remainder o f the sera tested for anti-IgM, however the anti- 
IgG profile varied. Fifteen o f 22 sera were EBNA1 positive, o f these 15, 10 were also 
p l8V C A  positive. Two serum samples showed a positive IgG response to pl8V C A  but a 
negative response to EBNA1, the majority were EA-D-negative (17/22) as expected. In 
the case o f the 5 samples which were EBNA1 and pl8VCA-negative (also EA-D- 
negative), this would indicate the absence o f an EBV infection. Those showing both 
EBNA1 and pl8VCA-positive IgG responses may have had a previous, active infection 
resulting in the persistence o f an anti-pl8VCA IgG response. For those who were 
EBNA1-positive but pl8VCA-negative for IgG, this would suggest the presence o f a 
latent EBV infection. The presence o f anti-pl8VCA IgG antibodies in the absence o f 
anti-EBNAl IgG is not to be expected. As immune responses vary between individuals it 
might be that certain individuals have a higher pl8V C A  titer than EBNA1 titer. It is 
possible, although unlikely for normal serum samples, that these patients were in the 
convalescent stage o f IM, if the infection was at an acute stage an anti-pl8VCA IgM 
response would also be expected. The reference point for determining positive or 
negative results may be too high to detect low anti-EBNAl IgG responses, therefore, 
these individuals could also have had a low level o f anti-EBNAl IgG antibodies. Eighty 
two percent o f the normal sera appeared to be EBV seropositive, this is close to the 
expected percentage for the general population (~ 90%), while 100% were IgM- 
negative.
Sixteen o f 19 o f the IM+ sera tested, were shown to be positive for anti-pl8VCA IgM, 
this would be indicative o f an acute IM infection. There were no IgM responses to 
EBNA1 or EA-D, except for serum 14495, which showed an IgM response to EBNA1. 
The OD reading for this sample was considerably higher than the other EBNA1 IgM 
readings and was not taken into consideration when establishing the reference point 
(section 3.4.4). O f the 16 pl8V C A  IgM-positive samples, 3 were also anti-pl8VCA 
IgG-positive, in these cases the infection may have progressed by 3-4 weeks at which
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stage the IgG response to pl8VCA is expected to peak All 19 sera were anti-EBNAl 
IgG-negative which is characteristic of EBV-induced IM Six of 19 samples were anti- 
EA-D IgG-positive, only one of these was also pl8VCA IgG-positive The EA-D IgG 
response peaks at approximately the same time as the pl8VCA IgG response but anti- 
EA-D IgG antibodies only appear in 80% of infected individuals As the majority of the 
samples were pl8VCA IgM-positive and pl8VCA IgG-negative it is most likely that the 
samples were taken at the acute stage of IM before the development of pl8VCA and 
EA-D IgG antibodies Of the 11 sera tested with the Monosticon DRI-DOT kit, 7 were 
positive and 4 were negative All of the positive samples were also pl8VCA IgM- 
positive, and 2 of those which were negative were also pi 8 VC A IgM-and IgG-negative 
However, the other two samples which were negative for the heterophile antibody test 
were positive for pl8VCA IgM (15941 and 11531) The OD reading for each serum was 
well above the point cut-off point (0 349), 15941 (OD @ 414nm = 0 686) and 11531 
(OD @ 414nm = 0 806) If these individuals were children (less than 10 yrs) it is possible 
that the heterophile antibody test could show a false-negative result (Lenette, 1991)
Seven of 10 EBNA+ sera were EBNA1 IgG-positive by ELISA The BIOTEST anti- 
EBV test kit used a 46 kD recombinant EBNA1 which is considerably larger than the 
truncated form used here (29 kD, does not have the gly-ala repeat sequence, see figure 
12) The larger recombinant protein would encompass a greater number of epitopes, it is 
possible that those epitopes were not present in the truncated protein, hence the negative 
response in the case of 3 serum samples It is possible that this test, with the truncated 
recombinant EBNA1, is more specific due to the absence of the gly-ala repeat sequence 
which may result in false-positive results (Milman et a l , 1985) Two EBNA- sera 
showed a positive response (OD - 0 394 and 0 302), both were close to the cut-off point 
for IgG responses (0 302) As the recombinant EBNA1 was fused to thioredoxin, this 
may be the result of non-specific interaction with the thioredoxin moiety However, 
increasing concentrations of free thioredoxin were added to serum samples analysed by 
ELISA, with no reduction in the ELSIA signal (data not shown) This would indicate the 
absence of any thioredoxin-specific antibody response
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All VCA-negative sera were also negative for pl8V C A  IgM by ELISA. Two o f 9 VCA+ 
sera were negative for p l8V C A  IgM. This may be due to the fact that the Gull VC A 
IgM ELISA was based on the EBV gpl25 glycoprotein. As the antigen was different it is 
quite possible that the test results would also differ. Individuals elicit antibody responses 
to different epitopes, it may be that these conflicting results are a consequence o f this 
phenomenon. The Baxter Bartels EBV  IgM EIA was also based on IgM responses to the 
EBV gpl25 glycoprotein, only 5 the 8 sera characterised as EBV+ by this assay were 
also positive for anti-pl8VCA IgM by ELISA. As with the VCA+ sera this may be due 
to differences in antigen presentation and epitope recognition in each individual. Loss o f 
specific antibodies due to storage/freeze-thawing may also have been a factor here. 
Differences in other reagents and test procedures may also account for the observed 
inconsistencies.
3.5.6 Cross-reactivity with Sera from CMV-Positive Individuals
Cytomegalovirus (HHV5) is a member o f the betaherpesviriniae subfamily, and it’ s 
genomic structure is very different to that o f EBV (a member o f the 
gammaherpesviriniae subfamily). This virus causes a mononucleosis-like syndrome also, 
and can be maintained in a latent form in lymphoreticular cells, secretory glands, kidneys 
and other tissues. Human CM V is often isolated from apparently normal human adenoids 
and salivary glands. (IARC Monographs 1998). Fourteen CMV+ sera were tested for 
IgM antibody to rVCApl8 by ELISA for cross-reactivity o f IgM antibodies. Anti- 
rVCApl8 IgM was the chosen test as this response appears to be o f the most significant 
diagnostic value in relation to acute EBV-IM infection (in this assay system). A  positive 
reaction would be indicative o f an acute IM infection, a case o f cross-reactivity between 
CMV-specific antibodies and rVCApl8 or reactivity with the background E.coli proteins. 
It was found that o f 14 samples, 4 showed a positive reaction with rVCApl8 (i.e. an OD 
reading @ 414nm greater than 0.349) i.e. 29% were cross-reactive. Those giving a 
positive reaction were subsequently analysed by western blot for IgM antibodies to all 
three recombinant antigens. Two sera showed a strong response to rVCA while the other 
two showed no specific IgM responses. In general the level o f background signal was 
high for each o f the 4 serum samples and also for one serum sample which had shown a 
negative rVCApl8 IgM response.
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It cannot be confirmed from these results whether the IgM response to rV C A pl8 was a 
cross reaction of CMV specific IgM antibodies It is possible that the ‘cross reacting’ 
samples were taken from individuals with coincident EBV primary infection It might 
also be the case that the two ELISA +/Blot- sera exhibited non-specific IgM responses 
with the native cellular proteins in the EBV p i8 antigen preparation The samples 
showing a positive IgM response to rV C A pl8 by western blot may have specific anti- 
pl8VCA antibodies, however this may be a clear case of cross-reaction between anti- 
CMV antibodies and rV C A pl8 In order to clarify these results it would be necessary to 
simultaneously test these sera by gpl25 and pl8VCA ELISA and western blot Also pre- 
mcubation of the sera with total CMV purified antigens, prior to assay by ELISA or 
western blot for EBV would allow adsorption of CMV-specific antibodies If the assay 
results were still positive this would indicate an EBV-specific antibody response, if the 
result was negative it would seem that the CMV-specific antibodies were cross-reactmg 
with rV C A pl8 This could also be done in reverse, by pre-adsorption with EBV antigen 
and subsequent testing for the presence of CMV-specific antibodies It would also be 
necessary to test other serotypes against these recombinant antigens, such as HSV, 
adenovirus, varicella zoster and HIV-positive individuals
Cross-reactivity and false-positive results are problems which must be eliminated in any 
diagnostic test system If the specificity of the assay is low the level of misdiagnosis 
would be too great to allow the commercial availability of such a diagnostic kit This 
further emphasises the need for complete purification of the recombinant antigens It may 
also be necessary to cleave the thioredoxin moiety from the fusion proteins to further 
reduce the possibility of cross-reactmty and the appearance of false-positive results 
However, as was shown on western blot analysis, figures 44-47, many sera show 
reactivity with just one antigen, or none of the antigens If there was a specific 
interaction with thioredoxin this would be evident for each antigen
3.5.7 Expression of other recombinant EBV antigens
The EBV glycoprotein gpl25 (gpl25 is part of the VCA complex) has been used in the 
development of many diagnostic methods, tbs glycoprotein can be purified from P3HR-1
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cells in culture The three commercial tests used for partial characterisation of the sera 
analysed here, IF A, VCA IgM ELISA (both from Gull Laboratones) and a second VCA 
IgM ELISA (Baxter Bartels) all use gpl25 purified from P3HR-1 cells This protein has 
also been expressed in the baculovirus expression system and has been tested with EM+ 
sera for IgG antibodies in an immunoblot assay, m comparison with anti-VCA IFA 
(Sanchez-Martmez et a l , 1995) The assay showed 97% sensitivity and 100% 
specificity, with no crossreactivity with other human herpesviruses It may also be 
possible to express the gpl25 glycoprotein in the Thiofusion expression system, 
however, the absence of the carbohydrate residues is likely to influence the 
immunogemcity However, as the gpl25 shares significant homology with other 
herpesvirus glycoproteins, cross-reactivity cannot be excluded in all test systems (van 
Grunsven et a l , 1994)
Other recombinant EBV antigens have also been evaluated as diagnostic reagents for 
NPC, these include DNA polymerase (DP), in E coli (Lin et a l , 1995), EBV DNase, 
thymidine kinase (TK) and gp3 50/220 in baculovirus or bovine papillomavirus (Littler et 
a l , 1991) IgG antibodies to DP were detected in 43 of 48 NPC-positive sera, without 
any crossreactivity with CMV or HSV-1 Thymidine kinase was shown to be the most 
sensitive marker for NPC in comparison with DNase and gp3 50/220 Recombmant EBV 
DNA binding protein (DBP), p i38, has been shown to be effective in diagnosis of IM in 
conjunction with other antigens, i e EA-D, VCA and EBNA1 (Gorgievski-Hnsoho et 
a l , 1990) Thymidine kinase, DBP (p i38) and DP are also candidates for expression m 
the Thiofiision expression system
No one EBV antigen is sufficient to diagnose the type or stage of all types of EBV 
infection However, a panel of antigens already expressed by the thiofusion expression 
system, and expression of a number of other antigens such as TK, DBP, gpl25, and DP 
by this method, could provide a selection of the most diagnostically sensitive proteins, 
for an effective means of diagnosis of many EBV-related diseases
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* Further purification of each of the fusion proteins - either by sub-cloning into a 
vector which allows an alternative method of affinity purification, or using more 
effective purification procedures such as reverse-phase HPLC
* Testing of a larger panel of sera by several serology-based methods - based on 
specific antibody responses, this would provide a consistent reference for the results 
of this ELISA method using the recombinant antigens
* Testing a broader range of sera - from individuals whose age, medical history and 
symptomology is known, this would allow more informed critical analysis of the test 
results
* Testing of sera from patients at different stages of EBV-induced IM - acute, 
convalescent and re-activation for whom medical data is available
* Testing of a number of serum samples from one patient with IM - samples taken 
at different stages during the progression of the disease from initial diagnosis through 
to convalesence
* Analysis of sera from patients with other EBV-related diseases - such as Burkitt’s 
lymphoma (BL), Hodgkin’s disease (HD) and Nasopharyngeal carcinoma (NPC), 
also, immunocompromised individuals (HIV+ and Post-transplant patients)
* Testing of sera from patients with other non-EBV viral infections - such as HSV, 
adenovirus and varicella zoster
* Assay for anti-pl8VCA IgA and anti-EA-D IgA antibodies - with sera from IM 
re-activation patients and NPC+ individuals
*• Testing of saliva samples from NPC+ and NPC- individuals - detection of anti- 
EA-D IgA antibodies in saliva has been proven effective in the diagnosis of NPC 
(Nadalae/a/, 1996)
* Development of a more rapid assay format - possibly usmg a membrane based 
system
3.5.8 Future Recommendations
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Chapter 4
Identification of anti-gp350 MAb-binding peptides using phage display.
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4.1 Introduction
The most abundant protein of the EBV envelope is the glycoprotein gp350/220 This 
protein mediates virus adsorption and penetration of the host cell via the complement 
receptor molecule CR2 A number of anti-gp3 50/220 monoclonal antibodies prevent 
virus infection and abolish it’s ability to transform B cells As gp350/220 can induce 
antibodies which can both neutralise the virus and inhibit it’s binding to target cell 
receptors, it has been the focus of EBV vaccine preparations The monoclonal antibody 
72Al, an IgG2a class munne antibody has been shown to neutralise both type A and 
type B strains of EBV via binding with gp350/220 (Sairenji et a l , 1988) It is thought 
. that the epitope recognised by 72A1 is the only glycoprotem domain with a dual role in 
EBV neutralisation and binding to target cell receptors (Stocco et a l , 1990) If the 
epitope recognised by 72A1 were known it might then be possible to develop a subunit 
vaccine with this peptide as a component In this way a vaccine would both neutralise the 
virus and simultaneously prevent binding of the virus to it’s target receptor The purpose 
of the following experiments was to identify peptides that bind to 72A1 and also the 
monoclonal antibodies F29 167 and F2 1, both IgG2a class munne antibodies that are 
also capable of virus-neutralisation, by screening random peptide phage libraries
Phage display libranes have been used in many instances to identify the epitopes of a 
particular antigen as discussed in section 1 8 Although this is mostly successful with 
epitopes known to be continuous, it is also possible to identify discontinuous epitopes 
The type of library and the nature of the antibody are both significant factors in the 
success of epitope mapping The preference for a given library in yielding the best- 
binding peptides, depends on the structural framework within which a random peptide is 
presented, and so the chances of success are increased Four libranes were chosen for 
screening with the anti-gp350/220 monoclonal antibody 72A1, these are summansed in 
table 18 and descnbed in turn below
186
4.1.1 The Random Phage Peptide Libraries (RPLs)
Library Vector Type Peptide length Complexity Concentration
(amino acids) (transformants) (virions/ml)
pill 15 mer fUSE5 15 1.1*10 ° 1014
pill 7 mer M13 7 2*109 2*1013
pill 12 mer M13 12 1.9*109 4*1012
pill 7 mer M13 7 3.7*109 2*1013
constrained
Table 18: Phage display libraries.
The 15 mer library was constructed in vector fUSE5 (Scott and Smith, 1990), which was 
derived from the tetracycline resistant filamentous phage fd-tet. Vectors which are 
derivatives o f fd-tet do not kill their host, probably due to a reduced RF (replicative 
form) copy number that is caused by a defect in minus-strand DNA synthesis. As a result, 
these derivatives have less than 5% infectivity as compared to 50% in wild type 
filamentous phage. fUSE5 differs from other fd-tet derivatives in having two Sfil sites 
with different overhanging 3-base 3’ ends, and a frameshift mutation in gene III 2-3 
amino acids downstream of the signal sequence. The library was constructed by splicing 
degenerate oligonucleotide inserts into the Sfil sites, thus restoring the reading frame, 
leading to a recombinant pill that is incorporated as a ring o f five molecules at one tip of 
the virion. The presence o f a peptide insert restores the ORF and the majority o f gene III 
is uninterrupted by inserts. As this vector does not kill it’ s host the demand for pill 
function is minimised (pill is required for both infection and morphogenesis). Therefore, 
there might not be a strong selection against inserts which impair pill, during 
propagation. The K91Kan Escherichia coli strain was used for propagation o f these 
phage, this strain is kanamycin resistant, and upon infection with phage it also acquires 
tetracycline resistance. Successfully infected host bacteria can then be selected on media 
with both kanamycin and tetracycline. This library, a gift from Dr.A.J.Conley (University 
o f Missouri), was supplied as a secondary amplification o f the primary library yielding
1.1 * 1012 transductant clones.
1 8 7
The 7 mer library consisted of 2*109 electroporated sequences, amplified once to yield 
approximately 100 copies of each sequence in 10 pi of the phage The displayed 
heptapeptides are expressed directly at the N-termmus of pill, that is the first residue of 
the mature protein is the first randomised position The peptide is followed by a short 
spacer (Gly-Gly-Gly-Ser) and then the wild-type pin sequence
The 12 mer library consisted of approximately 1 9*109 electroporated sequences, 
amplified once to yield approximately 20 copies of each sequence in 10 pi of the phage 
supplied Similar to the 7 mer library the peptides are expressed at the N-termmus of 
pill, again followed by the 4 mer spacer and then the wild-type pill sequence
Unlike these libraries the random peptide of the 7 mer constrained library phage is 
flanked by a pair of cysteine residues Under non-reducing conditions the cysteines will 
spontaneously form a disulphide cross-link, resulting in phage display of cyclised 
peptides The peptide is expressed at the same position of the pill protein as that of the 7 
mer and 12 mer libraries, with the first cysteine being preceeded by an alanine residue 
This library consists of 3 7*109 electroporated sequences which when amplified yield 
approximately 50 copies of each sequence per 10 pi of supplied phage
4.1.2 The Anti-EBV Monoclonal Antibodies
The antibodies used in biopanmng are described in table 19 below
Antibody Subtype Antigen Virus neutralising capacity Concentration
72A1 IgG2a gp3 50/220 with or without complement 360 pg/ml
F2 1 IgG2a gp85 only with complement 500 pg/ml
F29 167 IgG2a gp3 50/220 with or without complement 1 0 mg/ml
Table 19: Anti-EBV monoclonal antibodies.
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4.2 Results
4.2.1 Biopanning of the RPLS
Primarily the 15 mer library was panned with both 72A1 and F2 1 Six ammo acids is a 
typical size for a continuous epitopes, however, using a 15 mer library increases the 
effective size of the library, since each phage represents several short peptide 
determinants (eg  up to 10 hexapeptides) in various contexts of flanking residues (Scott 
and Smith 1990) The longer peptide makes it possible to select epitopes composing 
more than six residues, also the peptides displayed in libraries with longer randomized 
regions may have some structural features not present in ‘shorter’ libraries The 
biopannmg procedure used is detailed in section 2 6 5 This involved covalent linkage of 
biotin to the target molecule, this was done prior to incubation with the phage library 
Phage able to bind the target were then selected by ‘panning’ the mixture of phage and 
target molecule on a streptavidin-coated dish This exploited the strong biotin- 
streptavidm interaction, retaining the target molecule and consequently the phage bound 
to it Bound phage were then eluted from the complexes and subjected to further rounds 
of amplification m E  coh and biopannmg, three rounds of panning were earned out See 
figure 47 for a flow diagram of this procedure
A 7 mer, 12 mer and 7 mer constrained library were also screened The 7 mer 
constrained library was chosen for screemng as it has been shown that screening libraries 
which are constrained often prove to be a ncher source of mimotopes than linear 
peptides expressed in an unconstrained format (Ladner et a l , 1995) Constraining the 
peptide confers the advantage of restricting the peptide to fewer conformations, allowing 
the determination of more structurally complex epitopes Two alternative procedures 
were used for these libraries
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Repeat twice
I
Coat plate with streptavidm
Biotinylate monoclonal antibody
I
Immobilise biotinylated 
antibody on streptavidm 
coated plate
1
Add phage to the plate
i
Wash away unbound phage 
1
Elute bound phage 
1
Titer eluate and amplify in E coh K91Kan
Figure 47: Flow diagram of the biopanning procedure for the 15 mer phage library.
An alternative method was used in panning the 7 mer library from New England Biolabs 
(See section 2 5 3) In this case the antibody was immobilised without exploiting the 
streptavidin-biotin interaction, as a result a number of steps could be removed from the 
procedure thus simplifying the process It was not necessary to biotinylate the antibody 
or to coat the plate with streptavidm The remainder of the procedure is similar to that of 
the 15 mer library, figure 48 shows a flow diagram of the protocol
1 9 0
Repeat twice
Immobilise monoclonal antibody directly on plate
I
Add phage to the plate
I
Wash away unbound phage
I '
Elute bound phage
i
Titer and amplify m E  coli ER2537
Figure 48: Flow diagram of the biopanmng procedure for the 7 mer phage library.
Both the 12 mer and 7 mer constrained libraries were panned via solution binding with 
protein G capture (See section 2 5 6) By this method the library was allowed to react 
with the antibody in solution, followed by affinity capture of the antibody-phage 
complexes onto protein G (protein A can also be used in this procedure) In addition to 
requiring substantially less antibody than surface panning, solution panning can result in 
improved accessibility of the antigen binding site to phage-displayed peptides, as well as 
avoiding partial denaturation of the antibody on the plastic surface A flow diagram of 
solution panning is shown in figure 49
1 9 1
Repeat twice
-> Wash and block protein G agarose 
1
Mix monoclonal antibody and phage
I
Immobilise antibody/phage mix on protein G 
1
Wash away unbound phage 
1
Elute bound phage
Titer eluate and amplify in E  coti ER2537
Figure 49: Flow diagram of the biopannmg procedure for the 7 mer constrained phage
library and the 12 mer library.
Three rounds of panning were earned out in each case and the eluate from each round 
was amplified The third round was titered (sections 2 5 2 and 2 6 3) before amplification 
and single plaques were isolated for small-scale propagation and processing (sections 
2 5 4 and 2 6 5)
192
' - i
After eaeh round of panning the phage, the eluate was titered before and after 
amplification to ensure that a sufficient number of phage had been selected during 
panning and that the amplification procedure has produced enough virions to proceed 
with to the next round (See sections 2 5 2, 2 6 3, and 2 6 4) The following tables show 
typical titering results after each round of panning of the 7 mer library with the 
monoclonal antibodies 72 A1 and F29 167 and the 7 mer constrained library with 72 A1
4.2.2 Phage Titering^
Round no. Amp. (-/+) Phage titer (phage/|il) Volume used (p.1)
72A1 F29.167 72A1 F29.167
1 - 3 n o 5 6*104 - -
1 + 1 68*1010 5 52* 1010 12 5
2 - 8* 10s 6 3*103 - -
2. + 1 34*1010 2 2*1010 15 10
3 - 3 68*105 106 - -
Table 20A: Titering results for the 7 mer library when panned with 72A1 and F29.167.
Round no. Amp. (-/+) Phage titer 
(phage/nl)
Volume for next 
round (ill)
1 - 3*102 -
1 + 2*1010 30
2 - 2*102 -
2 + 2*1010 10
3 - 2 5H02 -
3 + 3 3*1010 -
Table 20B: Titering results for the 7 mer constrained library when panned with 72A1.
Theoretically the number of phage eluted in each round should increase if selection is 
occurring As can be seen in tables 20A and 20B, the number of phage eluted does not
increase with increasing rounds of panning However, amplification is successful in 
amplifying the number of phage eluted It may be that the phage being amplified do not 
have high affinity for the selecting antibody, thus on subsequent rounds of panning there 
is no increase m the number, of phage displaying 72A1-specific peptides The 
concentration of monoclonal antibody used during biopannmg is decreased with 
increased round number This is done to increase the number of peptides selected which 
have a high affinity for 72A1 and minimise low affinity peptide selection Therefore, the 
lack of increase in the number of phage selected may reflect the selection of only those 
peptides with high affinity for 72A l, and the loss of phage displaying peptides with low 
affinity for 72A1
4.2.3 Sequencing of Selected Phage Clones
It was decided to proceed with sequencing of selected phage clones from each library 
regardless of the findings of the phage titers Phage DNA was isolated from the selected 
plaques isolated from the third round and DNA sequencing template was prepared 
(sections 2 5 5 and 2 6 7) The template preparations were analysed by electrophoresis 
on 0 8% agarose gel (IX TBE) before proceeding with the sequencing reactions Figures 
50 and 51 show the DNA preparations for clones selected from the 7 mer, 12 mer and 7 
mer constrained libraries The sequencing reactions and sequencing gel were prepared 
and electrophoresed as described in section 2 7
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Figure 50: Analysis of phage template DNA prior to sequencing. Phage clones were selected
from the eluate of the third round of panning of the 7 mer library panned with 72A1. Lanes are as 
follows, 1-4- DNA preps of phage clones selected from the 7 mer library with the anti-gp350/220 
monoclonal antibody 72Al(phage propagated in 1 5 ml microfuge tubes, 5-19- DNA prep s o f phage 
clones selected from the 7 mer library with the anti-gp350/220 monoclonal antibody F29 167, 20- DNA  
ladder
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Figure 51: Analysis of phage template DNA pnor to sequencing. Phage clones selected from
the eluate of the third round of panning of the 12 mer library and the 7 mer constrained library 
panned with 72A1. Lanes are as follows, 1- DNA ladder, 2-6- DNA prep s of phage clones selected 
from the 7 mer constrained primary (un-panned) library, 7-19- DNA preps o f phage clones selected 
from the 12 mer primary (un-panned) library, 20- DNA ladder
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Figure 52 shows a photograph of the developed autoradiograph, indicating the variable 
region (insert) for a number of the 15 mer clones selected with 72A1 The majority of
i
sequences were clearly legible, as a control, M l3 template DNA was also sequenced In 
general the sequences of individual clones from each library were grouped according to 
similarities in ammo acid composition and positioning From the 15 mer library three 
distinct groups were observed, clones from the 7 mer library were divided into five 
groups, while the sequences found in the 7 mer constrained library were divided into just 
two groups Sequencmg of clones isolated from the 12 mer library yielded only phage 
with the native pill protein sequence, 1 e no inserts present It is possible, although 
unlikely that the antibody selected these phage or that phage without inserts (or wild type 
contaminating phage) may have had a growth advantage over those with an insert in the 
pill protein, and during amplification outgrew any phage specifically selected by, the 
monoclonal antibody 72A1
A small number of clones selected from the 15 mer library with the F2 1 monoclonal 
antibody were also sequenced Tables 21-24 show lists and groupings of sequenced 
clones
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Figure 52: Photograph of the DNA sequencing autoradiograph, showing sequences from the
15 mer library. The sequencing reactions were run in the order A,C,G,T (left to nght) Set 1- clone 1 1, 
set 2- clone 1 2, set 3- clone 2 4, set 4- clone 1 6
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(N-term) G P S P Y  (C-term)
Group no. Clone no. Protein Sequence
Ungrouped
1 1 
1 11 
1 7
1 14
1 6
2 12 
2 15
1 6 
2 8  
1 12 
1 1
I 13 
1 15
1 9
1 8 
2 4  
2 6
2 7" 
2 13 
2 14
GP Y K N H L W W K S P I S R L R  S P V  
GP F Y H S H K W W  V L P M P R G  S P V  
GP R H W W F S S  A G R H P L R G  S P V  
GP R G W  W T H V H T N R G W L A  S P V
G P . C T E L S R W G S W R K A N M  S P V  
GP K Q R K H W F P W S P G V S  V S P V  
GP R K W G F W  Q H L Q V H R D S S P V
GP C T H L S R W G S W R K A N M  S P V  
GP E S F L H V P R W  A S L V S R  S P V  
GP Y R S W R G G W  S S H L K  G H S P V  
GP Y K N H L W W K S P I S R L R  S P V
GP H S F  Y I H A L T G G S M H R  S P V  
GP H C H R W S C R E Y R A Q D R  S P V  
GP H C H R R S C M S Y A R K D M  S P V
GP R S H F G H Y K E R  V R T R Y  S P V  
GP H A I R S G K C R W W A  CM S S P V  
GP G A F L K S F G C H G F R P S  S P V  
GP S H K W H L Y F G K P T R T K  S P V  
GP V L T R K H K T D R F W V I R  S P V  
GP R G D W R Y G L H R W Q I R N  S P V
Table 21: Peptide sequences of phage clones selected with, the anti-gp350 virus-neutralising
MAb 72A1 from the 15 mer library. The amino acids in bold type are those which have been noted as 
being common to a number of different selected clones Some clones are repeated as they show 
homology to 2 ‘groups’
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(N-term) S G (C-term)
Group no. Clone no. Protein Sequence
1
2522 S R R K S G I L G
2523 S R T K S D I L G
2
25212 s S S S T Y R Y G
25215 s S H P D T Y R G
25219 s S H P I T Y R G
3
2525 s T R V D S S P G
2529 s T R V D S S H G
2526 s S P R V P R - G
4
25212 s S S S T Y R Y G
2526 s S P R V P R - G
25218 s S L W A R H R G
2524 s S V M S V T T G
25215 s S H P D T Y R G
25219 s S H P I T Y R G
2521 s S H Q Q S S T G
25214 s S H L I Q Q R G
2525 s T R V D S S P G
2529 s T R V D S S H G
5
25211 s V D L R T A F G
25213 s T F L R F P L G
Ungrouped
25216 s A A P G T L P G
Table 22: Amino acid sequences displayed on phage clones selected with the anti-gp350
virus-neutralising MAb 72A1 from the 7 mer unconstrained library. The amino acids in bold type 
are those which have been noted as being common to a number of different selected clones Some clones 
are repeated as they show homology to 2 ‘groups’
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(N-term) S C C G (C-term)
Group no. Clone no. Protein Sequence
1
C7CN S C Y K S L P E Q C G
C7C18 s C H P W F  Q T I C G
C7C4 s C S P A Q F L A C G
C7C5 s C N P N Q L Y L C G
C7CC s C P T L L Q L H C G
C7C28 s C L G S G Q Y W C G
2
C7C10 s C T - L Q K P W M C G
C7C14 s C H L K D P N K C G
C7C15 s C D R L S G P R C G
C7C27 s C F T E L P F S C G
Ungrouped
C7CB s C I I N G P  V N C G
C7C7 s C N T P T P R S C G
C7C9 s C T T T L N T S C G
C7C21 s C S K S S V R S C G
Table 23: Ammo acid sequences displayed on phage clones selected with the anti-gp350
virus-neutralising Mab 72A1 from the 7 mer constrained library. The amino acids in bold type are 
those which have been noted as being common to a number of different selected clones
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(N-term) G P S P Y  (C-term)
Group no. Clone no. Protein Sequence
1
, F21B4 GP R S H W F T D R W D P R D H R SP V
F21A3 GP K Y V R R H W F G H G H K T S SP V
L
F21A2 GP K K R H L S H F Y T Q S V K V SP V
'X
F21B1 GP S L A E V I N F F S Y G V R V SP V
F21B2 GP H C H R W  S C R E Y R A Q D R SP V
F21A4 GP H S F Y I H A L T G G S M H R S P Y
Table 24: Amino acid sequences displayed on phage clones selected with the anti-gp350
virus-neutralising MAb F2.1 from the 15 mer library. The amino acids in bold type are those which 
have been noted as being common to a number of different selected clones
The gp350/220 peptide sequence shows similarity with group three from the 15 mer 
library only, no other significant similarity between any of these sequences and the 
primary aa sequence of gp350 was found Screemng the library with a different 
monoclonal antibody selects clones expressing peptide sequences completely unrelated to 
those selected with 72A1 However, two identical sequences were found after three 
rounds of biopanmng of the 15 mer library with 72 A1 and F2 1, these are 1 13 and 115 
in table 21, and F21A4 and F21B2 in table 24
Both the 7 mer constrained and unconstrained libraries showed deletions within the insert 
or absence of an insert in almost 50% of the clones sequenced As with the 12 mer 
library this may have been due to non-specific selection of phage In order to determine 
at what stage the selection of phage without inserts took place, a number of clones were 
selected from the primary libraries and from various stages throughout the biopanmng 
procedure The sequences of the selected clones are detailed in table 25 below
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Library Round no Clone no. Protein Sequence
7 mer Unselected 1 S S L N P P N P G
7 mer Unselected 2 S N P W A Y Y Q G
C7C Unselected 1 C S L V K L G A C
C7C Unselected 2 C S T R S V V L C
C7C Round 2 C7C1 no insert
C7C Round 2 C7C2 C T T T A Y Q T C
C7C Round 2 C7C6 C A P F I N R S C
C7C Round 2 C7C10 C N P A N T D M C
12 mer Unselected 1 S L S S I C V T T V A S A G
12 mer Unselected 2 S F A A N K M P F G P G S G
12 mer Unselected 3 S G S A L V T E P S I A W G
12 mer Unselected 4 S A V V V F P Y P S N L A G
12 mer Round 2 12M1 deletion mutant (a single base missing)
12 mer Round 2 12M4 S H F N H S I R L H N A A G
12 mer Round 2 12M5 S T D L Q I K R H L G H G G
12 mer Round 3 12M2 no msert
12 mer Round 3 12M3 no insert
12 mer Round 3
✓
12M6 deletion mutant (a smgle base missing)
Table 25: Amino acid sequences displayed on clones selected from the primary libraries and
form various stages throughout the biopanning procedure.
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All clones isolated from the un-panned libraries had complete inserts without any 
deletions, this suggested that selection of phage without inserts or with deletions within 
the inserts, occurred during the biopanmng process Four clones were selected from the 
7 mer constrained library and six from the 12 mer library These represented phage from 
7 mer constrained library round two eluate, un-amplified and 12 mer library round two 
and round three eluate, un-amplified
These findings indicate that the selection of clones without inserts and with mutations 
within the insert occurs before the final round of panning and with amplification of the 
eluate from each round, these clones are being amplified also It may be that phage 
without inserts may have a growth advantage over those with an insert If a small 
fraction of the phage population are without inserts after the first or second round of 
panning, these may outgrow phage with inserts during the amplification However, 
deletions withm the insert disrupts the ORF of the pill gene, as this protein is involved in 
infection of host cells, it would be expected that these phage could not propagate during 
amplification As all phage from the primary unpanned library were without mutation, it 
is likely that phage without inserts not expressing a peptide have a growth advantage
4.2.3.1 Comparison of Sequenced Clones
15 mer Library panned with 72A1 (Table 21)
These clones were divided into three groups which had similarities in amino acid 
sequence, a fourth group was found which consisted of two sequences 100% identical to 
two sequences found after panning this library with the monoclonal antibody F2 1 (1 13 
and 1 15 in table 21, and F21A4 and F21B2 in table 24), which is specific for the 
glycoprotein gp85 This may have occurred due to binding of phage to streptavidin or 
the plate or non-specific binding to this class of antibody (class IgG2a), these phage may 
then be released into the eluate However, measures were taken to prevent this occurring 
(section 2 6) Clones 1 1 and 1 6 are allocated to two groups as their amino acid 
sequences fit the consensus sequences of both groups Six of the 18 peptides isolated 
possessed no evident common pattern in their ammo acid sequences
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Group 2 R K W G F W ______V ___
Group3 Y  H L _ R W _ S  K/S R _
The amino acids in bold type are those which feature m every peptide within that group, the other 
residues appear in at least 2 peptides withm each group
Peptides from group three had a number of ammo acids which were common to a region 
close to the carboxy terminus of the gp3 50/220 protein, this was the only sequence 
found within the native protein which could be directly correlated with any of the 
selected peptides
gp 350/220 aa 862 L V L Q W A S L A V L T aa 873
As the epitope may be conformational (Morgan et a l , 1984a), it is possible that a 
number of the ammo acids which constitute the epitope are located in this region of the 
protein The remainder of the ammo acids which complete the epitope may be located at 
positions on the primary sequence which are distant form the carboxy terminus When 
the protein is folded in it’s three dimensional form these residues may then be in a close 
spatial arrangement
7 mer Library panned with 72A1 (Table 22)
Of these 15 peptides, 5 groups were identified All the peptides m groups 2 and 3 are 
also present in group 4 One clone was found which had no similarity to the other 
peptides that were sequenced
G roupl R _K S _ IL
Group2 S H P  T Y R
Group 3 T R V D  S S _
G roupl Y RH  W W  S P  R L R G
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Group 4 S S H/P
Group 5 __ L R ____
In comparison with the ammo acid sequence of g350/220 there were no apparent 
similarities, however, the double senne motif which appears frequently in group 4 and 
also appears in group 3 can be seen at eight locations on the gp350/220 primary ammo 
acid sequence, predominantly toward the carboxy terminal half of the protein
7 mer constrained Library panned with 72A1 (Table 23)
The set of peptides selected from this library were divided into two specific groups Four 
of the 14 clones sequenced had no particular similarity to the others m the set
Group 1 __ L/P Q L
Group2  L K _ P __
As with the 7 mer library there were no significant homologies (2-3 aa) between these 
groups of ammo acids and the native gp3 50/220 sequence could be found
15 mer Library panned with F2 1 (Table 24)
Six clones were sequenced from the third eluate after panning the 15 mer library with 
F29 167 These sequences were compared with the peptides found when panning with 
72A1 to determine if the panning procedure was isolating sequences which did not have 
particular specificity for the antibody used m the panning procedure Two specific groups 
were noted which possessed a number of identical ammo acids, and two peptides were 
found which had identical sequences to two of those selected by 72A l, these are shown 
in group 4 of table 22, and group 3 of table 24
Group 1 R H W F
Group 2 F F _ Y  V _ V
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In general there are differences in the relative positioning of the amino acids which are 
common, within each group, they may differ in space by 1-2 ammo acids The interaction 
between an antibody and it’s epitope is very precise and specific, however as these 
peptides are displayed freely on the surface of the phage via the pill protein it may be 
possible for these peptides to adapt the required conformation in order to bind the 
antibody
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4.2.3.2 Sequence Alignment according to Amino Acid class
The sequences selected from each library were also compared in relation to the class of 
amino acid present as opposed to the individual amino acids, i.e. polar, charged +/-; 
polar, uncharged; nonpolar. These alignments are shown in figures 53-56, for each figure 
the following colours denote the different classes of aa:
S T N Q Y  C polar, uncharged
K  R  H polar, + charge
D E polar, - charge
G A V L IM P F  W Nonpolar
Figure 53: Alignment of the sequences selected from the 15 mer peptide library using 72A1,
according to amino acid class.
Comparison of the sequences according to the class o f amino acid allows comparison of 
all the selected sequences without division into smaller groups. Figure 53 shows a 
definite pattern in the majority of the sequences, there is a core of nonpolar amino acids
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flanked by one or more polar positively charged amino acids, alternating with polar, 
uncharged amino acids in many cases.
R T K S |
S S S T Y ] 
V D  
H | j V D  
R V D _ _ 
jP D T Y 
P IT Y  
QQ :
H o  Q s S T 
R V P B -
W A R H R
M S V 
A P G
TT
TL
Figure 54: Alignment of the sequences selected from the 7 mer peptide library using 72A1,
according to amino acid class.
Comparison of the sequences selected from the 7 mer library (by 72A1) by this method 
also shows a definite pattern in the aa arrangement between all the sequences (figure 54). 
The pattern does not compare closely to that of the 15 mer sequences, however there is 
consistently the presence of a polar, uncharged aa followed by a positively charged, polar
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Figure 55: Alignment of the sequences selected from the 7 mer constrained peptide library
using 72A1, according to amino acid class.
The pattern observed with the 7 mer constrained sequences (figure 55) shows no 
similarity with those of the 15 mer and 7 mer unconstrained sequences (figures 53 and 
54). This may be due to the fact that these peptides are constrained and thus bind the 
antibody in a different way to the linear peptides.
Figure 56: Alignment of the sequences selected from the 15 mer peptide library using F2.1,
according to amino acid class.
The sequences selected from the 15 mer library by F2.1 (figure 56) do not show any 
consistent pattern, however, had a greater number of clones been analysed, a specific 
pattern of aa.s might have begun to emerge. There is no obvious relationship with those 
selected using 72A1 from any of the other libraries.
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Figure 57 shows the primary amino acid sequence of gp350, with the amino acids coded 
according to amino acid class using the same colour code previously described.
Figure 57: The primary amino acid sequence of gp350 colour coded for amino acid class.
According to this method of comparison there was no significant similarity between the 
selected sequences from any of the libraries and the primary gp350 sequence. If  the 
epitope is conformational or has a sugar component this would be expected.
4.2.4 Deglycosylation of gp350 and Western blotting
Western blot analysis was performed using two of the monoclonal antibodies, 72A1 and 
F29167, to aid the determination of the type of epitope recognised by each antibody. 
Both purified gp350 (a gift from Dr. A. Morgan, University of Bristol, purified by 
affinity selection from cell culture). Figure 58 shows a 7.5% SDS PAGE protein gel of 
the gp350 protein. The protein was blotted as described in section 2.4.8, and probed with 
both 72A1 and F29.167. As can be seen in figure 59 (western blot) both antibodies 
bound to the purified gp350 molecule (500ng) in it’s fully glycosylated form. There were 
two high molecular weight bands, gp350 and possibly a gp350 aggregate, however with 
absence of appropriate size markers it is not possible to confirm this. The higher band 
was not visible when analysed on SDS-PAGE (figure 58), but could be seen on western
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blot (figure 59) This result confirms that both monoclonal antibodies recognise the 
glycosylated form of the protein Conjugate only did not bind (data not shown)
It has previously been shown that 72A1 does not interact with gp350/220 in a denatured 
state, indicating that the epitope is most likely discontinuous (Morgan et a l , 1984a) 
However, peptide reaction m immunoblots may also be achieved by non-linear epitopes 
where the reacting portions are in relatively close proximity (Fack et a l , 1997) This may 
explain this interaction of 72A1 with gp350/220 as can be seen in figure 59, lanes 2 and 
3
1 2  3 4
Figure 58: A 7.5%SDS PAGE gel of purified gp350. Lanes are as follows, 1- Protein markers,
2- gp350/ (50 ng), 3- gp350 (250 ng), 4- gp350 (500 ng)
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Figure 59: Western blot analysis of punfied gp350, probed with F29.167 (lane 1) and 72A1
(lanes 2 and 3) from a 7.5% SDS PAGE. Lanes 1-3 gp350 (500 ng), lane 4 - Protein markers
A sample of punfied gp350 was deglycosylated in order to determine if the carbohydrate 
(CHO) moiety is required for antibody recogmtion, the sugars may form part of the 
epitope or may be required structurally for binding of the monoclonal antibodies to an 
epitope on the ammo acid sequence The carbohydrate moiety of gp3 50/220 is known to 
be made up of both O-linked and N-linked types and to constitute about 50% of the 
molecular mass This high carbohydrate content of gp350/220 appears to confer 
resistance to proteolysis (Morgan et a l , 1984)
A cocktail of the deglycosylation enzymes, N-glycosidase F, O-glycosidase, and 
Neuraminidase was used N-glycosidase F cleaves all types of asparagine bound N- 
glycans provided that the amino-group as well as the carboxyl-group are present in a 
peptide linkage and that the oligosacchande has the minimum length of the chitobiose 
core (Data sheet - Boehnnger Mannheim) O-glycosidase liberates the dissachande Gal 
b(l-3) GalNAc from O-glycans, which is bound to senne or threonine as a core umt 
(Data sheet - Boehnnger Mannheim) Neuraminidase cleaves terminal sialic acid residues 
which are a2,3-, a2,6- or a2,8- linked to Gal, GlcNAc, GalNAc, AcNeu, GlcNeu, 
oligosacchandes, glycolipids or glyoproteins (Boehnnger Mannheim catalogue, 1998) 
The protein had been punfied from cell culture supernatant, but it’s concentration was
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had not been determined A 100 ¡j.1 volume was denatured and a 30 (xl sample was used 
for deglycosylation As a negative control 30 (il of the denatured protein was incubated 
as for deglycosylation without the deglycosylation enzymes (all other reagents were 
included), see section 2 5 10
Both the glycosylated and deglycosylated forms were analysed on a 6% SDS-PAGE, and 
blotted onto nitrocellulose as described m section 2  4 8 and 10 |xl of each deglycosylation 
reaction was run on the gel The blot was probed with F29 167 and MDP 61 14, a 
polyclonal anti-gp3 50/220 preparation from a rabbit (supplied by Dr A Morgan), all 
were diluted 1/1000 in blotto As can be seen in figure 60 the polyclonal antibody 
preparation recogmses both the glycosylated and deglycosylated forms o f the
I
glycoprotein The main band in figure 60, lane 1, of the deglycosylated gp350 appears at 
approximately 130 kD, as would be expected (Morgan £t a l , 1984) It is possible that 
small indigestible traces of CHO remain and contribute to antibody-binding F29 167 
reacts with the deglycosylated form, but not with the glycosylated form in this particular 
blot, possibly due to a low protein concentration This was not due to gp350 degradation 
as it wasn’t  degraded under similar conditions i e  lane 2 shows the same material as lane 
4, figure 60, it may have been a localised problem with protein transfer on this region of 
the filter during blotting However, as can be seen in figure 59, F29 167 does recognise
f
the glycosylated form of gp350 These results suggest that the epitope recognised by 
F29 167 is linear and that the carbohydrate moiety is not required for recognition nor 
does it mask the epitope This experiment was not performed with 72A l, although this 
would have been desirable Unfortunately this antibody was no longer ^ available-at that 
time The MAb F2 1 reacts with gp85 which was not available
2 1 3
Glycosylated 18
Deglycosylayted
175 kD
<—  83 kD
3 4 5
Figure 60: Western blot analysis of gp350/220, glycosylated and deglycosylated, probed with
F29.167 and MDP 61.1.4 antibody preparations. The lanes are as follows, 1- gp350/220 
deglycosylated, 2- gp35/220 glycosylated, 3- gp350/220 deglycosylated, 4- gp350/220 glycosylated, 5- 
Protem markers Lanes 1&2 were probed with the polyclonal antibody preparation MDP 6114,  Lanes 
3&4 were probed with F29 167
4.2.5 Screening of Selected Phage Clones
A number of procedures were earned out to identify selected phage from the third round 
eluate, which displayed peptides which bound specifically to the monoclonal antibody 
used in the biopanning procedure, they are now desenbed in turn
4.2.5.1 Colony Lifts and Plaque Lifts
The absence of cell killing in fd-tet and it’s denvatives, including fUSE5 used here (15 
mer library), is probably due to a defect in minus-strand synthesis (Smith, 1988) This 
defect allows titenng of this library as transducing umts (TU) in the appropnate bacterial 
strain, m this instance Escherichia coh K91Kan Each colony or TU represents a single 
successful infection This method of titenng is more appropnate for this vector as titenng 
as plaque forming umts (pfii) is not practical due to the very tiny plaques which are 
formed The 7 mer, 12 mer, and 7 mer constrained libranes could all be titered as pfu s
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These methods enable one to screen larger numbers of plaques and colonies The colony 
lifts and plaque lifts involved a format which was completely different from that which 
took place during biopanning, the phage were immobilised on nitrocellulose in each case 
as opposed to plastic Both colony lifts and plaque lifts were performed as described in 
section 2 6 8, colony lifts of TUs for the 15 mer library and plaque lifts of pfu s for the 
M l3 based libraries The screemng was performed on titers of the eluate from the third 
round of panning, before amplification Positive and negative controls were dotted onto 
nitrocellulose and incubated as for the lifts themselves (See table 26 for details of the 
control reagents)
Control Concentration Volume (|il) Reaction (+/-)
Anti-mouse-AP Antibody 
Anti-mouse-POD 
72A1
neat 
neat 
1 mg/ml 
50 iig/ml 
100 (ig/ml
10
2
2
+
+
+
gp350
BSA 2
2 +
Table 26: The Controls used for the Colony/Plaque Lifts, (see figures 61A and 61B)
2 1 5
Figure 61A: Plaque lift of pfu.s from the eluate of the third round of panning with the 7 mer
constrained library using the alkaline phosphatase anti-mouse conjugate and BCIP/NBT substrate.
The plate used was a 10'1 dilution of the eluate with 30-300 plaques.
Figure 61B: The controls used for the plaque lift. Column 1- Anti-mouse-AP conjugate (2 (il
neat), column 2- 72A1 (2 ng), column 3- gp350 (lOOng), column 4- BSA (200ng).
Figure 62A: Plaque lift of pfu.s from the eluate of the third round of panning with the 7 mer
constrained library using the peroxidase anti-mouse conjugate and a chemiluminescent substrate.
The plate used was a 10'1 dilution of the eluate with 30-300 plaques
Figure 6211: The controls used for the plaque lift Row 1- Anti-mouse-POD conjugate, 200 p.1
(1/1000, 1/500, 1/100), row 2- 72A1 (2 ng, 10 ng, 20 ng, 200 ng, 2 jig), row 3- gp350 (2 ng, 10 ng, 100 
ng, 1 ng), row 4 - BSA (10 ng, 20 ng, 2 ng)
2 1 7
As can be seen from figures 61A-62B the controls reacted as expected, however no 
positive clones were visible on the plaque/colony lifts No positive clones were found 
using the alkaline phosphatase conjugate and BCIP/NBT as substrate, therefore a 
chemiluminescence-based detection system was used (Supersignal, see section 2 1 4) for 
greater sensitivity However, even with increased sensitivity there were no positive 
clones identified Initially it was reasoned that this might have been due to a low 
concentration of phage in each plaque If the peptides displayed were of low affinity and 
at a low concentration then it might be possible that this method for detection would not 
be sensitive enough to detect such peptides Because the peptide is displayed on the pill 
protein there are only 5 copies per phage particle, this method might be more suitable for 
phage displaying the peptide on the pVIII protein as there are -2700 copies of this 
protein on each vinon Therefore, even low affinity peptides could be detected due to 
their abundance A DOT blot procedure was then considered as a means of detecting 
positive clones, as it would be possible to screen at a higher phage concentration, thus 
allowing the detection of positive clones which may have a low affinity for 72A1
4.2.5.2 DOT Blotting
A number of phage clones were screened using the same phage purification procedure as 
that designed for analysis by ELISA (section 2 5 4 and section 2 6 6) This was done in 
order to sufficiently concentrate the number of vinons thus possibly enabling the 
detection of clones positive for 72A1 binding peptides using a DOT blot The phage 
were titered before using in the DOT blot, to determine the concentration of pfu s The 
following table gives an example of the concentration of phage used in the DOT blot 
experiment
2 1 8
Clone no. Titer (*109 pfu/fj.1)
2522 3.6
2523 4.5
25212 12.2
25215 12.8
25219 5.6
Table 27: Titering results of a selection of phage purified from the eluate from the third
round of panning of the 7 mer library with 72A1.
The procedure was carried out as detailed in section 2.5.9. Figure 63 shows in 
diagramatic form, the format of the assay. A chemiluminescence-based detection system 
was used in order to achieve a higher level of sensitivity.
Figure 63: DOT blot format for detection of 72A1 - specific peptides on phage particles
selected during biopanning.
The same controls were used as for the plaque lifts, i.e. BSA, gp350, 72A1 and anti­
mouse peroxidase conjugate, at a range of concentrations. Phage purified from the 
primary, un-panned libraries, were also used as negative controls. This method of 
screening was used for both the 7 mer and 7 mer constrained library. As with the 
plaque/colony lifts all the positive controls showed a very strong signal (indicating the 
high sensitivity of this method) and all negative controls were negative. Figure 64 shows
219
a photograph of the auto-radiograph developed after 30 s exposure to the nitrocellulose 
filter Five clones from the 7 mer constrained library were spotted m triplicate on 
nitrocellulose using a dot-blotting apparatus which was connected to a vacuum pump
1 
2
3
4
5
6
7
8
Figure 64: Auto-radiograph of DOT Blot assay earned out with phage from the 7 mer
constrained library. Rows are as follows, 1- gp350 (100 ng), 2- 72A1 (2*20 ng, 10 ng, 1 ng), 3- Anti- 
mouse-POD conjugate (3*1/1000, 1/500), 4- BSA (50 ng, 20 ng), 5- clones 31,32,33,34, 6- clones 
35,36,A,B, 7- clones 37,38,39,310, 8- clones 311,312,C,D (A-D are clones selected from the primary, 
un-panned library)
No positive clones were identified It was thought that as the method of immobilisation 
of phage was different to that used during biopannmg, that detection by the monoclonal 
antibody binding may be somewhat diminished
4.2.5.3 BIAcore Analysis
It was thought that lack of sensitivity might also be a contributory factor m the failure to 
isolate positive clones BIAcore analysis was then considered, as this technology 
represents one of the most sensitive antibody-antigen assay techniques available This
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technology involves immobilisation of the target molecule, i.e. 72A1, on a sensor chip, 
and then passing a preparation of phage library over this chip. The interaction is 
measured as a change in response units (RU ), which is caused by change in the refractive 
index of the chip surface due to the increase in mass on the surface of the chip (Jonsson 
and Malmqvist, 1992). A very low signal (243.9 RU) was obtained when assaying the 
interaction between 72A1 and purified gp350. (Figures 65 and 66  show the sensorgrams 
obtained in the control reaction, i.e. initial binding of 72A1 to the sensor chip followed 
by binding of gp350.) A typical response for ~1013 pfu/ml, from a third round eluate, 
reacted with the target molecule is 1870 RU (Lasonder et al., 1994). Phage would be 
expected to have a much lower signal than that of gp350 therefore a higher 
concentration of phage would be required. In conclusion, BIAcore analysis was not able 
to show satisfactory Ab-Ag interaction under the conditions used. As not enough MAb 
or purified gp350 was available for optimisation of the procedure, it was decided not to 
proceed with analysis of phage clones by this method.
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Figure 65: Scnsorgram of immobilisation of 72A1 on the sensor chip. Between 1750 s and
2250 s the change in response units is ~  1000 RU, this represents immobilisation of the antibody.
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Figure 66: Sensorgram of the bmdmg of gp350. The change m RU of 243 9 RU at ~500 s
represents binding of gp350
4.2.S.4 ELISA Analysis
As all of these methods of screening use a different format to that used m the biopanning 
procedure it was decided to try an ELISA format which would be more similar to the 
method of panning, which, in the case of the 15 mer and 7 mer libraries, involved prior 
immobilisation of the target antibody on plastic followed by the addition of free phage 
The plaque/colony lifts and DOT blot method required immobilisation of the phage onto 
mtocellulose, which does not occur during solution biopanmng and which may have 
resulted in a difference in the accessibility/binding characteristics of the displayed peptide 
with respect to the target antibody 72A1 A number of different ELISA formats were 
considered, see figure 67 (A-C), for a schematic representation of these assays
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C
Figure 67: Possible ELISA formats for detection of 72A1 - specific peptides on phage
particles selected during biopanning.
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The first method considered (A) involves direct immobilisation of the phage on the 96 
well plate which may result in uneven coating of the different clones, using a monoclonal 
antibody to immobilise the phage would give more uniform coating of the phage particles 
as in diagram (B) However, to follow the biopanmng procedure more closely it was 
decided to coat the plate with 72A l, and follow this with incubation with the purified 
phage clones A rabbit anti-phage antibody was then used, followed by an anti-rabbit 
alkaline phosphatase conjugate, and pNPP as substrate Phage selected by F29 167 and 
randomly chosen phage that were purified from the primary library (without panning) 
were used as negative controls
ELISA results showed a positive reaction between phage purified from the unselected 
library as well as those selected during biopannmg There was no direct interaction 
between 72A1 and either the anti-phage antibody or the anti-rabbit alkaline phophatase 
antibody (this was indicated by the absence of signal) When phage were present from 
the un-panned library or from the third round of panning with 72A1 there was always a 
positive result Increasing the stringency of the washes (with 0 5% Tween 20) between 
the incubation periods did not appear to reduce this interaction
As this procedure replicates on a smaller scale the interactions which take place during 
biopanmng, it highlights the possibility that this monoclonal antibody (72A1) may be 
capable of binding filamentous phage at some site other than specifically with the surface 
displayed peptide As a result the antibody binds phage from a number of different 
sources which do not necessarily display a peptide which mimics it’s epitope However, 
this still does not explain the fact that related phage clones were obtained This binding 
was not seen in DOT blotting or in colony/plaque lifts In the case of the plaque/colony 
lifts this may be due to low concentration of phage particles In DOT blotting it may be 
that as the format is different and involves direct immobilisation of the phage on 
nitrocellulose followed by probing with 72A1, that the accessibility of the particular 
binding site is reduced
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4.3 Discussion
4.3.1 Epitope mapping of gp350 and the neutralising Mab 72A1
The monoclonal antibody 72A1 neutralises both B95-8 and P3HR-1 indicating that the 
epitope is present in both type A and type B viruses (Sairenji et a l , 1988), this epitope 
was thought to be located within the amino-terminal 162 aa (Tanner et a l , 1988) 
However, there appears to be species-specific variation in the immune response to EBV, 
as the epitopes found using serum from healthy seropositive humans were located 
toward the carboxy terminus of gp350 and were thought to be discontinuous m nature 
(Pither et a l , 1992a), while those found after immunisation of rabbits were amino- 
terminal and continuous (Pither et a l , 1992b) This difference m response may also 
depend on whether the individual is naturally infected or vaccinated, also, the molecule’s 
host cell-specific pattern of glycosylation will influence the accessibility and structure of 
the gp350/220 molecule It has been shown that 72A1 binds gp350 on western blot of a 
denaturing SDS-PAGE (section 4 2 2, figure 59), therefore it may be that the reacting 
portions of a discontinuous epitope are in relatively close proximity and are capable of 
reaction in immunoblot (Fack et a l , 1997)
4.3.2 Sequence Comparisons
As shown in section 4 2 3 1, there are a number of defined groups within each set of 
sequenced clones for each particular library, divided on the basis of sequence similarity 
Within the 15 mer library the three defined groups showed many apparent sequence 
comparisons with up to six of the fifteen amino acids conserved between two sequences 
within each group This indicates that there was some level of affinity selection In the 
case of the 7 mer library, groups one to three showed between five and six conserved 
residues between two sequences within each group Due to the high number of deletion 
mutants and clones without inserts which were found, there were a limited number of 
sequences for comparison, however, affinity selection does appear to have occurred As 
can be seen in section 4 2 3, sequencing albeit a small number of clones from either the 
primary library or earlier rounds of panning showed no relationship between the 
sequences of each clone If there were no affinity selection after three rounds of panning 
this would also have been the case for the clones sequenced after round three Clones
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selected from the 7 mer constrained library show a lower degree of sequence homology, 
with only up to three conserved residues
Comparison of the peptides according to ammo acid class, as in section 4 2 3 2 shows a 
more defined pattern for the sequences selected, by 72A l, from both the 15 mer and 7 
mer linear peptide libraries (figures 21 and 22) The type of amino acid is important in 
defining an epitope or mimotope, although the actual aa s may not be identical, if aa s of 
the same type are present in similar positions the same interaction between the peptide 
and antibody may occur In the case of the 15 mer sequences there is a core of nonpolar 
aa s in the majority of the peptides, preceded by at least one polar, positively charged aa, 
in many cases a polar uncharged aa is present between two of the positively charged aa s 
Five of the 15 peptides selected from the 7 mer library are similar m that they too have a 
polar, uncharged amino acid, followed by a positively charged residue and then a 
nonpolar residue However, there was no obvious relationship between the primary 
amino acid sequence of gp350 and the selected phage clones by this method of 
comparison This reinforces the possibility that the epitope is conformational In general, 
alignment by this method allows a less rigid means of sequence comparison, which may 
reflect more clearly the type of selection permitted by phage display technology
Ammo acid sequence patterns may be very obvious or often very obscure, and the type 
of library screened may play a crucial role in identification of some binding domains as 
may the type of interactive domain itself In some cases the consensus sequence is 
evident in 100% of clones, however it is also possible that despite persistent effort and 
varied strategies that a consensus sequence may not be obtained (Bumtt et a l , 1995) It 
is usually desirable to select several similar but umque clones which support a consensus 
ammo acid sequence It is frequently the case that the conserved residues of the phage 
sequences are specifically spaced and may demonstrate which, if any, conservative 
substitutions can exist m these positions There may also be a number of positions in 
which almost any residue appears, possibly indicating ammo acids in which the side chain 
faces away from the interactive surface of the molecule The small number of conserved 
residues found in the inserts selected from the constrained library may reflect this type of 
situation As the inserts are constrained and have restricted conformational freedom, it is 
possible that only a small number of residues are required for high affinity binding to the
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antibody The other positions may therefore be redundant in antibody binding and thus 
allow for the presence of almost any ammo acid
As only one group of clones from the set of 15 mer sequences bears any similarity to the 
native gp3 50/220 primary amino acid sequence, it is likely the epitope is conformational, 
or that all other selected peptides are mimotopes of a linear epitope
4.3.3 Methods of Panning
As the interaction between any antibody and it’s particular epitope is so specific, 
different biopannmg methods and a panel of libraries were used m order to maximise the 
possibility of isolating the specific epitope or mimotope The way in which the target 
molecule, in this case 72 A l, is presented to the phage may also be critical to the selection 
of phage displaying peptides with high affinity for that molecule
The high-affimty biotin-streptavidin interaction was exploited when panning the 15 mer 
library This method was chosen in order to increase yields and reduce the requirement 
for antibody, compared to direct immobilisation of antibody on polystyrene However, 
there may have been losses during the concentration procedure required poor to 
biotinylation and the extent of biotinylation of the antibody was not assayed Due to 
these factors, the level of antibody immobilisation may not have been optimal The fact 
that there were two identical sequences found after panning with two different antibodies 
72Al and F2 1, may indicate a non-specific interaction between the phage and 
streptavidin A subtraction step was earned out in further biopannmg, directly after the 
first round in order to remove these non-specific phage clones This involved incubation 
of the eluate with a streptavidin coated plate and subsequent removal of the eluate 
followed directly by amplification These factors may influence the type of peptides 
selected, using this particular method
Bivalent binding of phage to the antibody may also occur using the biotin-streptavidin 
immobilisation method, or using direct immobilisation (for the 7 mer library) One 
antibody may bind more than one peptide on a particular vinon or it may bind peptides 
from two different phage clones, and this bivalent binding may be ineversible Therefore, 
affinity panning may not be able to distinguish between moderately high affinity peptides
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and very high affinity peptides (Scott and Smith, 1990) As a result low affinity binders 
may have bound the monoclonal antibody, 72A1 On screemng selected clones by 
colony/plaque lifts or DOT blot, the absence of any visible interaction with 72 A 1 may be 
explained by the low affinity of these peptides
Limiting phage concentration m rounds two and three of biopannmg was earned out in 
order to increase the number of high affinity peptides selected, however this also results 
in competition between phage for antibody binding If lower affinity binders were 
preferentially selected in round one (due to bivalent bmding, and the availability of excess 
antibody) and were in much greater excess than those with higher affinity, such a 
limitation on available antibody may have resulted in further reduction in the number of 
higher affinity clones selected and amplified m subsequent rounds of panning
Both the 12 mer and 7 mer constrained library were panned via the solution bmding 
procedure, using Protein G agarose beads This method was chosen as it requires 
substantially less antibody than surface panning, can improve accessibility of the antigen 
bmding site to phage-displayed peptides and can avoid potential partial denaturation of 
the antibody on the plastic surface These beads have pores that are large compared to 
ligate but small compared to the long dimension of the vinon, therefore it is likely that 
only a fraction of the immobilised ligate is available to the vinons The vinons are 
probably thin enough to penetrate the pores end first and could bind a ligate inside the 
mtenor and become trapped very close to the ligate, thus increasing the chances of 
binding between peptides and antibody molecules However, this may also result m the 
selection of phage with very low affinity peptides, as in this case it is the physical 
proximity of phage and antibody which enables binding as opposed to the presence of a 
peptide with a high affinity for the particular antibody
Each method has advantages and disadvantages which influence the type of peptides 
selected The use of small impermeable beads, such as polyacrylic oxirane beads may be 
a more suitable method for the selection of high affinity peptides This method provides 
the advantages of increased surface area to volume ratio, reduced antibody usage and 
reduction m antibody denaturation, without the problem created by the porous nature of 
agarose These beads have been successfully used in previous work by Bass et a l , 1990
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It appears that the method which proves successful in the identification of a particular 
epitope or ligand is very much dictated by the nature of the specific protein-protein 
interaction.
4.3.4 Methods of Screening
Four different screening methods were used in order to maximise the chances that the 
clones selected had specific affinity for the antibody 72A l, and that they could 
specifically bind the antibody under alternative conditions. BIAcore analysis was 
abandoned due to the poor signal obtained using gp350 as positive control. None of the 
four methods proved successful in definitive identification of 72A 1 specific peptides. In 
the case of the plaque/colony lifts this may have been due to the fact that, although more 
clones could be screened the phage were not at a high concentration, in addition if  the 
displayed peptides are not of very high affinity it would be difficult to detect them by this 
method.
Using a DOT blot or ELISA  format allowed concentration of the phage, thus increasing 
the possibility of detecting phage despite the probability that they displayed low affinity 
peptides. However, as with the plaque/colony lifts, DOT blotting of limited numbers of 
phage did not result in any positive clones. This might have been due to the differences, 
in antibody presentation to the phage. As discussed in section 4.3.3, the method of 
antigen presentation can be of great importance in selection of high affinity peptides, 
similarly, in the post-panning screening, antibody presentation may be of equal 
significance. Therefore, ELISA  assay, which had the most closely related format, would 
be the likely method to give a reflection of the level of interaction between the selected 
phage and the monoclonal antibody.
Using this method of screening, 72A 1 was seen to interact with all phage clones, 
including those from the primary un-panned library. This finding would indicate that the 
phage were binding the antibody by some means other than via the displayed peptide. If  
this were the case the significance of the sequence comparisons found would be highly 
questionable. It may be possible that there existed a combination of phage-antibody 
interactions, which involved the displayed peptide in some cases and not in others. This 
may also explain the selection of such a large number of phage without peptide inserts. If
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these phage were capable of binding the antibody by some means other than via the 
displayed peptide, and these clones may have had a growth advantage due to the lack of 
an insert (possibly making them more infectious) and are preferentially propagated, this 
may be the reason that these clones constitute such a high percentage of the phage 
selected. These results reinforce the importance of the use of a range of different 
screening methods in conjunction with a range of alternative panning procedures and 
different libraries, for any particular ligand.
4.3.5 Screening Different Libraries
The screening of a number of different libraries is important in order to maximise the 
possibility of selecting the phage clone displaying the peptide or protein with the highest 
affinity for the ligate in question. The four main variables in any library are:
• phage vector
• fusion protein, p III/p V III
• peptide length
• choice of invariant flanking residues.
Manipulation of these variables w ill determine the success of ligate selection in 
conjunction with the chosen panning method. As discussed previously, the identification 
of short linear epitopes can be achieved using 6  to 15 mer linear peptide libraries, 
however the search for conformational or discontinuous epitopes generally requires 
longer inserts which are themselves constrained. The 12 mer library and 15 mer library 
were thought to be of sufficient length in order to select a discontinuous 
epitope/mimotope, however it is not only the length of the peptide which is significant. 
The library must encompass all the possible combinations of amino acid sequence in 
sufficient numbers. A 15 mer library involving all 20 amino acids has the potential to 
display 3.3* 1019 (2015) unique sequences. One of the primary limiting factors in the 
production of such a complex library is the efficiency of electrotransfection of host 
bacteria with recombinant phage DNA, therefore it is not possible to generate a library 
with this complexity. In the case of the 15 mer library used here, the complexity was 
1.1*1012, considerably less than the number of possible sequences. It is possible that the 
sequence with the greatest affinity for 72A1 is not present in this library. The same may
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be the case for the other linear peptide libraries which were screened, however, all 
combinations are not required
Binding domains may contain a relatively small number of anchor residues along longer 
peptide regions, identification of this type of epitope may depend more on probing 
libraries of longer peptides than those with the greatest diversity Libraries have been 
produced with up to 38 residues which are more diverse than libraries with the same 
number of phages bearing shorter peptides Peptides o f this length as well as bemg more 
chemically diverse, can assume a variety of secondary structural motifs, such as a- 
helices, (5-tums, and mimics of antigenic loops on the surface of different protems Also, 
peptides of this length allow greater diversity in the regions flanking bmding residues 
which could lead to improved affinity based on mechanisms which are dependent on 
secondary interactions between flanking residues and the target If these types of 
secondary interactions are important for the monoclonal antibody 72A l, the peptides of 
each of the linear libraries used may have been too short to select the epitope
The conformation assumed by longer peptides is dependent on the free energies of their 
ammo acid sequences in the suspending medium This conformation may be quite 
different from that of the same amino acid sequence as it exists in the native form or 
bound forms of a protein, therefore, selection of certain binding motifs may only be 
possible when using libraries displaying peptides that assume specific conformation The 
cyclic form of the peptides m a constrained library should have restncted conformational 
freedom thus providing higher affinity and specificity for a receptor The more tightly a 
peptide segment is constrained, the less likely it is to bmd any particular target, if it does 
bind, this binding is likely to be tighter and more specific It has also been found that 
phage from constrained peptide libraries are more effective as immunogens as they are 
more stable, and have a longer plasma half life than those from unconstrained peptide 
libraries (Ladner, 1995) One constrained library was screened, which had just seven 
residues, this peptide length may also have been too short in order to identify the epitope 
of the 72A1 antibody A constrained library with a longer insert would be more ideal, but 
didn’t exist at the time of this research
2 3 1
Screening of a gene-fragment library may prove to be the most successful method of 
isolating the epitope or mimotope of 72 A 1. Construction of such a library would involve 
DNasel digestion of plasmid DNA encoding the gp350/220 gene, and cloning of the 
resulting fragments into an appropriate phage vector such as fUSE5, as described by 
Fack et al., 1997. As the 15 mer library was the longest peptide library we screened, 
using a gene-fragment library would increase the possibility of recognising the 72A1 
epitope if  it is greater than 15 amino acids in length. Also, this type of library would 
encompass a much greater diversity of secondary structures which may also be crucial to 
the identification of this epitope. It has been shown using a gene-fragment library, that a 
single round of panning is sufficient to determine an epitope (Fack et al., 1997), this is 
possibly due to the fact that the library is several orders of magnitude smaller than a 
random peptide library. With just one round of panning required, the procedure is much 
simplified as the library is specific for a particular antigen.
4.3.6 Phage Display Technology
Screening of a wider range of libraries may not be successful in determining the epitope 
of 72A 1 or identifying a mimotope. However, the results presented indicate that this 
technology does show affinity selection of peptides which may be reactive with 72A l. 
The interaction between the selected peptides and the monoclonal antibody is very 
dependent on the physical and chemical conditions in which these entities are presented 
to each other. As all antibody-antigen interactions are highly specific, a number of 
variables must be manipulated in order to find the conditions which most successfully 
replicate this interaction in vivo. In vitro interactions can vary considerably from those 
occurring in the body and it may not be possible to reproduce the necessary conditions 
for a particular protein-protein interaction, however 72A 1 was shown to interact with 
gp350 on western blot.
The type of library screened appears to be the most influential factor in the selection of a 
specific ligand. In the case of epitope mapping, some knowledge of the type of epitope 
involved, aids the selection of a particular type of library or libraries to be screened. If  
the epitope is linear it is more likely to be identified using an unconstrained peptide 
library than if  the epitope is known to be conformational. To date very little success has 
been had in the identification of discontinuous epitopes from linear peptide libraries. In
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these cases constrained libraries with longer amino acid sequences, or gene-fragment 
libraries have proven to have more potential m epitope identification Ideally, to have 
peptides of different lengths, that are constrained in several different frameworks of 
varying ngidity, would give the best opportunity of isolating the most specific, high 
affinity sequence Construction of an antigen-specific library and the use of non- 
permeabie beads for antibody immobilisation, may be the most effective way to identify 
the 72A1 epitope using phage display technology
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Chapter 5
Conclusions
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5.1 Expression of recombinant EBV antigens in E.coli
Three recombinant EBV antigens, pl8VCA, EA-D and truncated EBNA1 were 
expressed by the thiofusion expression system in E coh, and were affinity purified using 
PAO These have proven to be effective reagents for the identification of IM+ sera and 
sera from normal healthy individuals The majority of serum samples, normal 
(seropositive), ‘VCA+/-,’ ‘EBNA+/-’ and ‘IM+’, showed antibody responses similar to 
those expected, according to serological profiles determined by other methods (IFA and 
ELISA usmg cell culture-derived antigens) An IgM response to recombinant pl8VCA, 
in conjunction with a rEBNAl IgG negative response, showed greatest correlation with 
previously characterised ‘IM+’ sera Eighty four percent of ‘IM+’ sera were also ‘IM+’ 
by this method, none of the normal sea were ‘IM+’, 68% were EBV seropositive Of the 
‘VCA+’ sera, 78% were also VCA IgM-positive by this method and 70% of ‘EBNA+’ 
were EBNA1-positive In the case of sera that were characterised as being from 
individuals with primary CMV infection, 29% appeared to cross-react with rVCApl8 
although this would need to be investigated further
The presence of a strong background signal due to non-specific interactions with native 
Ecoli protems, may cause problems in effective diagnosis There was no reactivity 
observed when western blotting was earned out with thioredoxin and a number of ‘IM+’ 
sera, therefore it does not appear to be necessary to remove the thioredoxin moiety usmg 
enterokinase Also increasing concentrations of free thioredoxin were added to serum 
samples analysed by ELISA, with no reduction in the ELSIA signal (data not shown) 
This would indicate the absence of any thioredoxin-specific antibody response Affinity 
punfication with PAO agarose effectively removed the majonty of cellular E coh 
protems, however there was also substantial loss of recombinant fusion protein
The results obtained show the potential of these recombinant EBV antigens for use as 
immunodiagnostic reagents for EBV-related disease
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5.2 Identification of anti-gp350 MAb-binding peptides
Comparison of the peptides selected from each of the RPLs by the EBV neutralising 
antibody 72 A l, shows similarity in both amino acid content and the class of amino acids 
which predominate in the peptides. Particularly those selected from the 15 mer and 7 mer 
unconstrained libraries. Alignment by comparison of aa class (i.e. polar-charged, polar- 
uncharged and non-polar) allowed a less rigid means of sequence comparison, which may 
reflect more clearly the type of selection permitted by phage display o f peptides less than 
15 aa.s long. The small number of conserved residues found in the inserts selected from 
the constrained library may reflect the possibility that only a small number of residues are 
required for binding to the antibody. The other positions may therefore be redundant in 
antibody binding and thus allow for the presence of almost any amino acid, although 
some classes of aa may interfere with binding and would not be selected. This might be 
the case when one looks at the predominance o f nonpolar amino acids following the 
polar charged amino acids in the peptides selected form the 15 mer library (Section 
4.2.4.2, figure 53). The failure to demonstrate binding of 72A1 to any of the phage 
selected most likely indicates that the binding is (i) very low, or (ii) non-specific.
There was no apparent similarity between the primary amino acid sequence of gp350 and 
the amino acid sequences of the selected clones when compared with respect to amino 
acid class. This would be expected if  the epitope were conformational in nature. 
However, it may not be possible to identify the epitope or mimotopes of 72A1 through 
the use of phage display technology. There are limitations, as with any scientific method, 
to the successful application of this technology. Specifically the identification o f 
conformational epitopes has proven more elusive, than that of linear epitopes.
The identification of the neutralising epitopes on the gp3 50/220 molecule, and the 
subsequent synthetic production of these peptides could provide the basis of a subunit 
vaccine. A number of peptides could be incorporated in order to induce a broad 
immmunological response, T cell epitopes could also be included in this type of vaccine, 
possibly as part of immunostimulating complexes (ISCOM S) (Morein et al., 1984). 
Recombinant phage displaying immunogenic peptides may also be directly considered as 
cell-free vaccine candidates (Dulbecco 1982, Folgori el al., 1994).
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i General solutions
0 5 M E D T A
186 1 g EDTA
800 ml distilled water
6 g NaOH pellets
pH to 8 0 with 5 M  NaOH
Adjusted volume to 1 L with water
50X TAE
242 g Tns
57 1 ml Acetic acid
100 ml 0 5 M EDTA pH 8 0
Adjusted to 1L with distilled water
5X TBE
54 g Tns
27 5 g Bone acid
20 ml 0 5 M EDTA pH 8 0
Adjusted to 1L with distilled water
Ethidium bromide (lOmg/ml)
0 1 g Ethidium bromide
10 ml Distilled water
Stored in dark
DNAse-free RNAse (1 mg/ml)
1 mg RNAse A
1 ml Distilled water
100°C, 30 mm
Cool slowly, store -20°C
I Solutions for DNA work
Agarose gel loading dye 
400 mg Sucrose
2 5 mg Bromophenol blue
1 ml Distilled water
TE buffer
10 mM Tns
I mM EDTA pH 8 0
11 Solution for mini-preparation and maxi-preparation of plasmid DNA
Solution I
50 mM Glucose
25 mM Tns Cl (pH 8 0)
10 mM EDTA (pH 8 0)
Solution II
0 2 N NaOH (freshly diluted from a 10N stock)
1% SDS
Solution III
60 ml 5M Potassium acetate
II 5 ml Glacial acetic acid
28 5 ml Distilled water
11 Media and solutions for Thiofusion kit.
Ampicillin (100 mg/ml)
1 g Ampicillin
10 ml Distilled water
Filter sterilised, aliquoted in 1ml aliquots, stored at -20°C
b
10X M9 salts (per L)
60 g Na2HP04
30 g KH2PO4
5 g NaCl
10 g NH4CI
900 ml distilled water
pH 7 4 with 10 M NaOH
Autoclaved and stored at room temperature
RM medium (per L)
20 g Casamino acids
10 ml 100% Glycerol
880 ml Distilled water
Autoclaved and added the following 
100 ml 10XM9 salts
1 ml 1 M MgCb
1 ml Ampicillin (100 mg/ml)
Mixed and stored at 4°C
RMG-amp media (per L)
2 0  g Casamino acids
15 g Agar technical
875 ml Distilled water
Autoclaved and cooled to ~55°C, added the following
100 ml 1 OX M9 salts
1 ml 1M MgCl2
10 ml 50% Glucose
1 ml Ampicillin (100 mg/ml)
Plates stored at 4°C
Induction medium (per L)
2 g Casanuno acids
885 ml Distilled water
Autoclaved and added the following 
100 ml 1 OX M9 salts
1 ml 1M MgCb
10 ml 50% Glucose
1 ml Ampicillin (100 mg/ml)
LB medium (per L)
10 g Bacto-tryptone
5 g Yeast extract
5 g NaCl
Autoclaved and stored at room temperature 
LB agar
10 g Tryptone
5 g Yeast extract
5 g NaCl
15 g Agar technical
Autoclaved and plates stored at 4°C
SOB medium (per L)
20 g Tryptone
5 g Yeast extract
0 5 g NaCl
10 ml KC1 (250 mM)
Adjusted pH to 7 0 with 5 M NaOH 
Autoclaved, cooled to ~5°C and added 
10 ml 1 M MgCl2
Stored at room temperature
d
SOC medium (per L)
1 L SOB
7 5 ml 50% Glucose (filter sterilised)
Stored at room temperature
Osmotic Shock Solution # 1 
20 mM Tns-HCl, pH 8 
2 5 mM EDTA
Autoclaved,
20% Sucrose (Filter sterilised)
Stored at room temperature
Osmotic Shock Solution # 2 
20 mM Tns-HCl, pH 8
2 5 mM EDTA
Autoclaved and stored at room temperature
HI Solutions for SDS PAGE
1 M Tns Cl pH 6 8 
15 M Tns Cl pH 8 8 
10% SDS
10% Ammonium persulphate (APS)
Acrylagel
Bis-acrylagel
TEMED
1 M Dithiothreitol
10X Running buffer (500 ml)
15 138 g Tns
71 125 g Glycine
5 0 g SDS
To 500 ml with distilled water
2X Sample buffer 
0 8 ml 1M Tns Cl pH 6 8
0 4 g SDS
0 02 g Bromophenol blue
2 ml Glycerol
To 8 ml with stenle distilled water
Add Vi volume of 1 M dithothreitol to sample buffer, then dilute lA with distilled water 
before adding an equal volume to the protein sample
Destain (per L)
100 ml Acetic acid
400 ml Methanol
500 ml Distilled water
Coomassie blue stain (per 200 ml)
1 g coomassie blue R
200 ml destain
IV Solutions for Western Blotting
1 OX Tns Glycine buffer (per 500 ml)
14 5 g Glycine
29 g Tns
1 85 g SDS
Made up to 1 L with distilled water, adjusted to pH 8 3
Transfer Buffer (per L)
100 ml 1 OX Tns Glycine (pH 8 3)
700 ml Distilled water
200 ml Methanol
f
TBS (IX /L)
6 1 g Tns
8 8 g NaCl
Made up to 1 L with distilled water and adjusted to pH 7 5 with HC1 
Autoclaved and stored at room temperature
TBST (0 1%)
1 L TBS (as above)
1 ml Tween 20
Blotto
50 ml TBS (as above)
25 jj.1 0 05% Tween 20 (0 5 ml/L)
2 g 5% non-fat dry milk 50 g/L (Marvel)
0 5g NaN3
V Solutions for protein purification with PAO resin
1 M Phosphate buffer 
136 1 g KH2P 04
174 2 g K2HPO4
156 Og NaH2P 04
142 0 g Na2HP0 4  (anhydrous)
P-mercaptoethanol, 14 4 M stock 
Running buffer
100 mM Phosphate buffer
20 mM NaCl
0 1 mM EDTA
g
Leupeptin (2mg/ml)
20 mg Leupeptin
10 ml Stenie distilled water
Stored at -20°C
PMSF (17 4 mg/ml)
174 mg PMSF
10 ml Isopropanol
Stored at -20°C
VI Solutions for ELISA with recombinant EBV antigens
Coating buffer (per L)
4 24 g Na2C03
5 4 g NaH C 03
Made up to 1 L with distilled water and adjusted to pH 9 6
TBS, TBST and Blotto - As for Western blotting
Diluent for sera 
IX TBS
5 % Foetal calf serum (FCS)
0 05 % NaN3
0 05 % Tween
VQ Media and solutions for peptide libraries (NEB)
LB/EPTG/Xgal agar (per L)
1L LB medium (see section II)
15 g Agar technical
Autoclaved and cooled to <70°C
h
Agarose top (per L)
10 g Tryptone
5 g Yeast extract
5g NaCl
1 g MgCl2 6H20
7 g agar techmcal
Autoclaved and stored solid at room temperature in 50 ml aliquots 
Minimal media (per L)
100 ml 10X M9 salts (as for Thiofusion kit)
15 g Agar techmcal
8 ml 50% Glucose
2 ml 1 M MgS04
lm l 100 mM CaCl2
1 ml Thiamine (10 mg/ml)
All components are autoclaved separately and cooled to < 70°C (glucose and thiamine 
are filter sterilised) before combimng
Blocking buffer
0 1 M  N aHC03 (pH  8 6)
5 mg/ml BSA
0 02% NaN3
Filter sterilised and stored at 4°C
TBS (as for Western blotting)
PEG/NaCl
20% (w/v) Polyethylene glycol-8000
2 5 M NaCl
Autoclaved and stored at room temperature
i
Iodide buffer
10 mM Tns Cl (pH 8 0)
1 mM EDTA
4 M Nal 
Stored at room temperature
IPTG/Xgal
1 25 g IPTG (isopropyl P-D-thiogalactoside)
1 g Xgal (5-bromo-4-chloro-3-mdolyl-P-D-galactoside)
25 ml Dimethyl formamide
Stored at -20°C in the dark
Elution buffer
0 2 M Glycine (pH2 2 with HC1)
1 mg/ml BSA
Neutralising solution 
1 M Tns-HCl (pH9 1)
V m  Media and Reagents for 15mer library
Blocking solution (per ml)
1 ml 0 1 M NaHCOs
5 mg Dialysed BSA
0 1 (ig Streptavidin
4 nl NaN3 (5% stock)
Kanamycin
100 mg Kanamycin
1 ml Distiled water 
Filter sterilised and stored at 4°C
J
Sodium azide (5%)
50 mg NaN3
950 pi Distilled water
TB soft agar (100 ml)
1 g Tryptone
0 5 g NaCl
0 75 g Agar technical
100 ml Distilled water
Autoclaved and stored at room temperature 
TBS (as per Western blotting)
TBS/gelatin
0 1 g Gelatin
100 ml TBS
Autoclaved and stored at room temperature
TBS/Tween (0 5%)
200 ml TBS
1 ml Tween 20
Tetracycline
100 mg Tetracycline
5 ml Ethanol
Filter-stenlised and stored at -20°C
Potassium phosphate buffer (per 100 ml)
2  31 g KH2PO4 (anhydrous)
12 54 g K2HPO4 (anhydrous)
Made up to 100 ml with distilled water and autoclaved
k
Terrific broth (per L)
12 g Tryptone
24 g Yeast extract
4 ml Gycerol
Made up to 1L with distilled water and autoclaved in 90 ml portions
To each 90 ml portion 10ml autoclaved potassium phosphate buffer was added
NZY medium (per L)
10 g NZ amine A
5 g Yeast extract
5 g NaCl
Dissolved in 1 L distilled water, pH adjusted to 7 5 with NaOH, autoclaved and stored at 
room temperature
NZY agar - As above with 15 g agar technical 
TNT (per L)
1 21 g 10 mM Tns pH8 0
8 77 g 150 mM NaCl
0 5 ml 0 05% Tween 20
TBS and Blotto as for Western blotting
TNT A (per 100 ml)
100 ml TNT
0 1 g BSA
TNT B (per 100 ml)
100 ml TNT
0 1 g BSA
0 1 ml NP-40
1
Deglycosylation buffer 
20 raM Na2HP04
40 mM EDTA
Adjusted to pH 7 2
DC Reagents for sequencing
10X TBE (per 500 ml)
54 g Tns base
27 5g Bone acid
20 ml 0 5 M EDTA (pH 8 0)
Made up to 500ml with ultra pure water
IX concentration was used for polyacrylamide gel preparation
10% Ammonium persulphate
0 1 g APS
1 ml Ultra pure H2O
6% denatunng polyacrylamide gel was prepared for sequencing the Conley library phage 
and 8% for the NEB library phage 
Va = volume of acrylamide 
Vb = volume of bis-acrylamide 
Vt = total volume of gel mix 150 ml 
C = % crosslmkmg 5 2 %
A = % gel 6/8 %
Va = Avt Vb = ACVt
30 200
Va = 6*150/30 = 30 ml 
Vb = 6*5 2*150/= 24 ml
m
, 6 % Denatunng PAG 
63 g Urea
30 ml Acrylamide
24 ml Bisacrylamide
15 ml 10XTBE
made up to 150 ml w/ ultra pure water
650 (il 10% APS and 150 |il TEMED were added directly before pouring
Developer (5 L)
1 50 L H20
1 25 L Concentrated developer solution
2 25 L H20  
stir 2 min
Fixer (5 125 L)
3 625 L H20
1 250 L Concentrated fixer A
0 250 L Concentrated fixer B
stir 2 mm
n
